

CUMULATIVE
SUPPLEMENT 10
OCTOBER 2004



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

Department of Health and Human Services

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

RM
301.45
.A66
2004
v.24
suppl.10

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

Library Use Only

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

Cumulative Supplement 10

October 2004

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Applicant Name Changes	iv
1.3 Ribavirin 200mg Oral Capsule	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Change Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List.....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms.....	B-1

Please Note:

The 24th Edition of the Orange Book will be the last paper version. All the components of the paper Orange Book are and have been available on the Internet since 1997. Refer to the Introduction 1.3, Availability of the Edition, for specific locations. Additional details will be made available in future Cumulative Supplement publications.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

24th EDITION

**CUMULATIVE SUPPLEMENT 10
October 2004**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 24th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, are for exportation, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 23rd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 24th Edition. The current edition Section 2, How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section A, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

ALPHARMA INC
(ALPHARMA)
ALPHARMA USPD INC
(ALPHARMA)
AMERSHAM HEALTH
(AMERSHAM)
BERLEX
(BERLEX)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ALPHARMA US PHARMACEUTICALS DIVISION
(ALPHARMA US PHARMS)
ALPHARMA US PHARMACEUTICALS DIVISION
(ALPHARMA US PHARMS)
GE HEALTHCARE
(GE HEALTHCARE)
BERLEX INC
(BERLEX INC)

BERLEX LABORATORIES INC (BERLEX LABS)	BERLEX INC (BERLEX INC)
BERLEX LABORATORIES INC SUB SCHERING AG (BERLEX)	BERLEX INC (BERLEX INC)
PUREPAC PHARMACEUTICAL COMPANY DIVISION OF PUREPAC INC (PUREPAC PHARM)	PUREPAC INC (PUREPAC PHARM)

1.3 RIBAVIRIN 200MG ORAL CAPSULE

The footnote for Ribavirin 200MG capsule product 001 was inadvertently omitted from the 24th Edition. The footnote: Indicated for use and comarketed with interferon alfa-2b, recombinant (Intron A), as Rebetron Combination Therapy.

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342) and Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210) and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King/Jones Pharma NDA 021301) tablets.

Novothyrox (Genpharm NDA 021292) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Thyro-Tabs (Lloyd NDA 021116) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

Levolet (Vintage NDA 021137) requires further investigation and review to establish therapeutic equivalence to corresponding strengths of any other levothyroxine sodium drug products and is rated BX.

The chart outlines TE codes for all 0.025mg products with other products being similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	JONES PHARMA	0.025MG	AB1	21301	001

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
LEVOXYL	JONES PHARMA	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
NOVOTHYROX	GENPHARM	0.025MG	BX	21292	001
THYRO-TABS	LLOYD	0.025MG	BX	21116	001
LEVOLET	VINTAGE PHARMS	0.025MG	BX	21137	001

1.5 AVAILABILITY OF THE EDITION

The 24th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800 or toll free 866-512-1800. The cost is \$110.00 annually. A GPO Orange Book Subscription form is provided at the end of each cumulative supplement.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the monthly cumulative supplements.

The Internet version of the Orange Book annual edition is at <http://www.fda.gov/cder/orange/adp.htm>.

The Internet version of the monthly supplement is at <http://www.fda.gov/cder/orange/supplement/cspreface.htm>.

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the monthly cumulative supplements. Appendix A and Appendix B text files of the paper annual Orange Book are updated quarterly.

The 24th annual edition of the 2003 Orange Book Patent and Exclusivity List is at <http://www.fda.gov/cder/orange/24bookpub.pdf>.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at <http://www.fda.gov/cder/orange/supplement/patents.pdf>.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at <http://www.fda.gov/cder/orange/docket.pdf>. It is updated approximately weekly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from Program Support Center Forms Download Website,
<http://formspsc.gov/forms/FDA/fda.html>

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2003) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2003	MAR 2004	JUN 2004	SEP 2004
DRUG PRODUCTS LISTED	10665	10668	10702	10822
SINGLE SOURCE	2423 (22.7%)	2404 (22.5%)	2385 (22.3%)	2385 (22.0%)
MULTISOURCE	8134 (76.3%)	8156 (76.5%)	8209 (76.7%)	8329 (77.0%)
THERAPEUTICALLY				
EQUIVALENT	7856 (73.7%)	7885 (73.9%)	7995 (74.7%)	8116 (75.0%)
NOT THERAPEUTICALLY				
EQUIVALENT	278 (2.6%)	271 (2.5%)	214 (2.0%)	213 (2.0%)
EXCEPTIONS ¹	108 (1.0%)	108 (1.0%)	108 (1.0%)	108 (1.0%)
NEW MOLECULAR ENTITIES APPROVED	6	3	1	1
NUMBER OF APPLICANTS	601	586	602	605

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.


New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.

CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.



PRESCRIPTION DRUG PRODUCT LIST - 24TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-1

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

EPZICOM

+ SMITHKLINE BEECHAM EQ 600MG BASE;300MG

N21652 001 Aug 02, 2004 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

CAMPRAL

+ FOREST LABS 333MG

N21431 001 Jul 29, 2004 Sep CAHN

+ LIPHA 333MG

N21431 001 Jul 29, 2004 Jul NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

PHRENILIN FORTE

AB + VALEANT 650MG;50MG N88831 001 Jun 19, 1985 Aug CAHN

TABLET; ORAL

PHRENILIN

AB + VALEANT 325MG;50MG N87811 001 Jun 19, 1985 Aug CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB ANABOLIC LABS 325MG;50MG;40MG;30MG N76560 001 Jun 10, 2004 Jun NEWA

PHRENILIN WITH CAFFEINE AND CODEINE

AB VALEANT 325MG;50MG;40MG;30MG N74911 001 Aug 22, 2001 Aug CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC-A

@ LEITNER PHARMS 356.4MG;30MG;16MG

N89166 001 May 14, 1986 Oct CAHN

@ WOMEN FIRST HLTHCARE 356.4MG;30MG;16MG

N89166 001 May 14, 1986 Oct CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA + AMARIN PHARMS 120MG/5ML;12MG/5ML N86024 001 Apr CRLD

AA + VALEANT 120MG/5ML;12MG/5ML N86024 001 Aug CAHN

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ MUTUAL PHARM 300MG;15MG N85795 001 Aug CAHN

@ 300MG;30MG N85794 001 Aug CAHN

@ 300MG;60MG N89673 001 Feb 10, 1988 Aug DISC

ACETAMINOPHEN W/ CODEINE

@ MUTUAL PHARM 300MG;60MG N87653 001 Apr 13, 1982 Aug CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

@ CENT PHARMS 500MG;5MG N88898 001 Mar 27, 1985 Aug DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

+ MIKART 300MG;10MG N40556 001 Jun 23, 2004 Jun NEWA

AA MUTUAL PHARM 500MG;5MG N40236 001 Sep 25, 1997 Aug CAHN

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MUTUAL PHARM	650MG;7.5MG	N40240 002	Nov 26, 1997	Aug CAHN
AA		650MG;10MG	N40240 001	Nov 26, 1997	Aug CAHN
AA		750MG;7.5MG	N40236 002	Sep 25, 1997	Aug CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	MUTUAL PHARM	500MG;5MG	N40219 001	Jan 22, 1998	Aug CAHN
----	--------------	-----------	------------	--------------	----------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	MALLINCKRODT	325MG;7.5MG	N40545 001	Jun 30, 2004	Jun NEWA
AA		325MG;10MG	N40545 002	Jun 30, 2004	Jun NEWA
AA		500MG;7.5MG	N40550 001	Jun 30, 2004	Jun NEWA
AA		650MG;10MG	N40550 002	Jun 30, 2004	Jun NEWA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

WYGESIC

>A>	AA	+	LEITNER PHARMS	650MG;65MG	N84999 001	Oct CAHN
>D>	AA	+	WOMEN FIRST HLTHCARE	650MG;65MG	N84999 001	Oct CAHN

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

AB	AAIPHARMA	500MG;100MG	N76429 001	Sep 10, 2003	May CRLD
AB		500MG;100MG	N76429 001	Sep 10, 2003	Jun CFTG
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
@	MUTUAL PHARM	325MG;50MG	N70115 001	Jun 12, 1985	Aug CAHN
@		650MG;100MG	N70116 001	Jun 12, 1985	Aug CAHN
AB		650MG;100MG	N70615 001	Mar 21, 1986	Aug CAHN
AB		650MG;100MG	N70771 001	Mar 21, 1986	Aug CAHN
AB		650MG;100MG	N70775 001	Mar 21, 1986	Aug CAHN
	VINTAGE PHARMS	325MG;100MG	N76743 001	May 07, 2004	May NEWA
AB		500MG;100MG	N76750 001	Jun 28, 2004	Jun NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	HOSPIRA	EQ 500MG BASE/VIAL	N40108 001	Oct 30, 1995	May CAHN
----	---------	--------------------	------------	--------------	----------

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT	HOSPIRA	250MG/100ML	N17656 001	May CAHN
----	---------	-------------	------------	----------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

+	CUMBERLAND PHARMS	6GM /30ML(200MG/ML)	N21539 001	Jan 23, 2004	Jan NEWA
---	-------------------	---------------------	------------	--------------	----------

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	HOSPIRA	10%	N73664 001	Aug 30, 1994	May CAHN
AN		20%	N74037 001	Aug 30, 1994	May CAHN

ACITRETIN

CAPSULE; ORAL					
SORIATANE					
CONNEXICS	10MG				N19821 001 Oct 28, 1996 Mar CAHN
+	25MG				N19821 002 Oct 28, 1996 Mar CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION					
ACYCLOVIR SODIUM					
AP HOSPIRA	EQ 500MG BASE/VIAL				N74663 001 Apr 22, 1997 May CAHN
AP	EQ 500MG BASE/VIAL				N74758 001 Apr 22, 1997 May CAHN
AP	EQ 1GM BASE/VIAL				N74663 002 Apr 22, 1997 May CAHN
AP	EQ 1GM BASE/VIAL				N74758 002 Apr 22, 1997 May CAHN
AP MAYNE PHARMA USA	EQ 50MG BASE/ML				N75065 001 Feb 25, 1999 Apr CAHN

ADENOSINE

INJECTABLE; INJECTION					
ADENOCARD					
AP + FUJISAWA HLTHCARE	3MG/ML				N19937 002 Oct 30, 1989 Jun CPTG
ADENOSINE					
AP BAXTER HLTHCARE	3MG/ML				N76500 001 Jun 16, 2004 Jun NEWA
AP	3MG/ML				N76501 001 Jun 16, 2004 Jun NEWA
AP BEDFORD	3MG/ML				N76404 001 Jun 16, 2004 Jun NEWA
AP SICOR PHARMS	3MG/ML				N76564 001 Jun 16, 2004 Jun NEWA

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION					
TROVAN PRESERVATIVE FREE					
# PFIZER	EQ 200MG BASE/VIAL				N20760 001 Dec 18, 1997 Jun DISC
#	EQ 300MG BASE/VIAL				N20760 002 Dec 18, 1997 Jun DISC

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION					
JEANATOPE					
ISO TEX	100UCI/10ML(10UCI/ML)				N17836 003 Jun 08, 2004 Jun NEWA
	500uCi/0.5ML				N17836 001 Jun CMFD
+	1,000uCi/ML				N17836 002 Jun CMFD
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I-125					
@ MALLINCKRODT	10uCi/ML				N17844 001 Jun DISC

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION					
ALBUTEROL SULFATE					
>A> BX + IVAX RES	EQ 0.09MG BASE/INH				N21457 001 Oct 29, 2004 Oct NEWA
SOLUTION; INHALATION					
ACCUNEB					
AN + DEY	EQ 0.042% BASE				N20949 001 Apr 30, 2001 Jun CPTG
ALBUTEROL SULFATE					
AN + BAUSCH AND LOMB	EQ 0.083% BASE				N75358 001 Mar 29, 2000 Jun CRLD
AN +	EQ 0.5% BASE				N75050 001 Jun 18, 1998 Jun CRLD
AN NEPHRON	EQ 0.042% BASE				N76355 001 Jun 28, 2004 Jun NEWA
PROVENTIL					
@ SCHERING	EQ 0.083% BASE				N19243 002 Jan 14, 1987 Jun DISC
@	EQ 0.5% BASE				N19243 001 Jan 14, 1987 Jun DISC

	SYRUP; ORAL ALBUTEROL SULFATE		
AA	+ TEVA EQ 2MG BASE/5ML	N73419 001 Mar 30, 1992 Sep CRLD	
	TABLET, EXTENDED RELEASE; ORAL ALBUTEROL SULFATE		
	+ PLIVA EQ 4MG BASE	N76130 002 Sep 26, 2002 Jan CRLD	AP
	+ EQ 8MG BASE	N76130 003 Sep 26, 2002 Jan CRLD	AP
	VOLMAX		AP
	@ MURO EQ 4MG BASE	N19604 002 Dec 23, 1992 Jan DISC	AP
	@ EQ 8MG BASE	N19604 001 Dec 23, 1992 Jan DISC	AP
	<u>ALCLOMETASONE DIPROPIONATE</u>		
	OINTMENT; TOPICAL ACLOVATE		
AB	+ GLAXOSMITHKLINE 0.05%	N18702 001 Dec 14, 1982 Jul CFTG	
	ALCLOMETASONE DIPROPIONATE		
AB	TARO 0.05%	N76730 001 Jul 29, 2004 Jul NEWA	
	<u>ALCOHOL; DEXTROSE</u>		
	INJECTABLE; INJECTION ALCOHOL 5% IN D5-W		
AP	HOSPIRA 5ML/100ML;5GM/100ML	N83263 001	May CAHN
	<u>ALFENTANIL HYDROCHLORIDE</u>		
	INJECTABLE; INJECTION ALFENTANIL		
AP	HOSPIRA EQ 0.5MG BASE/ML	N75221 001 Oct 28, 1999 May CAHN	
	<u>ALLOPURINOL</u>		
	TABLET; ORAL ALLOPURINOL		
	@ MUTUAL PHARM 100MG	N70466 001 Dec 24, 1985 Aug CAHN	
	@ 300MG	N70467 001 Dec 24, 1985 Aug CAHN	
	<u>ALLOPURINOL SODIUM</u>		
	INJECTABLE; INJECTION ALLOPURINOL SODIUM		
AP	BEDFORD LABS EQ 500MG BASE/VIAL	N76870 001 Aug 26, 2004 Aug NEWA	
	ALOPRIM		
AP	+ NABI EQ 500MG BASE/VIAL	N20298 001 May 17, 1996 Aug CFTG	
	+ EQ 500MG BASE/VIAL	N20298 001 May 17, 1996 Jun CAHN	
	<u>ALMOTRIPTAN MALATE</u>		
	TABLET; ORAL AXERT		
	ORTHO MCNEIL PHARM EQ 6.25MG BASE	N21001 001 May 07, 2001 Jul CAHN	
	+ EQ 12.5MG BASE	N21001 002 May 07, 2001 Jul CAHN	
	<u>AMANTADINE HYDROCHLORIDE</u>		
	SYRUP; ORAL AMANTADINE HCL		
AA	SILARK 50MG/5ML	N76352 001 Sep 10, 2004 Sep NEWA	

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE						
@ BAXTER HLTHCARE	EQ 50MG BASE/ML	N63274	001	May 18, 1992	Aug	CAHN
@	EQ 250MG BASE/ML	N63275	001	May 18, 1992	Aug	CAHN
AP HOSPIRA	EQ 50MG BASE/ML	N63263	001	Nov 30, 1994	May	CAHN
	EQ 62.5MG BASE/ML	N63283	001	Oct 31, 1994	May	CAHN
AP	EQ 250MG BASE/ML	N63264	001	Nov 30, 1994	May	CAHN
AP	EQ 250MG BASE/ML	N64098	001	Jun 26, 1995	May	CAHN
@	EQ 250MG BASE/ML	N64099	001	Jun 20, 1995	May	CAHN
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
HOSPIRA	EQ 500MG BASE/100ML	N64146	001	Apr 02, 1997	May	CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE						
HOSPIRA	5.2% (5.2GM/100ML)	N18901	001	Apr 06, 1984	Aug	CAHN
AMINOSYN 10%						
HOSPIRA	10% (10GM/100ML)	N17673	003		May	CAHN
AMINOSYN 10% (PH6)						
HOSPIRA	10% (10GM/100ML)	N17673	008	Nov 18, 1985	May	CAHN
AMINOSYN 3.5%						
HOSPIRA	3.5% (3.5GM/100ML)	N17789	004		May	CAHN
AMINOSYN 5%						
HOSPIRA	5% (5GM/100ML)	N17673	001		May	CAHN
AMINOSYN 7%						
@ HOSPIRA	7% (7GM/100ML)	N17673	002		May	CAHN
AMINOSYN 7% (PH6)						
HOSPIRA	7% (7GM/100ML)	N17673	006	Nov 18, 1985	May	CAHN
AMINOSYN 8.5%						
@ HOSPIRA	8.5% (8.5GM/100ML)	N17673	004		May	CAHN
AMINOSYN 8.5% (PH6)						
HOSPIRA	8.5% (8.5GM/100ML)	N17673	007	Nov 18, 1985	May	CAHN
AMINOSYN II 10%						
HOSPIRA	10% (10GM/100ML)	N19438	005	Apr 03, 1986	May	CAHN
AMINOSYN II 10% IN PLASTIC CONTAINER						
HOSPIRA	10% (10GM/100ML)	N20015	001	Dec 19, 1991	May	CAHN
AMINOSYN II 15% IN PLASTIC CONTAINER						
HOSPIRA	15% (15GM/100ML)	N20041	001	Dec 19, 1991	May	CAHN
AMINOSYN II 3.5%						
@ HOSPIRA	3.5% (3.5GM/100ML)	N19438	001	Apr 03, 1986	May	CAHN
AMINOSYN II 5%						
@ HOSPIRA	5% (5GM/100ML)	N19438	002	Apr 03, 1986	May	CAHN
AMINOSYN II 7%						
HOSPIRA	7% (7GM/100ML)	N19438	003	Apr 03, 1986	May	CAHN
AMINOSYN II 8.5%						
HOSPIRA	8.5% (8.5GM/100ML)	N19438	004	Apr 03, 1986	May	CAHN
AMINOSYN-HBC 7%						
HOSPIRA	7% (7GM/100ML)	N19374	001	Jul 12, 1985	May	CAHN
AMINOSYN-HF 8%						
HOSPIRA	8% (8GM/100ML)	N20345	001	Apr 04, 1996	May	CAHN
AMINOSYN-PF 10%						
HOSPIRA	10% (10GM/100ML)	N19492	002	Oct 17, 1986	May	CAHN
AMINOSYN-PF 7%						
HOSPIRA	7% (7GM/100ML)	N19398	001	Sep 06, 1985	May	CAHN

INJECTABLE; INJECTIONAMINOSYN-RF 5.2%

HOSPIRA	5.2% (5.2GM/100ML)	N18429 001	May CAHN
NEOPHAM 6.4%			
# HOSPIRA	6.4% (6.4GM/100ML)	N18792 001	Jan 17, 1984 Aug CAHN
NOVAMINE 11.4%			
HOSPIRA	11.4% (11.4GM/100ML)	N17957 003	Aug 09, 1982 Aug CAHN
NOVAMINE 15%			
HOSPIRA	15% (15GM/100ML)	N17957 004	Nov 28, 1986 Aug CAHN
NOVAMINE 8.5%			
# HOSPIRA	8.5% (8.5GM/100ML)	N17957 002	Aug 09, 1982 Aug CAHN

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTIONAMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	3.5%;36.8MG/100ML;25GM/100ML;51MG /100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 001	Nov 07, 1988 May CAHN
---------	---	------------	-----------------------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;20GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 002	Nov 07, 1988 May CAHN
---------	--	------------	-----------------------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

HOSPIRA	4.25%;36.8MG/100ML;25GM/100ML;51M G/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 003	Nov 07, 1988 May CAHN
---------	--	------------	-----------------------

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

@ HOSPIRA	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N19683 004	Nov 07, 1988 May CAHN
-----------	--	------------	-----------------------

AMINO ACIDS; DEXTROSEINJECTABLE; INJECTIONAMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	3.5%;25GM/100ML	N19681 001	Nov 01, 1988 May CAHN
---------	-----------------	------------	-----------------------

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML	N19681 002	Nov 01, 1988 May CAHN
---------	----------------	------------	-----------------------

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

HOSPIRA	4.25%;10GM/100ML	N19681 004	Nov 01, 1988 May CAHN
---------	------------------	------------	-----------------------

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

HOSPIRA	4.25%;20GM/100ML	N19681 005	Nov 01, 1988 May CAHN
---------	------------------	------------	-----------------------

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	4.25%;25GM/100ML	N19681 003	Nov 01, 1988 May CAHN
---------	------------------	------------	-----------------------

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

HOSPIRA	5%;25GM/100ML	N19681 006	Nov 01, 1988 May CAHN
---------	---------------	------------	-----------------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTIONAMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

@ HOSPIRA	4.25%;10GM/100ML;51MG/100ML;176.5 MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML	N19682 003	Nov 01, 1988 May CAHN
-----------	---	------------	-----------------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEINJECTABLE; INJECTIONAMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	3.5%;5GM/100ML;30MG/100ML;97MG/10 OML;120MG/100ML;49.3MG/100ML	N19682 001	Nov 01, 1988 May CAHN
---------	--	------------	-----------------------

INJECTABLE; INJECTION

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER
 HOSPIRA 4.25%;5GM/100ML;30MG/100ML;97MG/1 N19682 002 Nov 01, 1988 May CAHN
 00ML;120MG/100ML;49.3MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN 3.5% M
 HOSPIRA 3.5%;21MG/100ML;40MG/100ML;128MG/ N17789 003 May CAHN
 100ML;234MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN 3.5% M
 @ HOSPIRA 3.5%;21MG/100ML;128MG/100ML;234MG N17789 005 May CAHN
 /100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATEINJECTABLE; INJECTION

VEINAMINE 8%
 @ HOSPIRA 8%;61MG/100ML;211MG/100ML;56MG/10 N17957 001 Aug CAHN
 0ML;388MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES
 HOSPIRA 10%;102MG/100ML;45MG/100ML;522MG/ N19437 004 Apr 03, 1986 May CAHN
 100ML;410MG/100ML

AMINOSYN II 7% W/ ELECTROLYTES
 @ HOSPIRA 7%;102MG/100ML;45MG/100ML;522MG/1 N19437 006 Apr 03, 1986 May CAHN
 00ML;410MG/100ML

AMINOSYN II 8.5% W/ ELECTROLYTES
 HOSPIRA 8.5%;102MG/100ML;45MG/100ML;522MG N19437 005 Apr 03, 1986 May CAHN
 /100ML;410MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATEINJECTABLE; INJECTION

AMINOSYN II 3.5% M
 @ HOSPIRA 3.5%;30MG/100ML;97MG/100ML;120MG/ N19437 007 Apr 03, 1986 May CAHN
 100ML;49MG/100ML

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDEINJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES
 HOSPIRA 7%;102MG/100ML;522MG/100ML;410MG/ N17789 002 May CAHN
 100ML

AMINOSYN 8.5% W/ ELECTROLYTES
 HOSPIRA 8.5%;102MG/100ML;522MG/100ML;410M N17673 005 May CAHN
 G/100ML

AMINOCAPROIC ACIDINJECTABLE; INJECTION

AMINOCAPROIC ACID
 AP HOSPIRA 250MG/ML N70888 001 Jun 16, 1988 May CAHN

AMINOCAPROIC ACID IN PLASTIC CONTAINER
 AP HOSPIRA 250MG/ML N70010 001 Mar 09, 1987 May CAHN

AMINOPHYLLINE

INJECTABLE; INJECTION
AMINOPHYLLINE

AP	HOSPIRA	25MG/ML	N87242 001 Oct 26, 1983 May CAHN
AP	+	25MG/ML	N87601 001 Jul 23, 1982 May CAHN
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%			
+	HOSPIRA	100MG/100ML	N88147 002 May 03, 1983 May CAHN
+		200MG/100ML	N88147 003 May 03, 1983 May CAHN
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
@	HOSPIRA	100MG/100ML	N18924 001 Dec 12, 1984 May CAHN
@		200MG/100ML	N18924 002 Dec 12, 1984 May CAHN
@		400MG/100ML	N18924 003 Dec 12, 1984 May CAHN
@		500MG/100ML	N18924 004 Dec 12, 1984 May CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HCL

AP	HOSPIRA	50MG/ML	N75955 001 Oct 18, 2002 May CAHN
AMIODARONE HYDROCHLORIDE			
AP	INTL MEDICATION SYS	50MG/ML	N21594 001 Feb 04, 2004 Feb NEWA
TABLET; ORAL			
AMIODARONE HCL			
@	TARO	400MG	N76362 001 Nov 29, 2002 Jul DISC

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
ELAVIL

@	ASTRAZENECA	10MG/ML	N12704 001 Sep DISC	
TABLET; ORAL				
AMITRIPTYLINE HCL				
@	MUTUAL PHARM	10MG	N85744 001 Aug CAHN	
@		25MG	N85627 001 Aug CAHN	
@		50MG	N85745 001 Aug CAHN	
@		75MG	N85743 001 Aug CAHN	
@		100MG	N85742 002 May 11, 1982 Aug CAHN	
@		150MG	N89423 001 Feb 17, 1987 Aug CAHN	
>D>	AB	SANDOZ	25MG	N85966 001 Oct CRLD
>A>	AB	+	25MG	N85966 001 Oct CRLD
ELAVIL				
@	ASTRAZENECA	10MG	N12703 001 Jul DISC	
@		25MG	N12703 003 Jul DISC	
@		50MG	N12703 004 Jul DISC	
@		75MG	N12703 005 Jul DISC	
@		100MG	N12703 006 Jul DISC	
@		150MG	N12703 007 Jul DISC	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HCL

@	MUTUAL PHARM	EQ 12.5MG BASE;5MG	N70765 001 Dec 10, 1986 Aug CAHN
@		EQ 25MG BASE;10MG	N70766 001 Dec 10, 1986 Aug CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL
PERPHENAZINE AND AMITRIPTYLINE HCL

@	MUTUAL PHARM	10MG;2MG	N71077 001 Nov 12, 1986 Aug CAHN
---	--------------	----------	----------------------------------

TABLET; ORAL
 PERPHENAZINE AND AMITRIPTYLINE HCL
 # MUTUAL PHARM 10MG;4MG
 # 25MG;2MG
 # 25MG;4MG

N71078 001 Nov 12, 1986 Aug CAHN
 N70297 001 Nov 12, 1986 Aug CAHN
 N71079 001 Nov 12, 1986 Aug CAHN

AMLEXANOX

PATCH; TOPICAL
 AMLEXANOX
 + ACCESS PHARMS 2MG

N21727 001 Sep 29, 2004 Sep NEWA

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

CADUET
 PFIZER
 EQ 2.5MG BASE;EQ 10MG BASE
 EQ 2.5MG BASE;EQ 20MG BASE
 EQ 2.5MG BASE;EQ 40MG BASE
 EQ 5MG BASE;EQ 10MG BASE
 EQ 5MG BASE;EQ 20MG BASE
 EQ 5MG BASE;EQ 40MG BASE
 EQ 5MG BASE;EQ 80MG BASE
 EQ 10MG BASE;EQ 10MG BASE
 EQ 10MG BASE;EQ 20MG BASE
 EQ 10MG BASE;EQ 40MG BASE
 EQ 10MG BASE;EQ 80MG BASE

N21540 009 Jul 29, 2004 Aug NEWA
 N21540 010 Jul 29, 2004 Aug NEWA
 N21540 011 Jul 29, 2004 Aug NEWA
 N21540 001 Jan 30, 2004 Jan NEWA
 N21540 002 Jan 30, 2004 Jan NEWA
 N21540 003 Jan 30, 2004 Jan NEWA
 N21540 004 Jan 30, 2004 Jan NEWA
 N21540 005 Jan 30, 2004 Jan NEWA
 N21540 006 Jan 30, 2004 Jan NEWA
 N21540 007 Jan 30, 2004 Jan NEWA
 N21540 008 Jan 30, 2004 Jan NEWA

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ
 # DR REDDYS LABS INC 2.5MG
 # 5MG
 # 10MG

N21435 001 Oct 31, 2003 Mar DISC
 N21435 002 Oct 31, 2003 Mar DISC
 N21435 003 Oct 31, 2003 Mar DISC

AMMONIUM CHLORIDE

INJECTABLE; INJECTION
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER
 + HOSPIRA 5MEO/ML

N88366 001 Jun 13, 1984 May CAHN

AMMONIUM LACTATE

LOTION; TOPICAL
 AMMONIUM LACTATE
 AB CLAY PARK EQ 12% BASE
 AB TARO EQ 12% BASE

N75570 001 Jun 23, 2004 Jun NEWA
 N76216 001 May 28, 2004 May NEWA

AMOXICILLIN

TABLET, CHEWABLE; ORAL
 AMOXIL
 # GLAXOSMITHKLINE 125MG
 # 250MG

N50542 002 Aug DISC
 N50542 001 Aug DISC

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL
 AMOXICILLIN AND CLAVULANATE POTASSIUM
 AB TEVA 200MG/5ML;EQ 28.5MG BASE/5ML
 AB 400MG/5ML;EQ 57MG BASE/5ML
 AB 600MG/5ML;EQ 42.9MG BASE/5ML

N65089 001 May 25, 2004 May NEWA
 N65089 002 May 25, 2004 May NEWA
 N65162 001 Mar 12, 2004 Mar NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-10

FOR SUSPENSION; ORAL

AUGMENTIN ES-600						
AB + GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755	001	Jun 22, 2001	Mar	CPTG
TABLET, EXTENDED RELEASE; ORAL						
AUGMENTIN XR						
+ GLAXOSMITHKLINE	1GM;EQ 62.5MG BASE	N50785	001	Sep 25, 2002	Sep	CPOT

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP IBI	EQ 2GM BASE/VIAL	N62797	002	Jul 12, 1993	Aug	CMFD
AP + SANDOZ	EQ 125MG BASE/VIAL	N61395	001		Jun	CAHN
AP +	EQ 250MG BASE/VIAL	N61395	002		Jun	CAHN
AP +	EQ 500MG BASE/VIAL	N61395	003		Jun	CAHN
AP +	EQ 1GM BASE/VIAL	N61395	004		Jun	CAHN
AP +	EQ 2GM BASE/VIAL	N61395	005		Jun	CAHN
AP +	EQ 10GM BASE/VIAL	N61395	006		Jun	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP BAXTER HLTHCARE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	N65074	001	Mar 19, 2002	Aug	CAHN
AP	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	N65074	002	Mar 19, 2002	Aug	CAHN
AP	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	N65076	001	Mar 19, 2002	Aug	CAHN

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

BERTEK	20MG/2ML (10MG/ML)	N21264	001	Apr 20, 2004	Apr	NEWA
+	30MG/3ML (10MG/ML)	N21264	002	Apr 20, 2004	Apr	NEWA
MYLAN BERTEK	20MG/2ML (10MG/ML)	N21264	001	Apr 20, 2004	Aug	CAHN
+	30MG/3ML (10MG/ML)	N21264	002	Apr 20, 2004	Aug	CAHN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SABEX 2002	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	NEWA
--------------	---	--------	-----	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID;
NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ MAYNE PHARMA USA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIA L;5MG/VIAL;0.01MG/VIAL;0.14MG/VIA L;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1 .4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920	001	Sep 21, 2000	Apr	CAHN
--------------------	--	--------	-----	--------------	-----	------

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

- M.V.I.-12
+ MAYNE PHARMA USA 10MG/ML;0.006MG/ML;0.5UGM/ML;1.5M N08809 004 Aug 08, 1985 Apr CAHN
G/ML;20
IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0
.36MG/ML;0.3MG/ML;330 UNITS/ML;1
IU/ML
- M.V.I.-12 (WITHOUT VITAMIN K)
+ MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.05UGM/ML;1.5 N08809 006 Sep 09, 2004 Sep NEWA
MG/ML;0.0005MG/ML;0.06MG/ML;4MG/M
L;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1
MG/ML;1IMG/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

- M.V.I. ADULT
+ AAIPHARMA LLC 200MG/VIAL;0.06MG/VIAL;0.005MG/VI N21625 001 Jan 30, 2004 Jan NEWA
AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V
IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL
;6MG/VIAL;1IMG/VIAL;10MG/VIAL;0.15
MG/VIAL
- + MAYNE PHARMA USA 200MG/VIAL;0.06MG/VIAL;0.005MG/VI N21625 001 Jan 30, 2004 Apr CAHN
AL;15MG/VIAL;0.005MG/VIAL;0.6MG/V
IAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL
;6MG/VIAL;1IMG/VIAL;10MG/VIAL;0.15
MG/VIAL
- M.V.I. ADULT (PHARMACY BULK PACKAGE)
+ AAIPHARMA LLC 200MG/5ML;0.06MG/5ML;0.005MG/5ML; N21643 001 Feb 18, 2004 Feb NEWA
15MG/5ML;0.005MG/5ML;0.6MG/5ML;40
MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;
1IMG/5ML;10MG/5ML;0.15MG/5ML
- + MAYNE PHARMA USA 200MG/5ML;0.06MG/5ML;0.005MG/5ML; N21643 001 Feb 18, 2004 Apr CAHN
15MG/5ML;0.005MG/5ML;0.6MG/5ML;40
MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;
1IMG/5ML;10MG/5ML;0.15MG/5ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

- M.V.I.-12
+ MAYNE PHARMA USA 20MG/ML;0.006MG/ML;0.5UGM/ML;1.5M N08809 005 Apr 22, 2004 May NEWA
G/ML;20
IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0
.36MG/ML;0.6MG/ML;330 UNITS/ML;1
IU/ML

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

- VITAPED
+ HOSPIRA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIA N20176 001 Dec 29, 1993 Aug CAHN
L;400
IU/10ML;0.14MG/VIAL;17MG/VIAL;5MG
/VIAL;0.2MG/10ML;1MG/VIAL;1.4MG/V
IAL;1.2MG/VIAL;EQ 2,300 UNITS
BASE/10ML;7 IU/10ML

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

- CAPSULE; ORAL
SYNALGOS-DC
+ LEITHNER PHARMS 356.4MG;30MG;16MG N11483 004 Sep 06, 1983 Sep CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
 DARVON COMPOUND
 @ AAIPHARMA LLC 389MG;32.4MG;32MG N10996 006 Mar 08, 1983 Jun DISC

ASPIRIN; MEPROBAMATE

TABLET; ORAL
 EQUAGESIC
 + LEITNER PHARMS 325MG;200MG N11702 003 Dec 29, 1983 Sep CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL
 OXYCODONE AND ASPIRIN
 AA MUTUAL PHARM 325MG;4.5MG;0.38MG N40260 001 Jul 17, 1998 Aug CAHN
 AA 325MG;4.5MG;0.38MG N87794 001 May 26, 1982 Aug CAHN

ATENOLOL

TABLET; ORAL
 ATENOLOL
 AB ABLE 25MG N76907 001 Jul 30, 2004 Jul NEWA
 AB 50MG N76907 002 Jul 30, 2004 Jul NEWA
 AB 100MG N76907 003 Jul 30, 2004 Jul NEWA
 AB TEVA 25MG N74056 003 Jul 19, 2004 Jul NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION
 ATRACURIUM BESYLATE
 AP BAXTER HLTHCARE 10MG/ML N74824 001 Sep 30, 1997 Aug CAHN
 AP HOSPIRA 10MG/ML N74632 001 Dec 23, 1996 May CAHN
 ATRACURIUM BESYLATE PRESERVATIVE FREE
 @ BAXTER HLTHCARE 10MG/ML N74825 001 Sep 30, 1997 Aug CAHN
 AP HOSPIRA 10MG/ML N74633 001 Dec 23, 1996 May CAHN
 AP 10MG/ML N74639 001 Mar 25, 1997 May CAHN
 TRACRIUM
 AP + HOSPIRA 10MG/ML N18831 002 Jun 20, 1985 May CAHN
 TRACRIUM PRESERVATIVE FREE
 AP + HOSPIRA 10MG/ML N18831 001 Nov 23, 1983 May CAHN

ATROPINE

INJECTABLE; INJECTION
 ATROPEN
 + MERIDIAN MEDCL TECHN EQ 0.25MG SULFATE/0.3ML N17106 004 Sep 17, 2004 Sep NEWA

ATROPINE SULFATE

INJECTABLE; IM-IV-SC
 ATROPINE SULFATE ANSYR PLASTIC SYRINGE
 HOSPIRA 0.05MG/ML N21146 002 Jul 09, 2001 May CAHN
 + 0.1MG/ML N21146 001 Jul 09, 2001 May CAHN

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
 MOTOFEN
 + VALEANT 0.025MG;1MG N17744 002 May CAHN
 MOTOFEN HALF-STRENGTH
 @ VALEANT 0.025MG;0.5MG N17744 001 May CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
MUTUAL PHARM 0.025MG;2.5MG N85506 001 Aug CAHN

AZACITIDINE

INJECTABLE; SUBCUTANEOUS
VIDAZA 100MG/VIAL N50794 001 May 19, 2004 May NEWA
+ PHARMION

AZATADINE MALEATE

TABLET; ORAL
OPTIMINE 1MG N17601 001 May DISC
SCHERING

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
TRINALIN 1MG;120MG N18506 001 Mar 23, 1982 May DISC
SCHERING

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE SODIUM
+ BEDFORD EQ 100MG BASE/VIAL N74419 001 Mar 31, 1995 May CRLD
IMURAN EQ 100MG BASE/VIAL N17391 001 May DISC
PROMETHEUS LABS

AZITHROMYCIN

CAPSULE; ORAL
ZITHROMAX EQ 250MG BASE N50670 001 Nov 01, 1991 Mar DISC
PFIZER

AZTREONAM

INJECTABLE; INJECTION
AZACTAM
+ BRISTOL MYERS SQUIBB 500MG/VIAL N50580 001 Dec 31, 1986 Jul CMFD
+ 1GM/VIAL N50580 002 Dec 31, 1986 Jul CMFD
+ 2GM/VIAL N50580 003 Dec 31, 1986 Jul CMFD

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN
AT MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG N50416 002 Mar CRLD
BASE/GM;10,000 UNITS/GM
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE
AT + BAUSCH AND LOMB 400 UNITS/GM;1%;EQ 3.5MG N64068 001 Oct 30, 1995 Mar CRLD
BASE/GM;10,000 UNITS/GM

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATE AND BACITRACIN ZINC
AT AKORN 400 UNITS/GM;EQ 3.5MG N65088 001 Feb 06, 2004 Feb NEWA
BASE/GM;10,000 UNITS/GM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
AT + BAUSCH AND LOMB 400 UNITS/GM;EQ 3.5MG N64064 001 Oct 30, 1995 Mar CRLD
BASE/GM;10,000 UNITS/GM

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-14

OINTMENT; OPHTHALMIC
NEOSPORIN

AT MONARCH PHARMS 400 UNITS/GM; EQ 3.5MG
BASE/GM; 10,000 UNITS/GM N50417 001 Mar CRLD

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT + BAUSCH AND LOMB 500 UNITS/GM; 10,000 UNITS/GM N64046 001 Jan 26, 1995 Mar CRLD
POLYSPORIN

AT MONARCH PHARMS 500 UNITS/GM; 10,000 UNITS/GM N61229 001 Mar CRLD

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

VANCERIL

+ SCHERING 0.042MG/INH N17573 001 Jun CTEC

VANCERIL DOUBLE STRENGTH

@ SCHERING 0.084MG/INH N20486 001 Dec 24, 1996 Jun DISC

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ GLAXOSMITHKLINE EQ 0.042MG DIPROP/SPRAY N19389 001 Jul 27, 1987 Jun CTEC

VANCENASE AQ

@ SCHERING EQ 0.042MG DIPROP/SPRAY N19589 001 Dec 23, 1987 Jun DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HCL

AB	ANDRX PHARMS	5MG	N76267 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76267 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76267 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76267 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG	N76402 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76402 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76402 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76402 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG	N76476 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76476 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76476 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76476 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG	N76333 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76333 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76333 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76333 004	Feb 11, 2004	Feb	NEWA
AB	KV PHARM	5MG	N76118 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76118 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76118 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76118 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG	N76430 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76430 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76430 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76430 004	Feb 11, 2004	Feb	NEWA
AB	RANBAXY	5MG	N76344 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76344 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76344 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76344 004	Feb 11, 2004	Feb	NEWA

TABLET; ORAL

BENAZEPRIL HCL

AB	TEVA	5MG	N76211 001	Feb 11, 2004	Feb	NEWA
AB		10MG	N76211 002	Feb 11, 2004	Feb	NEWA
AB		20MG	N76211 003	Feb 11, 2004	Feb	NEWA
AB		40MG	N76211 004	Feb 11, 2004	Feb	NEWA
	LOTENSIN					
AB	NOVARTIS	5MG	N19851 001	Jun 25, 1991	Feb	CFTG
AB		10MG	N19851 002	Jun 25, 1991	Feb	CFTG
AB		20MG	N19851 003	Jun 25, 1991	Feb	CFTG
AB	+	40MG	N19851 004	Jun 25, 1991	Feb	CFTG

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HCL AND HYDROCHLOROTHIAZIDE

AB	ANDRX PHARMS	5MG; 6.25MG	N76342 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76342 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76342 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76342 004	Feb 11, 2004	Feb	NEWA
AB	EON	5MG; 6.25MG	N76631 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76631 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76631 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76631 004	Feb 11, 2004	Feb	NEWA
AB	GENPHARM	5MG; 6.25MG	N76612 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76612 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76612 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76612 004	Feb 11, 2004	Feb	NEWA
AB	IVAX PHARMS	5MG; 6.25MG	N76348 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76348 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76348 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76348 004	Feb 11, 2004	Feb	NEWA
AB	MYLAN	5MG; 6.25MG	N76688 001	Feb 11, 2004	Feb	NEWA
AB		10MG; 12.5MG	N76688 002	Feb 11, 2004	Feb	NEWA
AB		20MG; 12.5MG	N76688 003	Feb 11, 2004	Feb	NEWA
AB		20MG; 25MG	N76688 004	Feb 11, 2004	Feb	NEWA
	LOTENSIN HCT					
AB	NOVARTIS	5MG; 6.25MG	N20033 001	May 19, 1992	Feb	CFTG
AB		10MG; 12.5MG	N20033 002	May 19, 1992	Feb	CFTG
AB		20MG; 12.5MG	N20033 004	May 19, 1992	Feb	CFTG
AB	+	20MG; 25MG	N20033 003	May 19, 1992	Feb	CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	DERMIK LABS	5%; 3%	N50557 001	Oct 26, 1984	Mar	CFTG
AB		ERYTHROMYCIN AND BENZOYL PEROXIDE					
AB		ATRIX	5%; 3%	N65112 001	Mar 29, 2004	Mar	NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ATRIX	EQ 0.05% BASE	N76603 001	Jan 23, 2004	Jan	NEWA	
	OINTMENT, AUGMENTED; TOPICAL						
>AB	AB	BETAMETHASONE DIPROPIONATE TARO	EQ 0.05% BASE	N76753 001	Oct 12, 2004	Oct	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

BRIMONIDINE TARTRATE

AT IVAX PHARMS 0.2% N76372 001 Sep 10, 2004 Sep NEWA

BROMOCRIPTINE MESYLATE

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB MYLAN EQ 2.5MG BASE N76962 001 Sep 24, 2004 Sep NEWA

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP HOSPIRA 0.25MG/ML N74160 001 Oct 30, 1997 May CAHN

AP 0.25MG/ML N74332 001 Oct 31, 1994 May CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HCL

AP HOSPIRA 0.25% N18053 002 May CAHN

AP 0.25% N70583 001 Feb 17, 1987 May CAHN

AP 0.25% N70586 001 Mar 03, 1987 May CAHN

AP 0.25% N70590 001 Feb 17, 1987 May CAHN

AP 0.5% N18053 001 May CAHN

AP 0.5% N70584 001 Feb 17, 1986 May CAHN

AP 0.5% N70597 001 Mar 03, 1987 May CAHN

AP 0.5% N70609 001 Mar 03, 1987 May CAHN

AP 0.75% N18053 003 May CAHN

AP 0.75% N70585 001 Mar 03, 1987 May CAHN

AP 0.75% N70587 001 Mar 03, 1987 May CAHN

BUPIVACAINE HCL KIT

@ HOSPIRA 0.075% N19978 001 Sep 03, 1992 May CAHN

@ 0.114% N19978 002 Sep 03, 1992 May CAHN

@ 0.23% N19978 003 Sep 03, 1992 May CAHN

MARCaine HCL

AP + HOSPIRA 0.25% N16964 001 May CAHN

AP + 0.5% N16964 006 May CAHN

MARCaine HCL PRESERVATIVE FREE

AP + HOSPIRA 0.25% N16964 012 May CAHN

AP + 0.5% N16964 005 May CAHN

AP + 0.75% N16964 009 May CAHN

INJECTABLE; SPINAL

BUPIVACAINE

AP HOSPIRA 0.75% N71810 001 Dec 11, 1987 May CAHN

MARCaine

AP + HOSPIRA 0.75% N18692 001 May 04, 1984 May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE

+ HOSPIRA 0.25%;0.005MG/ML N71165 001 Jun 16, 1988 May CAHN

0.25%;0.005MG/ML N71166 001 Jun 16, 1988 May CAHN

0.25%;0.005MG/ML N71167 001 Jun 16, 1988 May CAHN

+ 0.5%;0.005MG/ML N71168 001 Jun 16, 1988 May CAHN

0.5%;0.005MG/ML N71169 001 Jun 16, 1988 May CAHN

0.5%;0.005MG/ML N71170 001 Jun 16, 1988 May CAHN

INJECTABLE; INJECTION

BUPIVACAINE HCL AND EPINEPHRINE
+ HOSPIRA 0.75%;0.005MG/ML

N71171 001 Jun 16, 1988 May CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATEINJECTABLE; INJECTION

MARCAINE HCL W/ EPINEPHRINE

AP +	HOSPIRA	0.25%;0.0091MG/ML	N16964 004	May CAHN
AP +		0.5%;0.0091MG/ML	N16964 008	May CAHN
MARCAINE HCL W/ EPINEPHRINE PRESERVATIVE FREE				
AP +	HOSPIRA	0.25%;0.0091MG/ML	N16964 013	May CAHN
AP +		0.5%;0.0091MG/ML	N16964 007	May CAHN
AP +		0.75%;0.0091MG/ML	N16964 010	May CAHN

BUPRENORPHINE HYDROCHLORIDEINJECTABLE; INJECTION

BUPRENORPHINE HCL

AP	HOSPIRA	EQ 0.3MG BASE/ML	N74137 001 Jun 03, 1996 May CAHN
----	---------	------------------	----------------------------------

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL

BUPROPION HCL

AB1	EON	100MG	N75932 001 Nov 25, 2003 May CFTG
AB		150MG	N75932 002 Mar 22, 2004 Mar NEWA
AB1		150MG	N75932 002 Mar 22, 2004 May CTEC
AB	IMPAK LABS	100MG	N75913 001 Jan 28, 2004 Jan NEWA
AB1		100MG	N75913 001 Jan 28, 2004 May CTEC
AB1		150MG	N75913 002 Mar 22, 2004 May CTEC
AB		150MG	N75913 002 Mar 22, 2004 Mar NEWA
AB2		150MG	N75914 001 May 27, 2004 May NEWA
WELLBUTRIN SR			
AB1	GLAXOSMITHKLINE	100MG	N20358 002 Oct 04, 1996 May CTEC
AB	+	150MG	N20358 003 Oct 04, 1996 May CTEC
AB	+	150MG	N20358 003 Oct 04, 1996 Mar CFTG
AB1	+	150MG	N20358 003 Oct 04, 1996 Jun CTEC
ZYBAN			
AB	+	150MG	N20711 003 May 14, 1997 May CFTG
AB2	+	150MG	N20711 003 May 14, 1997 Jun CTEC

BUSPIRONE HYDROCHLORIDETABLET; ORAL

BUSPIRONE HCL

AB	TEVA	30MG	N75022 004 Mar 25, 2004 Mar NEWA
----	------	------	----------------------------------

BUTORPHANOL TARTRATEINJECTABLE; INJECTION

BUTORPHANOL TARTRATE

AP	HOSPIRA	1MG/ML	N75559 001 Mar 20, 2000 May CAHN
AP		2MG/ML	N75559 002 Mar 20, 2000 May CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE			
AP	HOSPIRA	1MG/ML	N74620 001 Jan 22, 1997 May CAHN
AP		1MG/ML	N74626 001 Jan 23, 1997 May CAHN
AP		2MG/ML	N74620 002 Jan 22, 1997 May CAHN
AP		2MG/ML	N74626 002 Jan 23, 1997 May CAHN

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS, ORAL
CAF'CIT
+ MEAD JOHNSON EQ 30MG BASE/3ML (EQ 10MG
BASE/ML) N20793 001 Sep 21, 1999 Sep CPOT

SOLUTION; ORAL
CAF'CIT
+ MEAD JOHNSON EQ 30MG BASE/3ML (EQ 10MG
BASE/ML) N20793 002 Apr 12, 2000 Sep NEWA

CAFFEINE/ ERGOTAMINE TARTRATE

	TABLET; ORAL		
>>> AB	ERCATAB	N84294 001	Oct CTEC
	+ SANDOZ	100MG;1MG	
>>> AA		N84294 001	Oct CTEC
		100MG;1MG	
AB		N84294 001	Sep CFTG
		100MG;1MG	
>>> AB	ERGOTAMINE TARTRATE AND CAFFEINE	N40510 001	Sep 17, 2004 Oct CTEC
	WEST WARD	100MG;1MG	
>>> AA		N40510 001	Sep 17, 2004 Oct CTEC
		100MG;1MG	
AB		N40510 001	Sep 17, 2004 Sep NEWA
		100MG;1MG	

CALCITRIOL

INJECTABLE; INJECTION
CALCITRIOL
AP MAYNE PHARMA USA 0.001MG/ML N75816 001 Jan 16, 2004 Jan NEWA
AP 0.002MG/ML N75816 002 Jan 16, 2004 Jan NEWA

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER
+ HOSPIRA 100MG/ML N21117 001 Jan 28, 2000 May CAHN

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER
AP HOSPIRA 33MG/100ML;5GM/100ML;30MG/100ML;8 N18254 001 May CAHN
60MG/100ML

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM LACTATE

	INJECTABLE; INJECTION		
AP	DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER HOSPIRA 20MG/100ML;5GM/100ML;30MG/100ML;6 N17608 001		May CAHN
	00MG/100ML;310MG/100ML		
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ HOSPIRA 20MG/100ML;5GM/100ML;104MG/100ML; N19685 005 Oct 17, 1988 May CAHN		
	600MG/100ML;310MG/100ML		
	@ 20MG/100ML;5GM/100ML;179MG/100ML; N19685 006 Oct 17, 1988 May CAHN		
	600MG/100ML;310MG/100ML		
	POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; N19685 007 Oct 17, 1988 May CAHN		
	600MG/100ML;310MG/100ML		
	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER AP HOSPIRA 20MG/100ML;5GM/100ML;179MG/100ML; N19685 002 Oct 17, 1988 May CAHN		
	600MG/100ML;310MG/100ML		
	20MG/100ML;5GM/100ML;328MG/100ML; N19685 008 Oct 17, 1988 May CAHN		
	600MG/100ML;310MG/100ML		
	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER @ HOSPIRA 20MG/100ML;5GM/100ML;254MG/100ML; N19685 003 Oct 17, 1988 May CAHN		
	600MG/100ML;310MG/100ML		

CARBIDOPA; LEVODOPATABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

AB	IMPAK LABS	25MG;100MG	N76521 001	May 14, 2004	May	NEWA
AB		50MG;200MG	N76521 002	May 14, 2004	May	NEWA
AB	KV PHARM	50MG;200MG	N76663 001	Jun 24, 2004	Jun	NEWA
AB	TORPHARM	25MG;100MG	N76212 001	Jun 16, 2004	Jun	NEWA
AB		50MG;200MG	N76212 002	Jun 16, 2004	Jun	NEWA
TABLET, ORALLY DISINTEGRATING; ORAL						
PARCOPA						
	SCHWARZ PHARMA	10MG;100MG	N76699 001	Aug 27, 2004	Aug	NEWA
		25MG;100MG	N76699 002	Aug 27, 2004	Aug	NEWA
+		25MG;250MG	N76699 003	Aug 27, 2004	Aug	NEWA

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

>A>	AP	AM PHARM PARTNERS	50MG/VIAL	N76235 001	Oct 14, 2004	Oct	NEWA
>A>	AP		150MG/VIAL	N76235 002	Oct 14, 2004	Oct	NEWA
>A>	AP		450MG/VIAL	N76235 003	Oct 14, 2004	Oct	NEWA
>A>	AP	BEDFORD	50MG/VIAL	N76099 001	Oct 14, 2004	Oct	NEWA
>A>	AP		150MG/VIAL	N76099 002	Oct 14, 2004	Oct	NEWA
>A>	AP		450MG/VIAL	N76099 003	Oct 14, 2004	Oct	NEWA
>A>	AP	MAYNE PHARMA USA	50MG/VIAL	N76473 001	Oct 27, 2004	Oct	NEWA
>A>	AP		150MG/VIAL	N76473 002	Oct 27, 2004	Oct	NEWA
>A>	AP		450MG/VIAL	N76473 003	Oct 27, 2004	Oct	NEWA
>A>	AP	PHARMACHEMIE	50MG/VIAL	N76162 001	Oct 14, 2004	Oct	NEWA
>A>	AP		150MG/VIAL	N76162 002	Oct 14, 2004	Oct	NEWA
>A>	AP		450MG/VIAL	N76162 003	Oct 14, 2004	Oct	NEWA
PARAPLATIN							
>D>	+	BRISTOL MYERS SQUIBB	50MG/VIAL	N19880 001	Mar 03, 1989	Oct	CFTG
>A>	AP	+	50MG/VIAL	N19880 001	Mar 03, 1989	Oct	CFTG
>D>	+		150MG/VIAL	N19880 002	Mar 03, 1989	Oct	CFTG
>A>	AP	+	150MG/VIAL	N19880 002	Mar 03, 1989	Oct	CFTG
>D>	+		450MG/VIAL	N19880 003	Mar 03, 1989	Oct	CFTG
>A>	AP	+	450MG/VIAL	N19880 003	Mar 03, 1989	Oct	CFTG

INJECTABLE; IV (INFUSION)

CARBOPLATIN

>A>	AP	AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001	Oct 21, 2004	Oct	NEWA
>A>	AP		EQ 150MG/15ML (10MG/ML)	N77247 002	Oct 21, 2004	Oct	NEWA
>A>	AP		EQ 450MG/45ML (10MG/ML)	N77247 003	Oct 21, 2004	Oct	NEWA
>A>	AP	BEDFORD LABS	EQ 50MG/5ML (10MG/ML)	N77244 001	Oct 15, 2004	Oct	NEWA
>A>	AP		EQ 150MG/15ML (10MG/ML)	N77244 002	Oct 15, 2004	Oct	NEWA
>A>	AP		EQ 450MG/45ML (10MG/ML)	N77244 003	Oct 15, 2004	Oct	NEWA
>A>	AP	MAYNE PHARMA USA	EQ 50MG/5ML (10MG/ML)	N76517 001	Oct 14, 2004	Oct	NEWA
>A>	AP		EQ 150MG/15ML (10MG/ML)	N76517 002	Oct 14, 2004	Oct	NEWA
>A>	AP		EQ 450MG/45ML (10MG/ML)	N76517 003	Oct 14, 2004	Oct	NEWA
>A>	AP	PHARMACHEMIE	EQ 50MG/5ML (10MG/ML)	N77269 001	Oct 14, 2004	Oct	NEWA
>A>	AP		EQ 150MG/15ML (10MG/ML)	N77269 002	Oct 14, 2004	Oct	NEWA
>A>	AP		EQ 450MG/45ML (10MG/ML)	N77269 003	Oct 14, 2004	Oct	NEWA

PARAPLATIN

>D>	+	BRISTOL MYERS SQUIBB	EQ 50MG /5ML(10MG/ML)	N20452 001	Jul 14, 2003	Oct	CFTG
>A>	AP	+	EQ 50MG /5ML(10MG/ML)	N20452 001	Jul 14, 2003	Oct	CFTG
>D>	+		EQ 150MG /15ML(10MG/ML)	N20452 002	Jul 14, 2003	Oct	CFTG
>A>	AP	+	EQ 150MG /15ML(10MG/ML)	N20452 002	Jul 14, 2003	Oct	CFTG
>D>	+		EQ 450MG /45ML(10MG/ML)	N20452 003	Jul 14, 2003	Oct	CFTG

INJECTABLE; IV (INFUSION)

PARAPLATIN

>A> AP + BRISTOL MYERS SQUIBB EQ 450MG /45ML(10MG/ML)
 + EQ 600MG /60ML(10MG/ML)

N20452 003 Jul 14, 2003 Oct CFTG
 N20452 004 Jan 15, 2004 Jan NEWA

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

@ ABBOTT

@

2.5MG

5MG

N19204 001 Dec 28, 1988 Jun DISC
 N19204 002 Dec 28, 1988 Jun DISC

CEFACLOR

CAPSULE; ORAL

CEFACLOR

AB CARLSBAD EQ 250MG BASE
 AB EQ 500MG BASE

N65146 001 Jan 22, 2004 Jan NEWA
 N65146 002 Jan 22, 2004 Jan NEWA

FOR SUSPENSION; ORAL

CECLOR

AB CEPH INTL EQ 125MG BASE/5ML
 AB EQ 187MG BASE/5ML
 AB EQ 250MG BASE/5ML
 AB + EQ 375MG BASE/5ML

N62206 001 May CAHN
 N62206 003 Apr 20, 1988 May CAHN
 N62206 002 May CAHN
 N62206 004 Apr 20, 1988 May CAHN

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

@ LILLY

EQ 500MG BASE

N50673 002 Jun 28, 1996 Jun DISC

CEFACLOR

AB + IVAX PHARMS EQ 500MG BASE

N65057 001 Jan 05, 2001 Jun CRLD

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

@ LILLY

EQ 1GM BASE/VIAL

N50504 002 Jul DISC
 N50504 003 Jul DISC

@

EQ 2GM BASE/VIAL

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

>D> AP + GLAXOSMITHKLINE EQ 500MG BASE/VIAL
 >A> @ EQ 500MG BASE/VIAL
 >D> AP + EQ 5GM BASE/VIAL
 >A> @ EQ 5GM BASE/VIAL

N50461 002 Oct DISC
 N50461 002 Oct DISC
 N50461 004 Oct DISC
 N50461 004 Oct DISC

CEFAZOLIN SODIUM

>A> AP HIKMA FARMACEUTICA EQ 10GM BASE/VIAL
 @ MARSAM PHARMS LLC EQ 250MG BASE/VIAL
 @ EQ 500MG BASE/VIAL
 @ EQ 1GM BASE/VIAL
 @ EQ 5GM BASE/VIAL
 @ EQ 10GM BASE/VIAL
 @ EQ 20GM BASE/VIAL

N65143 001 Oct 18, 2004 Oct NEWA
 N62988 001 Dec 29, 1989 Jun DISC
 N62988 002 Dec 29, 1989 Jun DISC
 N62988 003 Dec 29, 1989 Jun DISC
 N62989 001 Dec 29, 1989 Jun DISC
 N62989 002 Dec 29, 1989 Jun DISC
 N62989 003 Dec 29, 1989 Jun DISC

KEFZOL

@ LILLY

EQ 250MG BASE/VIAL

N61773 001 Jun DISC
 N61773 002 Jun DISC
 N61773 003 Jun DISC
 N61773 004 Jun DISC
 N61773 005 Sep 08, 1987 Jun DISC

@

EQ 500MG BASE/VIAL

@

EQ 1GM BASE/VIAL

@

EQ 10GM BASE/VIAL

@

EQ 20GM BASE/VIAL

CEFDINIR

FOR SUSPENSION; ORAL

OMNICEF

ABBOTT

125MG/5ML

250MG/5ML

N50749 001 Dec 04, 1997 Jul CRLD

N50749 002 Jul 29, 2004 Jul NEWA

+

CEFIXIME

SUSPENSION; ORAL

SUPRAX

+ LUPIN

100MG/5ML

N65129 001 Feb 23, 2004 Feb NEWA

TABLET; ORAL

SUPRAX

+ LUPIN

400MG

N65130 001 Feb 12, 2004 Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

+ B BRAUN EQ 2GM BASE

N50792 001 Jul 29, 2004 Jul NEWA

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

+ B BRAUN EQ 1GM BASE

N50792 002 Jul 29, 2004 Jul NEWA

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP ACS DOBFAR

500MG/VIAL

N62640 001 Nov 20, 1985 Apr CTNA

AP 1GM/VIAL

N62640 002 Nov 20, 1985 Apr CTNA

AP 2GM/VIAL

N62640 003 Nov 20, 1985 Apr CTNA

TAZICEF

AP HOSPIRA

500MG/VIAL

N62662 001 Mar 06, 1986 May CAHN

AP 1GM/VIAL

N62662 002 Mar 06, 1986 May CAHN

AP 1GM/VIAL

N64032 001 Oct 31, 1993 May CAHN

AP 2GM/VIAL

N62662 003 Mar 06, 1986 May CAHN

AP 2GM/VIAL

N64032 002 Oct 31, 1993 May CAHN

AP 6GM/VIAL

N62662 004 Mar 06, 1986 May CAHN

TAZIDIME

@ LILLY

1GM/VIAL

N62655 001 Nov 20, 1985 Apr DISC

@ 2GM/VIAL

N62655 002 Nov 20, 1985 Apr DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ SHIONOGI

EQ 400MG BASE

N50685 002 Dec 20, 1995 Sep CAHN

FOR SUSPENSION; ORAL

CEDAX

SHIONOGI

EQ 90MG BASE/5ML

N50686 001 Dec 20, 1995 Sep CAHN

+

EQ 180MG BASE/5ML

N50686 002 Dec 20, 1995 Sep CAHN

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB SANDOZ

EQ 250MG BASE

N65126 001 Oct 28, 2003 Aug CAHN

AB

EQ 500MG BASE

N65126 002 Oct 28, 2003 Aug CAHN

>AB AB TEVA

EQ 250MG BASE

N65190 001 Oct 18, 2004 Oct NEWA

>AB AB

EQ 500MG BASE

N65190 002 Oct 18, 2004 Oct NEWA

CEFUXIME SODIUM

INJECTABLE; IM-IV

CEFUXIME

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	N65048 001 Jan 09, 2004 Jan NEWA
	KEFUROX		
	@ LILLY	EQ 750MG BASE/VIAL	N62591 001 Jan 10, 1986 Jun DISC
	INJECTABLE; INJECTION		
	CEFUXIME		
AP	HIKMA FARMACEUTICA	EQ 1.5GM BASE/VIAL	N65048 002 Jan 09, 2004 Jan NEWA
AP		EQ 7.5GM BASE/VIAL	N65046 001 Jan 09, 2004 Jan NEWA
	KEFUROX		
	@ LILLY	EQ 1.5GM BASE/VIAL	N62591 002 Jan 10, 1986 Jun DISC
	@	EQ 1.5GM BASE/VIAL	N62592 002 Jan 10, 1986 Jun DISC
	@	EQ 7.5GM BASE/VIAL	N62591 003 Dec 17, 1987 Jun DISC
	INJECTABLE; INTRAVENOUS		
	KEFUROX		
	@ LILLY	EQ 750MG BASE/VIAL	N62592 001 Jan 10, 1986 Jun DISC

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

@ MISSION PHARMA

300GM/BOT

N18757 003 Oct 16, 1984 Sep DISC

CEPHALEXIN

CAPSULE; ORAL

KEFLEX

AB	ADVANCIS PHARM	EQ 250MG BASE	N50405 002
AB	+	EQ 500MG BASE	N50405 003

Jun CAHN

Jun CAHN

FOR SUSPENSION; ORAL

KEFLEX

@ ADVANCIS PHARM

EQ 100MG BASE/ML

N50406 003

Jun CAHN

@

EQ 125MG BASE/5ML

N50406 001

Jun CAHN

@

EQ 250MG BASE/5ML

N50406 002

Jun CAHN

TABLET; ORAL

KEFLET

@ LILLY

EQ 250MG BASE

N50440 003 Feb 26, 1987 Jun DISC

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

@ LILLY

EQ 500MG BASE

N50614 002 Oct 29, 1987 Jul DISC

CETIRIZINE HYDROCHLORIDE

TABLET, CHEWABLE; ORAL

ZYRTEC

PFIZER

5MG

N21621 001 Mar 16, 2004 Mar NEWA

+

10MG

N21621 002 Mar 16, 2004 Mar NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

EVOXAC

+ DAIICHI

EQ 30MG BASE

N20989 002 Jan 11, 2000 Jun CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION
 LIBRIUM
 @ VALEANT PHARM INTL 100MG/AMP N12301 001 Jun DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
 CHLORHEXIDINE GLUCONATE
 AT MORTON GROVE 0.12% N75006 001 Mar 03, 2004 Mar NEWA

CHLOROPROCaine HYDROCHLORIDE

INJECTABLE; INJECTION
 CHLOROPROCaine HCL
 AP HOSPIRA 2% N87447 001 Apr 16, 1982 May CAHN
 AP 3% N87446 001 Apr 16, 1982 May CAHN
 AP NESACaine ASTRazeneca 2% N09435 002 Jun CTEC

CHLOROTHIAZIDE

SUSPENSION; ORAL
 DIURIL
 @ MERCK 250MG/5ML N11870 001 Sep DISC
 TABLET; ORAL
 CHLOROTHIAZIDE
 AB + MYLAN 250MG N84388 001 Sep CRLD
 DIURIL
 @ MERCK 250MG N11145 004 Sep DISC
 @ 500MG N11145 002 Sep DISC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
 CHLORPHENIRAMINE MALEATE
 @ MUTUAL PHARM 4MG N80700 001 Aug CAHN

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL
 CODEPREX
 + CELLTECH PHARMS EQ 4MG MALEATE/5ML;EQ 20MG
 BASE/5ML N21369 001 Jun 21, 2004 Jun NEWA

CHLORTHALIDONE

TABLET; ORAL
 CHLORTHALIDONE
 @ MUTUAL PHARM 25MG N87292 001 Aug CAHN
 @ 50MG N87293 001 Aug CAHN

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION
 OVIDREL
 @ SERONO INC 0.25MG/VIAL N21149 001 Sep 20, 2000 May DISC
 INJECTABLE; SUBCUTANEOUS
 OVIDREL
 + SERONO INC EQ 0.25MG /0.5ML N21149 002 Oct 06, 2003 Apr CPOT

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER
+ HOSPIRA EQ 0.004MG CHROMIUM/ML

N18961 001 Jun 26, 1986 May CAHN

CICLOPIROX

SUSPENSION; TOPICAL

CICLOPIROX				
AB ALTANA	0.77%			N76422 001 Aug 06, 2004 Aug NEWA
LOPROX				
AT + MEDICIS	0.77%			N19824 001 Dec 30, 1988 Aug CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HCL				
AP HOSPIRA	EQ 300MG BASE/2ML			N74296 001 Mar 28, 1997 May CAHN
AP	EQ 300MG BASE/2ML			N74344 001 Jan 31, 1995 May CAHN
AP	EQ 300MG BASE/2ML			N74345 001 Jan 31, 1995 May CAHN
AP	EQ 300MG BASE/2ML			N74412 001 Mar 28, 1997 May CAHN
AP	EQ 300MG BASE/2ML			N74422 001 Jan 31, 1995 May CAHN
CIMETIDINE HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP HOSPIRA	EQ 6MG BASE/ML			N74269 001 Dec 27, 1994 May CAHN
+	EQ 90MG BASE/100ML			N74468 005 Dec 29, 1994 May CAHN
+	EQ 120MG BASE/100ML			N74468 006 Dec 29, 1994 May CAHN
+	EQ 180MG BASE/100ML			N74468 003 Dec 29, 1994 May CAHN
+	EQ 240MG BASE/100ML			N74468 004 Dec 29, 1994 May CAHN
+	EQ 360MG BASE/100ML			N74468 001 Dec 29, 1994 May CAHN
+	EQ 480MG BASE/100ML			N74468 002 Dec 29, 1994 May CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR				
AMGEN	EQ 30MG BASE			N21688 001 Mar 08, 2004 Mar NEWA
	EQ 60MG BASE			N21688 002 Mar 08, 2004 Mar NEWA
+	EQ 90MG BASE			N21688 003 Mar 08, 2004 Mar NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CILOXAN				
AT + ALCON	EQ 0.3% BASE			N19992 001 Dec 31, 1990 Sep CFTG
CIPROFLOXACIN				
AT BAUSCH AND LOMB	EQ 0.3% BASE			N76754 001 Jun 09, 2004 Jun NEWA
AT NOVEX	EQ 0.3% BASE			N75928 001 Jun 09, 2004 Jun NEWA

TABLET; ORAL

CIPRO				
AB BAYER PHARMS	EQ 100MG BASE			N19537 001 Apr 08, 1996 Jun CFTG
AB	EQ 250MG BASE			N19537 002 Oct 22, 1987 Jun CFTG
AB	EQ 500MG BASE			N19537 003 Oct 22, 1987 Jun CFTG
AB +	EQ 750MG BASE			N19537 004 Oct 22, 1987 Jun CFTG
CIPROFLOXACIN				
AB BARR	EQ 250MG BASE			N74124 001 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE			N74124 002 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE			N74124 003 Jun 09, 2004 Jun NEWA
AB COBALT	EQ 250MG BASE			N76794 002 Jun 09, 2004 Jun NEWA
AB	EQ 500MG BASE			N76794 003 Jun 09, 2004 Jun NEWA
AB	EQ 750MG BASE			N76794 004 Jun 09, 2004 Jun NEWA

TABLET; ORAL

CIPROFLOXACIN

DR REDDYS LABS LTD

EQ 100MG BASE

N75593 002 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N75593 003 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N75593 004 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N75593 001 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N76593 002 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N76593 003 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N76593 004 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N75817 002 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N75817 003 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N75817 004 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N76558 002 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N76558 003 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N76558 004 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N76089 002 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N76089 003 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N76089 004 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N76138 001 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N76138 002 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N76138 003 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N75685 002 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N75685 003 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N75685 001 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N75747 001 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N75747 002 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N75747 003 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N75939 002 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N75939 003 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N75939 004 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N76912 002 Oct 06, 2004 Oct NEWA

EQ 500MG BASE

N76912 003 Oct 06, 2004 Oct NEWA

EQ 750MG BASE

N76912 004 Oct 06, 2004 Oct NEWA

EQ 250MG BASE

N76136 001 Jun 09, 2004 Jun NEWA

EQ 500MG BASE

N76136 002 Jun 09, 2004 Jun NEWA

EQ 750MG BASE

N76136 003 Jun 09, 2004 Jun NEWA

EQ 250MG BASE

N76639 001 Sep 10, 2004 Sep NEWA

EQ 500MG BASE

N76639 002 Sep 10, 2004 Sep NEWA

EQ 750MG BASE

N76639 003 Sep 10, 2004 Sep NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

+ BAYER PHARMS

425.2MG; EQ 574.9MG BASE

N21473 002 Aug 28, 2003 Feb CDFR

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CELEXA

FOREST LABS

EQ 10MG BASE

N20822 001 Apr 27, 2000 Oct CFTG

EQ 10MG BASE

N20822 001 Apr 27, 2000 Oct CFTG

EQ 20MG BASE

N20822 002 Jul 17, 1998 Oct CFTG

EQ 20MG BASE

N20822 002 Jul 17, 1998 Oct CFTG

EQ 40MG BASE

N20822 003 Jul 17, 1998 Oct CFTG

EQ 40MG BASE

N20822 003 Jul 17, 1998 Oct CFTG

CITALOPRAM HYDROBROMIDE

AUROBINDO

EQ 10MG BASE

N77031 001 Oct 28, 2004 Oct NEWA

EQ 20MG BASE

N77031 002 Oct 28, 2004 Oct NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-28

TABLET; ORAL

>A>	CITALOPRAM HYDROBROMIDE					
>A> AB	AUROBINDO	EQ 40MG BASE	N77031	003	Oct 28, 2004	Oct NEWA
>A> AB	COREPHARMA	EQ 10MG BASE	N77036	001	Oct 28, 2004	Oct NEWA
>A> AB		EQ 20MG BASE	N77036	002	Oct 28, 2004	Oct NEWA
>A> AB		EQ 40MG BASE	N77036	003	Oct 28, 2004	Oct NEWA
>A> AB	DR REDDYS LABS LTD	EQ 10MG BASE	N77038	001	Oct 28, 2004	Oct NEWA
>A> AB		EQ 20MG BASE	N77038	002	Oct 28, 2004	Oct NEWA
>A> AB		EQ 40MG BASE	N77038	003	Oct 28, 2004	Oct NEWA
>A> AB	EON	EQ 10MG BASE	N77035	001	Oct 28, 2004	Oct NEWA
>A> AB		EQ 20MG BASE	N77035	002	Oct 28, 2004	Oct NEWA
>A> AB		EQ 40MG BASE	N77035	003	Oct 28, 2004	Oct NEWA
>A> AB	PUREPAC PHARM	EQ 10MG BASE	N77033	001	Oct 28, 2004	Oct NEWA
>A> AB		EQ 20MG BASE	N77033	002	Oct 28, 2004	Oct NEWA
>A> AB		EQ 40MG BASE	N77033	003	Oct 28, 2004	Oct NEWA

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATESOLUTION; IRRIGATIONUROLOGIC G IN PLASTIC CONTAINER

AT	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N16904	001	May 27, 1983	May CAHN
----	---------	--------------------------------------	--------	-----	--------------	----------

CLADRIBINEINJECTABLE; INJECTIONCLADRIBINE

AP	AM PHARM	1MG/ML	N76571	001	Apr 22, 2004	Apr NEWA
----	----------	--------	--------	-----	--------------	----------

CLARITHROMYCINTABLET, EXTENDED RELEASE; ORALBIAXIN XL

AB	+ ABBOTT	500MG	N50775	001	Mar 03, 2000	Jun CFTG
----	----------	-------	--------	-----	--------------	----------

AB	ANDRX PHARMS	500MG	N65145	001	Jun 24, 2004	Jun NEWA
----	--------------	-------	--------	-----	--------------	----------

TABLET; ORALBIAXIN

AB	+ ABBOTT	250MG	N50662	001	Oct 31, 1991	May CFTG
----	----------	-------	--------	-----	--------------	----------

AB	+ ABBOTT	500MG	N50662	002	Oct 31, 1991	May CFTG
----	----------	-------	--------	-----	--------------	----------

CLARITHROMYCIN

AB	RANBAXY	250MG	N65174	001	Sep 24, 2004	Sep NEWA
----	---------	-------	--------	-----	--------------	----------

AB		500MG	N65174	002	Sep 24, 2004	Sep NEWA
----	--	-------	--------	-----	--------------	----------

AB	ROXANE	250MG	N65178	002	May 25, 2004	May NEWA
----	--------	-------	--------	-----	--------------	----------

AB		500MG	N65178	001	May 25, 2004	May NEWA
----	--	-------	--------	-----	--------------	----------

CLEMASTINE FUMARATETABLET; ORALCLEMASTINE FUMARATE

AB	+ TEVA	2.68MG	N73283	001	Jan 31, 1992	Mar CRLD
----	--------	--------	--------	-----	--------------	----------

AB	TAVIST	2.68MG	N17661	001		Mar DISC
----	--------	--------	--------	-----	--	----------

@ NOVARTISCLINDAMYCIN HYDROCHLORIDECAPSULE; ORALCLINDAMYCIN HCL

AB	COREPHARMA	EQ 150MG BASE	N65194	001	Mar 22, 2004	Mar NEWA
----	------------	---------------	--------	-----	--------------	----------

AB		EQ 300MG BASE	N65194	002	Mar 22, 2004	Mar NEWA
----	--	---------------	--------	-----	--------------	----------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL
CLEOCIN
+ PHARMACIA AND UPJOHN EQ 75MG BASE/5ML

N62644 001 Apr 07, 1986 May CRLD

CLINDAMYCIN PHOSPHATE

AEROSOL; TOPICAL
EVOCLIN FOAM
+ CONNETICS 1%
INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE
BAXTER HLTHCARE EQ 150MG BASE/ML
AP BEDFORD EQ 150MG BASE/ML
AP HOSPIRA EQ 150MG BASE/ML
AP # EQ 150MG BASE/ML

N50801 001 Oct 22, 2004 Oct NEWA
N62953 001 Apr 21, 1988 Aug CAHN
N65206 001 Sep 24, 2004 Sep NEWA
N62800 001 Jul 24, 1987 May CAHN
N62801 001 Jul 24, 1987 May CAHN
N62943 001 Sep 29, 1988 May CAHN

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE
AT TARO PHARM IND'S EQ 1% BASE

N65184 001 Mar 31, 2004 Mar NEWA

CLOBETASOL PROPIONATE

SHAMPOO; TOPICAL
CLODEX
+ GALDERMA LABS 0.05%

N21644 001 Feb 05, 2004 Feb NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DURACLON
AAIPHARMA 0.1MG/ML
+ 0.5MG/ML
TABLET; ORAL
CLONIDINE HCL
AB MUTUAL PHARM 0.1MG
0.2MG
@ 0.3MG

N20615 001 Oct 02, 1996 Jun CRLD
N20615 002 Apr 27, 1999 Jun NEWA
N70925 001 Sep 04, 1987 Aug CAHN
N70924 001 Sep 04, 1987 Aug CAHN
N70923 001 Sep 04, 1987 Aug CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM
SANDOZ 7.5MG
TABLET; ORAL
CLORAZEPATE DIPOTASSIUM
AB RANBAXY 3.75MG
AB 7.5MG
AB 15MG

N72220 001 Aug 26, 1988 Aug DISC
N76911 001 Sep 29, 2004 Sep NEWA
N76911 002 Sep 29, 2004 Sep NEWA
N76911 003 Sep 29, 2004 Sep NEWA

CLOTIMAZOLE

TROCHE/LOZENGE; ORAL
CLOTIMAZOLE
AB ROXANE 10MG
MYCELEX
AB + BAYER PHARMS 10MG

N76387 001 Jul 29, 2004 Jul NEWA
N18713 001 Jun 17, 1983 Jul CFTG

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO						
ALAMO PHARMS	25MG			N21590	001	Feb 10, 2004 Feb NEWA
+	100MG			N21590	002	Feb 10, 2004 Feb NEWA
FAZACLO ODT						
ALAMO PHARMS	25MG			N21590	001	Feb 10, 2004 Jul CTNA
+	100MG			N21590	002	Feb 10, 2004 Jul CTNA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE						
AP	PADDOK	EQ 150MG BASE/VIAL		N65177	001	Mar 19, 2004 Mar NEWA

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL						
+	KING PHARMS	0.8MG/INH		N18887	001	Dec 05, 1985 Jan CAHN
SOLUTION; INHALATION						
INTAL						
AN	+	KING PHARMS	10MG/ML	N18596	001	May 28, 1982 Jan CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.4MG COPPER/ML		N18960	001	Jun 26, 1986 May CAHN
---	---------	--------------------	--	--------	-----	-----------------------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	BIONICHE ANIM HLTH	1MG/ML		N40451	001	Sep 23, 2003 Apr CAHN
AP	BIONICHE PHARMA	1MG/ML		N40451	001	Sep 23, 2003 Sep CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB	MUTUAL PHARM	10MG		N73541	001	May 23, 1995 Aug CAHN
----	--------------	------	--	--------	-----	-----------------------

CYCLOSPORINE

SOLUTION; ORAL

CYCLOSPORINE

AB1	ABBOTT	100MG/ML		N65025	001	Mar 03, 2000 Sep CTEC
AB2	MORTON GROVE	100MG/ML		N65133	001	Sep 17, 2004 Sep NEWA
AB1	PLIVA	100MG/ML		N65054	001	Dec 18, 2001 Sep CTEC
	NEORAL					
AB1	+	NOVARTIS	100MG/ML	N50716	001	Jul 14, 1995 Sep CTEC
	SANDIMMUNE					
AB2	+	NOVARTIS	100MG/ML	N50574	001	Nov 14, 1983 Sep CFTG

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HCL

+	ALPHARMA	2MG/5ML		N86833	001	Aug CRLD
	PERIACTIN					
	@ MERCK	2MG/5ML		N13220	002	Aug DISC

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HCL

@ HOSPIRA

7.25%

N19523 001 Oct 22, 1986 Aug CAHN

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AM PHARM

100MG/ML

N76512 001 Jan 15, 2004 Jan NEWA

AP + MAYNE PHARMA USA

100MG/ML

N75383 001 Nov 22, 1999 Jan CFTG

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HCL

BIGMAR BIOPEN PHARMS

EQ 20MG BASE/VIAL

N65000 001 May 25, 1999 Jul CAHN

AP

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

ABBOTT

500MG/VIAL

N76019 001 Mar 17, 2004 Mar NEWA

HOSPIRA

2GM/VIAL

N76019 002 Mar 17, 2004 Mar NEWA

AP

500MG/VIAL

N76019 001 Mar 17, 2004 May CAHN

DESFERAL

2GM/VIAL

N76019 002 Mar 17, 2004 May CAHN

AP + NOVARTIS

500MG/VIAL

N16267 001 Mar CFTG

AP +

2GM/VIAL

N16267 002 May 25, 2000 Mar CFTG

DEMECTOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

ESP PHARMA

150MG

N50261 002 Mar CFTG

AB +

300MG

N50261 003 Mar CFTG

DEMECLOCYCLINE HCL

IMPAK LABS

150MG

N65094 001 Mar 22, 2004 Mar NEWA

AB

300MG

N65094 002 Mar 22, 2004 Mar NEWA

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

@ ABBOTT

0.25MG;5MG

N12775 001 Jun DISC

ENDURONYL FORTE

@ ABBOTT

0.5MG;5MG

N12775 002 Jun DISC

DESIRUDIN

INJECTABLE; SUBCUTANEOUS

IPRIVASK

+ CANYON

15MG/VIAL

N21271 001 Apr 04, 2003 Apr CAHN

DESLORATADINE

SYRUP; ORAL

CLARINEX

+ SCHERING

0.5MG/ML

N21300 001 Sep 01, 2004 Sep NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
 DESMOPRESSIN ACETATE
 AP HOSPIRA 0.004MG/ML N75220 001 Aug 28, 2000 May CAHN
 SPRAY, METERED; NASAL
 STIMATE
 + ZLB BEHRING 0.15MG/SPRAY N20355 001 Mar 07, 1994 Sep CAHN

DESOGESTREL; ETHINYLMESTRADIOL

TABLET; ORAL-28
 CYCLESSA
 AB + ORGANON USA INC 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG N21090 001 Dec 20, 2000 Feb CFTG
 5MG,0.025MG
 VELIVET
 AB DURAMED PHARMS BARR 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG N76455 001 Feb 24, 2004 Feb NEWA
 5MG,0.025MG

DESOXIMETASONE

CREAM; TOPICAL
 TOPICORT
 AB + TARO PHARMS NORTH 0.25% N17856 001 Jun CAHN
 TOPICORT LP
 AB + TARO PHARMS NORTH 0.05% N18309 001 Jun CAHN
 GEL; TOPICAL
 TOPICORT
 AB + TARO PHARMS NORTH 0.05% N18586 001 Mar 29, 1982 Jun CAHN
 OINTMENT; TOPICAL
 TOPICORT
 @ TARO PHARMS NORTH 0.05% N18594 001 Jan 17, 1985 Jun CAHN
 AB + 0.25% N18763 001 Sep 30, 1983 Jun CAHN

DEXAMETHASONE

TABLET; ORAL
 DECADRON
 >D> BP MERCK 0.25MG N11664 004 Oct DISC
 >A> @ 0.25MG N11664 004 Oct DISC
 >D> AB 1.5MG N11664 003 Oct DISC
 >A> @ 1.5MG N11664 003 Oct DISC
 >D> AB 4MG N11664 005 Oct DISC
 >A> @ 4MG N11664 005 Oct DISC
 >D> BP + 6MG N11664 006 Jul 30, 1982 Oct DISC
 >A> @ 6MG N11664 006 Jul 30, 1982 Oct DISC
 DEXAMETHASONE
 @ MUTUAL PHARM 0.25MG N84013 001 Aug CAHN
 @ 0.25MG N84764 001 Aug CAHN
 @ 0.5MG N84084 001 Aug CAHN
 @ 0.5MG N84766 001 Aug CAHN
 @ 0.75MG N84081 001 Aug CAHN
 @ 0.75MG N84765 001 Aug CAHN
 @ 1.5MG N84086 001 Aug CAHN
 @ 1.5MG N84763 001 Aug CAHN
 >D> BP PAR PHARM 0.25MG N88149 001 Apr 28, 1983 Oct CRLD
 >A> BP + 0.25MG N88149 001 Apr 28, 1983 Oct CRLD
 >D> BP ROXANE 6MG N88316 001 Sep 15, 1983 Oct CRLD
 >A> BP + 6MG N88316 001 Sep 15, 1983 Oct CRLD

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON © MERCK	EQ 0.1% PHOSPHATE	N11984 001	Sep DISC
DEXAMETHASONE SODIUM PHOSPHATE AT + ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001	Jan 16, 1985 Sep CRLD

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN © NOVARTIS	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62544 001	Oct 29, 1984 Apr DISC
-------------------------	--	------------	-----------------------

DEXMEDETOMIDINE

INJECTABLE; INJECTION

PRECEDEX + HOSPIRA	EQ 100UGM BASE/ML	N21038 001	Dec 17, 1999 May CAHN
-----------------------	-------------------	------------	-----------------------

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE AP BEDFORD	EQ 250MG BASE/VIAL	N76068 001	Sep 28, 2004 Sep NEWA
	EQ 500MG BASE/VIAL	N76068 002	Sep 28, 2004 Sep NEWA
ZINECARD AP + PHARMACIA AND UPJOHN	EQ 250MG BASE/VIAL	N20212 001	May 26, 1995 Sep CFTG
	EQ 500MG BASE/VIAL	N20212 002	May 26, 1995 Sep CFTG

DEXTRAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE AB ABLE	5MG	N76814 001	Aug 25, 2004 Aug NEWA
	10MG	N76814 002	Aug 25, 2004 Aug NEWA
	15MG	N76814 003	Aug 25, 2004 Aug NEWA

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER AP HOSPIRA	10GM/100ML	N18080 001	May CAHN
DEXTROSE 2.5% IN PLASTIC CONTAINER © B BRAUN	2.5GM/100ML	N18358 001	May DISC
DEXTROSE 20% IN PLASTIC CONTAINER AP HOSPIRA	20GM/100ML	N18564 001	Mar 23, 1982 May CAHN
DEXTROSE 25% HOSPIRA	250MG/ML	N19445 002	Nov 23, 1998 May CAHN
DEXTROSE 30% IN PLASTIC CONTAINER AP HOSPIRA	30GM/100ML	N19345 001	Jan 26, 1985 May CAHN
DEXTROSE 40% IN PLASTIC CONTAINER AP HOSPIRA	40GM/100ML	N18562 001	Mar 23, 1982 May CAHN
DEXTROSE 5% IN PLASTIC CONTAINER AP HOSPIRA	50MG/ML	N16367 002	May CAHN
	50MG/ML	N19222 001	Jul 13, 1994 May CAHN
	5GM/100ML	N19466 001	Jul 15, 1995 May CAHN
	5GM/100ML	N19479 001	Sep 17, 1995 May CAHN
DEXTROSE 50% IN PLASTIC CONTAINER © HOSPIRA	500MG/ML	N19445 001	Jun 03, 1986 May CAHN
	50GM/100ML	N18563 001	Mar 23, 1982 May CAHN

INJECTABLE; INJECTION

AP	DEXTROSE 50% IN PLASTIC CONTAINER HOSPIRA	50GM/100ML	N19894 001 Dec 26, 1989 May CAHN
AP	DEXTROSE 60% IN PLASTIC CONTAINER HOSPIRA	60GM/100ML	N19346 001 Jan 25, 1985 May CAHN
AP	DEXTROSE 70% IN PLASTIC CONTAINER HOSPIRA	70GM/100ML	N18561 001 Mar 23, 1982 May CAHN
AP		70GM/100ML	N19893 001 Dec 26, 1989 May CAHN

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

AP	NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;21MG/100ML;128MG/100ML; 234MG/100ML	N17610 001 May CAHN
----	--	--	---------------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATEINJECTABLE; INJECTION

AP	ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19025 001 Dec 27, 1984 May DISC
----	--	---	----------------------------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTION

AP	TONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML; 100MG/100ML;180MG/100ML;280MG/100ML; 16MG/100ML	N19515 001 May 08, 1986 May CAHN
----	---	---	----------------------------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTION

AP	TONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;30MG/100ML;141MG/100ML; 15MG/100ML;260MG/100ML;25MG/100ML	N19513 001 May 08, 1986 May CAHN
----	--	--	----------------------------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION

AP	ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;2 20MG/100ML;140MG/100ML	N18273 001 May DISC
----	--	---	---------------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATEINJECTABLE; INJECTION

AP	NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;30MG/100ML;37MG/100ML;2 22MG/100ML;526MG/100ML;502MG/100ML	N17609 001 May CAHN
----	--	---	---------------------

DEXTROSE; POTASSIUM CHLORIDEINJECTABLE; INJECTION

AP	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;149MG/100ML	N18371 001 May CAHN
AP	POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;224MG/100ML	N18371 003 May CAHN
AP	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER HOSPIRA	5GM/100ML;298MG/100ML	N18371 002 May CAHN

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE,
MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;111MG/100ML;256MG/100ML N19514 001 May 08, 1986 May CAHN
;146MG/100ML;207MG/100ML

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;130MG/100ML N18270 001 May DISC
;280MG/100ML;91MG/100ML

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;225MG/100M N18365 002 Jul 05, 1983 May CAHN
L 5GM/100ML;149MG/100ML;225MG/100ML N18365 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;300MG/100M N18876 001 Jan 17, 1986 May CAHN
L 5GM/100ML;149MG/100ML;300MG/100ML N18876 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;74.5MG/100ML;450MG/100M N18362 005 Mar 28, 1988 May CAHN
L 5GM/100ML;74.5MG/100ML;450MG/100M N18362 009 Jul 05, 1983 May CAHN

AP HOSPIRA 5GM/100ML;74.5MG/100ML;900MG/100M N19691 002 Mar 24, 1988 May CAHN
AP HOSPIRA L 5GM/100ML;149MG/100ML;900MG/100M N19691 004 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 006 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;900MG/100ML N19691 006 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;149MG/100ML;225MG/100ML N18365 001 May CAHN
5GM/100ML;298MG/100ML;225MG/100ML N18365 009 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;298MG/100ML;300MG/100ML N18876 008 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;149MG/100ML;450MG/100ML N18362 010 Jul 05, 1983 May CAHN
5GM/100ML;298MG/100ML;450MG/100ML N18362 007 Mar 28, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;149MG/100ML;900MG/100ML N19691 005 Mar 24, 1988 May CAHN
5GM/100ML;298MG/100ML;900MG/100ML N19691 008 Mar 24, 1988 May CAHN

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;149MG/100ML;300MG/100ML N18876 002 Jan 17, 1986 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;225MG/100ML N18365 003 Jul 05, 1983 May CAHN

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;300MG/100ML N18876 003 Jan 17, 1986 May CAHN
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
HOSPIRA 5GM/100ML;224MG/100ML;450MG/100ML N18362 002 May CAHN

INJECTABLE; INJECTION

AP HOSPIRA POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;224MG/100ML;900MG/100ML N19691 007 Mar 24, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 5GM/100ML;298MG/100ML;225MG/100ML N18365 004 Jul 05, 1983 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 5GM/100ML;298MG/100ML;300MG/100ML N18876 004 Mar 28, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 5GM/100ML;298MG/100ML;450MG/100ML N18362 003 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;298MG/100ML;900MG/100ML N19691 009 Mar 24, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;225MG/100ML N18365 005 Mar 28, 1988 May CAHN
 L
 5GM/100ML;149MG/100ML;225MG/100ML N18365 007 Mar 28, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;300MG/100ML N18876 005 Mar 28, 1988 May CAHN
 L
 5GM/100ML;149MG/100ML;300MG/100ML N18876 009 Mar 28, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;450MG/100ML N18362 008 Mar 28, 1988 May CAHN
 L

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;149MG/100ML;450MG/100ML N18362 004 Mar 28, 1988 May CAHN

AP HOSPIRA POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;74.5MG/100ML;900MG/100ML N19691 001 Mar 24, 1988 May CAHN
 L

AP HOSPIRA 5GM/100ML;149MG/100ML;900MG/100ML N19691 003 Mar 24, 1988 May CAHN

DEXTROSE; SODIUM CHLORIDEINJECTABLE; INJECTION

AP HOSPIRA DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 2.5GM/100ML;450MG/100ML N18096 001 May CAHN

AP HOSPIRA DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
 5GM/100ML;225MG/100ML N17606 001 May CAHN

AP HOSPIRA DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
 5GM/100ML;300MG/100ML N17799 001 May CAHN

AP HOSPIRA DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
 5GM/100ML;450MG/100ML N17607 001 May CAHN

AP ABBOTT DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
 5GM/100ML;900MG/100ML N17585 001 May CAHN

AP HOSPIRA 5GM/100ML;900MG/100ML N17585 001 Aug CAHN

DIATRIZOATE MEGLUMINEINJECTABLE; INJECTION

HYPaque
 @ GE HEALTHCARE 30% N16403 002 May DISC

RENO-DIP
 + BRACCO 30% N10040 012 May CRLD

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUMINJECTABLE; INJECTION

HYPaque-76
 >D> @ GE HEALTHCARE 66%;10% N86505 001 Oct CMFD

>A> AP @ GE HEALTHCARE 66%;10% N86505 001 Oct CMFD

@ 66%;10% N86505 001 May DISC

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM					
@ BAXTER HLTHCARE	5MG/ML	N70311	001	Dec 16, 1985	Aug CAHN
@	5MG/ML	N70312	001	Dec 16, 1985	Aug CAHN
@	5MG/ML	N70313	001	Dec 16, 1985	Aug CAHN
AP + HOSPIRA	5MG/ML	N71583	001	Oct 13, 1987	May CAHN
AP	5MG/ML	N71584	001	Oct 13, 1987	May CAHN
AP	5MG/ML	N72079	001	Dec 20, 1988	May CAHN
AP PARENTA PHARMS	5MG/ML	N76815	001	Apr 15, 2004	Apr NEWA
TABLET; ORAL					
DIAZEPAM					
@ PAR PHARM	10MG	N70464	001	Feb 25, 1986	Sep DISC

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM					
TORPHARM	50MG	N76561	001	Mar 18, 2004	Mar NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ BIOGLAN PHARMS CORP	3%	N21005	001	Oct 16, 2000	Aug CAHN
SOLUTION/DROPS; OPHTHALMIC					
VOLTAREN					
+ NOVARTIS	0.1%	N20037	001	Mar 28, 1991	Aug CAHN

DICLOxacillin Sodium

CAPSULE; ORAL

DICLOxacillin Sodium					
SANDOZ	EQ 125MG BASE	N61454	002	Mar	CAHN
AB	EQ 250MG BASE	N61454	001	Mar	CAHN
AB +	EQ 500MG BASE	N61454	003	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL

@ MUTUAL PHARM

10MG	N84505	001	Oct 21, 1986	Aug CAHN
------	--------	-----	--------------	----------

TABLET; ORAL

DICYCLOMINE HCL

@ MUTUAL PHARM

20MG	N84600	001	Jul 29, 1985	Aug CAHN
------	--------	-----	--------------	----------

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

+ BRISTOL MYERS SQUIBB	10MG/ML	N20156	001	Oct 09, 1991	Jun CRLD
@	100MG/PACKET	N20155	003	Oct 09, 1991	Jun DISC
@	167MG/PACKET	N20155	004	Oct 09, 1991	Jun DISC
@	250MG/PACKET	N20155	005	Oct 09, 1991	Jun DISC

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB	25MG	N20154	002	Oct 09, 1991	Jul CRLD
+	200MG	N20154	006	Oct 28, 1999	Jul CRLD

DIENESTROL

CREAM; VAGINAL
 DIENESTROL
 @ ORTHO MCNEIL PHARM 0.01%

N06110 005

Jul CAHN

DIGOXIN

ELIXIR; ORAL
 DIGOXIN
 + ROXANE 0.05MG/ML N21648 001 Aug 26, 2004 Aug NEWA
 INJECTABLE; INJECTION
 DIGOXIN
 AP BAXTER HLTHCARE 0.25MG/ML N83391 001 Aug CAHN
 AP HOSPIRA 0.25MG/ML N40093 001 May 16, 1996 May CAHN
 AP 0.25MG/ML N40206 001 Aug 28, 1998 May CAHN
 DIGOXIN PEDIATRIC
 AP HOSPIRA 0.1MG/ML N40092 001 Apr 25, 1996 May CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 CARDIZEM SR
 @ AVENTIS PHARMS 60MG N19471 001 Jan 23, 1989 Jun DISC
 @ 90MG N19471 002 Jan 23, 1989 Jun DISC
 @ 120MG N19471 003 Jan 23, 1989 Jun DISC
 DILT-CD
 AB3 TORPHARM 120MG N76151 001 May 20, 2004 May NEWA
 AB3 180MG N76151 002 May 20, 2004 May NEWA
 AB3 240MG N76151 003 May 20, 2004 May NEWA
 AB3 300MG N76151 004 May 20, 2004 May NEWA
 DILTIAZEM HCL
 @ BIOVAIL 60MG N74845 001 Sep 15, 1999 Jun DISC
 @ 90MG N74845 002 Sep 15, 1999 Jun DISC
 @ 120MG N74845 003 Sep 15, 1999 Jun DISC
 + MYLAN 60MG N74910 001 May 02, 1997 Jun CRLD
 + 90MG N74910 002 May 02, 1997 Jun CRLD
 + 120MG N74910 003 May 02, 1997 Jun CRLD
 @ TEVA 60MG N74079 001 Nov 30, 1993 Jun DISC
 @ 90MG N74079 002 Nov 30, 1993 Jun DISC
 @ 120MG N74079 003 Nov 30, 1993 Jun DISC
 INJECTABLE; INJECTION
 DILTIAZEM HCL
 AP HOSPIRA 5MG/ML N74941 001 Apr 15, 1998 May CAHN
 AP 5MG/ML N75004 001 Feb 16, 2000 May CAHN
 AP 100MG/VIAL N75853 001 Dec 17, 2002 May CAHN
 TABLET, EXTENDED RELEASE; ORAL
 CARDIZEM LA
 BIOVAIL 120MG N21392 001 Feb 06, 2003 Jan CRLD
 180MG N21392 002 Feb 06, 2003 Jan CRLD
 240MG N21392 003 Feb 06, 2003 Jan CRLD
 300MG N21392 004 Feb 06, 2003 Jan CRLD
 360MG N21392 005 Feb 06, 2003 Jan CRLD

DIMENHYDRINATE

INJECTABLE; INJECTION
 DIMENHYDRINATE
 AP AM PHARM 50MG/ML N40519 001 Jun 23, 2004 Jun NEWA
 AP + STERIS 50MG/ML N80615 001 Jun CFTG

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

+ IMCOR PH

0.92MG/VIAL;0.092MG/VIAL

N21191 001 May 31, 2002 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HCL

AA MUTUAL PHARM 25MG

N84506 001

Aug CAHN

INJECTABLE; INJECTION

DIPHENHYDRAMINE HCL

AP HOSPIRA 50MG/ML

N40140 001 Nov 20, 1998 May CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP BAXTER HLTHCARE 5MG/ML

N74521 001 Oct 18, 1996 Aug CAHN

AP HOSPIRA 5MG/ML

N74601 001 Dec 19, 1997 May CAHN

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

@ LILLY RES LABS

250MG

N50678 001 Jun 19, 1995 Jul DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@ MUTUAL PHARM

EQ 100MG BASE

N70351 001 Dec 17, 1985 Aug CAHN

@

EQ 150MG BASE

N70352 001 Dec 17, 1985 Aug CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

@ ODYSSEY PHARMS

250MG

N07883 003

Jun CAHN

@

500MG

N07883 002

Jun CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

ABBOTT

EQ 125MG VALPROIC ACID

N18723 003 Oct 26, 1984 Jan CRLD

EQ 250MG VALPROIC ACID

N18723 001 Mar 10, 1983 Jan CRLD

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HCL

AP HOSPIRA EQ 12.5MG BASE/ML

N74086 001 Nov 29, 1993 May CAHN

AP EQ 12.5MG BASE/ML

N74292 001 Feb 16, 1995 May CAHN

AP EQ 1.25GM BASE/100ML

N74634 001 Sep 27, 1996 May CAHN

AP DOBUTAMINE HCL IN DEXTROSE 5%

N20269 001 Oct 19, 1993 May CAHN

AP + HOSPIRA EQ 50MG BASE/100ML

N20269 002 Oct 19, 1993 May CAHN

AP + EQ 100MG BASE/100ML

N20269 003 Oct 19, 1993 May CAHN

AP + EQ 200MG BASE/100ML

AP DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER

N20201 003 Oct 19, 1993 May CAHN

AP + HOSPIRA EQ 50MG BASE/100ML

N20201 002 Oct 19, 1993 May CAHN

AP + EQ 100MG BASE/100ML

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-40

INJECTABLE; INJECTION

DOBUTAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
 AP + HOSPIRA EQ 200MG BASE/100ML
 AP + EQ 400MG BASE/100ML
 DOBUTREX
 @ LILLY EQ 12.5MG BASE/ML

N20201 001 Oct 19, 1993 May CARN
 N20201 006 Jul 07, 1994 May CARN
 N17820 002 Jun DISC

DONEPEZIL HYDROCHLORIDE

>A> SOLUTION; ORAL
 >A> ARICEPT
 >A> + EISAI MEDCL RES 5MG/5ML N21719 001 Oct 18, 2004 Oct NEMA
 >A> TABLET, ORALLY DISINTEGRATING; ORAL
 >A> ARICEPT ODT
 >A> EISAI MEDCL RES 5MG N21720 001 Oct 18, 2004 Oct NEMA
 >A> + 10MG N21720 002 Oct 18, 2004 Oct NEMA

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DOPAMINE HCL
 AP + HOSPIRA 40MG/ML N18132 001 May CARN
 AP 40MG/ML N74403 001 May 23, 1996 May CARN
 AP + 80MG/100ML N18132 002 Feb 04, 1982 May CARN
 AP + 80MG/ML N18132 004 Jul 09, 1982 May CARN
 AP + 160MG/100ML N18132 003 Feb 04, 1982 May CARN
 DOPAMINE HCL IN DEXTROSE 5%
 @ HOSPIRA 1.6MG/ML N20542 001 Aug 30, 1995 Jun DISC
 AP + 1.6MG/ML N20542 001 Aug 30, 1995 May CARN
 DOPAMINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER
 AP + HOSPIRA 80MG/100ML N18826 001 Sep 30, 1983 May CARN
 AP + 160MG/100ML N18826 002 Sep 30, 1983 May CARN
 AP + 320MG/100ML N18826 003 Sep 30, 1983 May CARN

DOXAZOSIN MESYLATE

TABLET; ORAL
 DOXAZOSIN MESYLATE
 AB CLONMEL HLTHCARE EQ 1MG BASE N76161 001 Jun 10, 2004 Jun NEMA
 AB EQ 2MG BASE N76161 002 Jun 10, 2004 Jun NEMA
 AB EQ 4MG BASE N76161 003 Jun 10, 2004 Jun NEMA
 AB EQ 8MG BASE N76161 004 Jun 10, 2004 Jun NEMA

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL
 DOXEPIN HCL
 @ MUTUAL PHARM EQ 25MG BASE N71502 001 Feb 18, 1988 Aug CARN
 @ EQ 50MG BASE N71653 001 Feb 18, 1988 Aug CARN
 @ EQ 75MG BASE N71654 001 Feb 18, 1988 Aug CARN
 @ EQ 100MG BASE N71521 001 Feb 18, 1988 Aug CARN
 @ SANDOZ EQ 25MG BASE N70827 001 May 15, 1986 Sep DISC
 @ EQ 50MG BASE N70828 001 May 15, 1986 Sep DISC
 @ EQ 100MG BASE N71562 001 Mar 02, 1987 Sep DISC
 CONCENTRATE; ORAL
 DOXEPIN HCL
 AA PHARM ASSOC EQ 10MG BASE/ML N75924 001 Jan 15, 2004 Jan NEMA
 CREAM; TOPICAL
 ZONALON
 + BIOGLAN PHARMS CORP 5% N20126 001 Apr 01, 1994 Aug CARN

DOXERCALCIFEROL

CAPSULE; ORAL
HECTOROL
BONE CARE

0.5UGM

N20862 002 Apr 23, 2004 Apr NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN 10MG/VIAL
20MG/VIAL
50MG/VIAL

N50467 001 Jun DISC
N50467 003 May 20, 1985 Jun DISC
N50467 002 Jun DISC

#

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

WATSON LABS

EQ 50MG BASE
EQ 100MG BASE

N65041 001 Apr 28, 2000 Apr CAHN
N65041 002 Apr 28, 2000 Apr CAHN

AB
ABDOXYCYCLINE HYCLATE

CAPSULE, COATED PELLETS; ORAL

DORYX

FH FAULDING CO LTD

EQ 75MG BASE
EQ 100MG BASE

N50582 002 Aug 13, 2001 Jul CAHN
N50582 001 Jul 22, 1985 Jul CAHN

AB

+ CAPSULE; ORAL

DOXYCYCLINE HYCLATE

MUTUAL PHARM

EQ 50MG BASE
EQ 100MG BASE

N62418 001 Jan 28, 1983 Aug CAHN
N62418 002 Jan 28, 1983 Aug CAHN

AB
AB

WATSON LABS

EQ 50MG BASE
EQ 100MG BASE

N61717 001 Apr CAHN
N61717 002 Apr CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

MUTUAL PHARM

EQ 100MG BASE

N62391 001 Sep 30, 1982 Aug CAHN

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

HOSPIRA

2.5MG/ML
2.5MG/ML

N71981 001 Feb 29, 1988 May CAHN
N72272 001 Aug 31, 1995 May CAHN

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

HOSPIRA

2.5MG/ML; EQ 0.05MG BASE/ML
2.5MG/ML; EQ 0.05MG BASE/ML

N71982 001 May 04, 1988 Sep DISC
N71982 001 May 04, 1988 May CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

LILLY

EQ 20MG BASE
EQ 30MG BASE
EQ 60MG BASE

N21733 001 Sep 03, 2004 Sep NEWA
N21733 002 Sep 03, 2004 Sep NEWA
N21733 004 Sep 03, 2004 Sep NEWA

+ CAPSULE; ORAL

CYMBALTA

LILLY

EQ 20MG BASE
EQ 30MG BASE

N21427 001 Aug 03, 2004 Aug NEWA
N21427 002 Aug 03, 2004 Aug NEWA

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-42

CAPSULE; ORAL

CYMBALTA

+ LILLY

EQ 60MG BASE

N21427 004 Aug 03, 2004 Aug NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB CLAY PARK 1%

N76479 001 Jun 23, 2004 Jun NEWA

EDETADE DISODIUM

INJECTABLE; INJECTION

EDETADE DISODIUM

STERIS

150MG/ML

N80391 001

Sep DISC

ENDRATE

AP + HOSPIRA 150MG/ML

N11355 001

May CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

AP HOSPIRA 10MG/ML

N40131 001 Feb 24, 1998 May CAHN

EFAVIRENZ

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB 300MG

N21360 001 Feb 01, 2002 Jun DISC

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA

13.9%

N21145 001 Jul 27, 2000 Jul CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

+ GILEAD 200MG;300MG

N21752 001 Aug 02, 2004 Aug NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>A> AB APOTEX 5MG;12.5MG

N76486 001 Oct 27, 2004 Oct NEWA

>A> AB 10MG;25MG

N76486 002 Oct 27, 2004 Oct NEWA

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

AP HOSPIRA 1.25MG/ML

N75456 001 Aug 22, 2000 May CAHN

AP 1.25MG/ML

N75458 001 Aug 22, 2000 May CAHN

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

+ HOLLISTER STIER LABS EQ 0.15MG /DELIVERY

N20800 002 May 28, 2004 May NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP	HOSPIRA	0.005MG/ML; 0.5%	N89635 001 Jun 21, 1988 May CAHN
AP		0.005MG/ML; 1%	N89649 001 Jun 21, 1988 May CAHN
AP		0.005MG/ML; 1.5%	N88571 001 Sep 13, 1985 May CAHN
AP		0.005MG/ML; 1.5%	N89645 001 Jun 21, 1988 May CAHN
AP		0.005MG/ML; 1.5%	N89650 001 Jun 21, 1988 May CAHN
AP		0.005MG/ML; 2%	N89651 001 Jun 21, 1988 May CAHN
AP		0.01MG/ML; 1%	N89644 001 Jun 21, 1988 May CAHN
AP		0.01MG/ML; 2%	N89646 001 Jun 21, 1988 May CAHN

PATCH; IONTOPHORESIS

LIDOSITE TOPICAL SYSTEM KIT

+ VYTERIS	1.05MG/PATCH; 100MG/PATCH	N21504 001 May 06, 2004 May NEWA
-----------	---------------------------	----------------------------------

SOLUTION; IONTOPHORESIS

IONTOCAINE

+ IOMED	0.01MG/ML; 2%	N20530 001 Dec 21, 1995 May MAGC
LIDOCAINE HCL AND EPINEPHRINE		
+ EMPI	0.01MG/ML; 2%	N21486 001 Oct 26, 2004 Oct NEWA

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

# MUTUAL PHARM	1MG	N88891 001 Nov 01, 1985 Aug CAHN
----------------	-----	----------------------------------

TABLET; SUBLINGUAL

ERGOLOID MESYLATES

# MUTUAL PHARM	0.5MG	N87407 001 Aug CAHN
8	1MG	N87552 001 Aug CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB WARNER CHILCOTT	250MG	N62338 001 Jan CMFD
--------------------	-------	---------------------

GEL; TOPICAL

ERYGEL

AT + MERZ PHARMS	2%	N50617 001 Oct 21, 1987 Jul CAHN
------------------	----	----------------------------------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT + FOUGERA	0.5%	N62447 001 Sep 26, 1983 Jul CRLD
ILOTYCIN		
# DISTA	0.5%	N50368 001 Jul DISC

SOLUTION; TOPICAL

C-SOLVE-2

8 BIOGLAN PHARMA	2%	N62468 001 Jul 03, 1985 Jun DISC
------------------	----	----------------------------------

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA	EQ 125MG BASE/5ML	N62353 001 Nov 18, 1982 Jan CTEC
+	EQ 250MG BASE/5ML	N62409 001 Dec 16, 1982 Jan CRLD
ILOSONE		
8 LILLY	EQ 125MG BASE/5ML	N50010 001 Jan DISC
8	EQ 250MG BASE/5ML	N50010 002 Jan DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN

AP	+	HOSPIRA	EQ 500MG BASE/VIAL	N50182 002	May	CAHN	
AP			EQ 500MG BASE/VIAL	N50609 001	Sep 24, 1986	May	CAHN
AP			EQ 500MG BASE/VIAL	N62638 001	Oct 31, 1986	May	CAHN
AP	+		EQ 1GM BASE/VIAL	N50182 003		May	CAHN
AP			EQ 1GM BASE/VIAL	N50609 002	Sep 24, 1986	May	CAHN
AP			EQ 1GM BASE/VIAL	N62638 002	Oct 31, 1986	May	CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL
LEXAPRO
FOREST LABS

5MG

N21323 001 Aug 14, 2002 Apr CMFD

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

AP	+	BAXTER HLTHCARE CORP	10MG/ML	N19386 006	Feb 25, 2003	Aug	CFTG
AP		BEDFORD LABS	10MG/ML	N76323 001	Aug 10, 2004	Aug	NEWA

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL
MENOSTAR

+	BERLEX LABS	0.014MG/24HR	N21674 001	Jun 08, 2004	Jun	NEWA	
VIVELLE							
AB1	+	NOVARTIS	0.025MG/24HR	N20323 005	Aug 16, 2000	Jul	CTEC
@			0.0375MG/24HR	N20323 001	Oct 28, 1994	Jul	DISC
@			0.075MG/24HR	N20323 003	Oct 28, 1994	Jul	DISC

VIVELLE-DOT

AB1	NOVARTIS	0.025MG/24HR	N20538 009	May 03, 2002	Jul	NEWA
BX		0.0375MG/24HR	N20538 005	Jan 08, 1999	Jul	CTEC
BX		0.075MG/24HR	N20538 007	Jan 08, 1999	Jul	CTEC

GEL, METERED; TOPICAL

ESTROGEL

+	SOLVAY	0.06%	N21166 002	Feb 09, 2004	Aug	CRLD
		0.06%	N21166 002	Feb 09, 2004	Feb	NEWA
GEL; TOPICAL						
ESTROGEL						
@ SOLVAY		0.06%	N21166 001	Feb 09, 2004	Aug	DISC
		0.06%	N21166 001	Feb 09, 2004	Feb	NEWA
+		0.06%	N21166 001	Feb 09, 2004	Mar	CRLD

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

GALEN LTD	EQ 0.05MG BASE/24HR	N21367 001	Mar 20, 2003	May	CPOT
+	EQ 0.1MG BASE/24HR	N21367 002	Mar 20, 2003	May	CPOT

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT	0.45MG	N21633 001	Aug 20, 2004	Aug	NEWA
	0.9MG	N21633 002	Aug 20, 2004	Aug	NEWA
+	1.8MG	N21633 003	Aug 20, 2004	Aug	NEWA

ESTROGENS, CONJUGATED

TABLET; ORAL
PREMARIN
@ WYETH PHARMS INC 2.5MG N04782 002 May DISC

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL
CENEESTIN
DURAMED 0.45MG N20992 005 Feb 05, 2004 Feb NEWA

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL			
ENJUVIA		N21443 003	May 10, 2004 May NEWA
DURAMED	0.625MG	N21443 003	May 10, 2004 Jul DISC
@	0.625MG	N21443 004	May 10, 2004 May NEWA
+	1.25MG	N21443 004	May 10, 2004 Jul DISC
@	1.25MG		

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL			
MYAMBUTOL		N16320 001	Feb CAHN
@ ELAN PHARMS	100MG	N16320 002	Feb CAHN
@	200MG	N16320 003	Feb CAHN
@	400MG	N16320 004	Feb CAHN
@	500MG	N16320 001	May CMFD
AB STAT TRADE	100MG	N16320 002	May CAHN
@	200MG	N16320 003	May CMFD
AB	400MG	N16320 004	May CAHN
@	500MG		

ETHINYL ESTRADIOL

TABLET; ORAL			
ESTINYL		N05292 001	Apr DISC
@ SCHERING	0.02MG	N05292 002	Apr DISC
@	0.05MG	N05292 003	Apr DISC
@	0.5MG		

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL			
PREVEN EMERGENCY CONTRACEPTIVE KIT			
@ DURAMED	0.05MG;0.25MG	N20946 001	Sep 01, 1998 Jul DISC
+	0.05MG;0.25MG	N20946 001	Sep 01, 1998 Feb CAHN

TABLET; ORAL-21			
ALESSE		N20683 001	Mar 27, 1997 Aug DISC
@ WYETH PHARMS INC	0.02MG;0.1MG		
AVIANE-21		N75796 002	Apr 30, 2001 Aug CRLD
+ DURAMED PHARMS BARR	0.02MG;0.1MG		
LEVILITE		N20860 001	Jul 13, 1998 May CTEC
AB2 + BERLEX	0.02MG;0.1MG		

TABLET; ORAL-28			
ALESSE		N20683 002	Mar 27, 1997 Jul CRLD
AB1 + WYETH PHARMS INC	0.02MG;0.1MG		
LESSINA-28		N75803 002	Mar 20, 2002 May CTEC
AB2 BARR	0.02MG;0.1MG		
LEVILITE		N20860 002	Jul 13, 1998 Jul CRLD
AB2 + BERLEX	0.02MG;0.1MG		

TABLET; ORAL-28

LEVLITE

AB2 BERLEX 0.02MG;0.1MG N20860 002 Jul 13, 1998 May CTEC
 TRIPHASICL-28
 @ WYETH PHARMS INC 0.03MG,0.04MG,0.03MG;0.05MG,0.075 N19190 001 Nov 01, 1984 Aug DISC
 MG,0.125MG

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

AB BARR 0.035MG;0.4MG N76198 001 Apr 22, 2004 Apr NEWA
 OVCONE-35
 AB + WARNER CHILCOTT 0.035MG;0.4MG N18127 001 Apr CFTG
 TABLET; ORAL-28
 ARANELLE
 AB BARR 0.035MG,0.035MG,0.035MG;0.5MG,1MG N76783 001 Sep 29, 2004 Sep NEWA
 ,0.5MG
 BALZIVA-28
 AB BARR 0.035MG;0.4MG N76238 001 Apr 22, 2004 Apr NEWA
 ORTHO-NOVUM 1/35-28
 AB + ORTHO MCNEIL PHARM 0.035MG;1MG N17919 002 Mar CRLD
 OVCONE-35
 AB + WARNER CHILCOTT 0.035MG;0.4MG N17716 001 Apr CFTG
 TRI-NORINYL 28-DAY
 AB + WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,1MG N18977 002 Apr 13, 1984 Sep CFTG
 ,0.5MG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

+ WARNER CHILCOTT 0.005MG;1MG N21065 002 Oct 15, 1999 Aug CAHN

TABLET; ORAL-21

ESTROSTEP 21

@ WARNER CHILCOTT 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N20130 001 Oct 09, 1996 Aug CAHN

LOESTRIN 21 1.5/30

AB + WARNER CHILCOTT 0.03MG;1.5MG N17875 001 Aug CAHN

LOESTRIN 21 1/20

AB + WARNER CHILCOTT 0.02MG;1MG N17876 001 Aug CAHN

TABLET; ORAL-28

ESTROSTEP FE

+ WARNER CHILCOTT 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N20130 002 Oct 09, 1996 Aug CAHN

LOESTRIN FE 1.5/30

AB + WARNER CHILCOTT 0.03MG;1.5MG N17355 001 Aug CAHN

LOESTRIN FE 1/20

AB + WARNER CHILCOTT 0.02MG;1MG N17354 001 Aug CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

* ORTHO MCNEIL PHARM 0.025MG,0.025MG,0.25MG;0.18MG,0.2 N21241 001 Aug 22, 2002 Jun CAHN
 15MG,0.25MG

PREVIFEM

AB ANDRX PHARMS 0.035MG;0.25MG N76334 001 Jan 09, 2004 Jan NEWA

TRI-PREVIFEM

AB ANDRX PHARMS 0.035MG,0.035MG,0.035MG;0.18MG,0. N76335 001 Mar 26, 2004 Mar NEWA
 215MG,0.25MG

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

AB	LO/OVRAL # WYETH PHARMS INC	0.03MG;0.3MG	N17612 001	Aug	DISC
	LOW-OGESTREL-21 + WATSON LABS	0.03MG;0.3MG	N75288 001	Jul 28, 1999	Aug CRLD
	OGESTREL 0.5/50-21 + WATSON LABS	0.05MG;0.5MG	N75406 001	Dec 15, 1999	Aug CRLD
	OVRAL # WYETH PHARMS INC	0.05MG;0.5MG	N16672 001	Aug	DISC
AB	TABLET; ORAL-28 OGESTREL 0.5/50-28 + WATSON LABS	0.05MG;0.5MG	N75406 002	Dec 15, 1999	Aug CRLD

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL # MGI PHARMA INC	50MG/ML	N19545 001	Apr 20, 1987	Jun	DISC
------------------------------	---------	------------	--------------	-----	------

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

AB	LODINE XL WYETH PHARMS INC	400MG	N20584 001	Oct 25, 1996	May	CRLD
AB	+ WATSON LABS	500MG	N20584 003	Jan 20, 1998	Jul	CRLD
AB	500MG	N20584 003	Jan 20, 1998	May	CRLD	
	# WATSON LABS	600MG	N20584 002	Oct 25, 1996	Jul	DISC

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE AP + HOSPIRA	2MG/ML	N18227 001	Sep 07, 1982	May	CAHN
-------------------------	--------	------------	--------------	-----	------

ETOPOSIDE

INJECTABLE; INJECTION

ETOPOSIDE AP HOSPIRA	20MG/ML	N74320 001	Aug 30, 1995	May	CAHN
	20MG/ML	N74351 001	Aug 30, 1995	May	CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN MSP SINGAPORE	10MG;10MG	N21687 001	Jul 23, 2004	Jul	NEWA
	10MG;20MG	N21687 002	Jul 23, 2004	Jul	NEWA
	10MG;40MG	N21687 003	Jul 23, 2004	Jul	NEWA
+	10MG;80MG	N21687 004	Jul 23, 2004	Jul	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE AP HOSPIRA	10MG/ML	N75870 001	Nov 23, 2001	May	CAHN
	10MG/ML	N75905 001	Nov 23, 2001	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID SCHWARZ PHARMA	20MG	N21712 001	Sep 24, 2004	Sep	NEWA
+	40MG	N21712 002	Sep 24, 2004	Sep	NEWA

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION				
CORLOPAM				
AP	+	HOSPIRA	EQ 10MG BASE/ML	N19922 001 Sep 23, 1997 May CAHN
FENOLDOPAM MESYLATE				
>A>	AP	BEDFORD LABS	EQ 10MG BASE/ML	N76582 001 Oct 12, 2004 Oct NEWA

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL			
DURAGESIC			
+ ALZA		0.6MG/24HR	N19813 004 Aug 07, 1990 Jul CTEC
		1.2MG/24HR	N19813 003 Aug 07, 1990 Jul CTEC
		1.8MG/24HR	N19813 002 Aug 07, 1990 Jul CTEC
		2.4MG/24HR	N19813 001 Aug 07, 1990 Jul CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION			
FENTANYL CITRATE			
AP	HOSPIRA	EQ 0.05MG BASE/ML	N19115 001 Jan 12, 1985 May CAHN
FENTANYL CITRATE PRESERVATIVE FREE			
AP	HOSPIRA	EQ 0.05MG BASE/ML	N72786 001 Sep 24, 1991 May CAHN
TROCHE/LOZENGE; ORAL			
ACTIQ			
CEPHALON		EQ 0.2MG BASE	N20747 001 Nov 04, 1998 Feb CAHN
		EQ 0.4MG BASE	N20747 002 Nov 04, 1998 Feb CAHN
+		EQ 0.4MG BASE	N20747 002 Nov 04, 1998 Sep CRLD
		EQ 0.6MG BASE	N20747 003 Nov 04, 1998 Feb CAHN
		EQ 0.8MG BASE	N20747 004 Nov 04, 1998 Feb CAHN
		EQ 1.2MG BASE	N20747 005 Nov 04, 1998 Feb CAHN
+		EQ 1.6MG BASE	N20747 006 Nov 04, 1998 Feb CAHN
		EQ 1.6MG BASE	N20747 006 Nov 04, 1998 Sep CRLD

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL			
ALLEGRA D 24 HOUR			
>A>	+ AVENTIS PHARMS	180MG/240MG	N21704 001 Oct 19, 2004 Oct NEWA

FLUCONAZOLE

FOR SUSPENSION; ORAL			
DIFLUCAN			
AB	Pfizer	50MG/5ML	N20090 001 Dec 23, 1993 Jul CFTG
AB	+	200MG/5ML	N20090 002 Dec 23, 1993 Jul CFTG
FLUCONAZOLE			
AB	RANBAXY	50MG/5ML	N76332 001 Jul 29, 2004 Jul NEWA
AB		200MG/5ML	N76332 002 Jul 29, 2004 Jul NEWA
AB	ROXANE	50MG/5ML	N76246 001 Jul 29, 2004 Jul NEWA
AB		200MG/5ML	N76246 002 Jul 29, 2004 Jul NEWA
INJECTABLE; INJECTION			
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	+ Pfizer	200MG/100ML	N19950 003 Sep 29, 1992 Jul CFTG
DIFLUCAN IN SODIUM CHLORIDE 0.9%			
AP	+ Pfizer	200MG/100ML	N19950 001 Jan 29, 1990 Jul CFTG
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	+ Pfizer	200MG/100ML	N19950 002 Jan 29, 1990 Jul CFTG
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER			
AP	HOSPIRA	200MG/100ML	N76304 001 Jul 29, 2004 Jul NEWA

INJECTABLE; INJECTION

AP	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%	N76145 001 Jul 29, 2004 Jul NEWA
	AM PHARM PARTNERS 200MG/100ML	N76087 001 Jul 29, 2004 Jul NEWA
AP	BEDFORD 200MG/100ML	N76653 001 Jul 29, 2004 Jul NEWA
AP	SICOR PHARMS 200MG/100ML	
AP	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
AP	BAXTER HLTHCARE 200MG/100ML	N76766 001 Jul 29, 2004 Jul NEWA
AP	HOSPIRA 200MG/100ML	N76303 001 Jul 29, 2004 Jul NEWA
AP	MAYNE PHARMA USA 200MG/100ML	N76617 001 Jul 29, 2004 Aug CRLD
AP	200MG/100ML	N76617 001 Jul 29, 2004 Jul NEWA

TABLET; ORAL

AB	DIFLUCAN PFIZER 50MG	N19949 001 Jan 29, 1990 Jul CFTG
AB	100MG	N19949 002 Jan 29, 1990 Jul CFTG
AB	150MG	N19949 004 Jun 30, 1994 Jul CFTG
AB	200MG	N19949 003 Jan 29, 1990 Jul CFTG
AB	FLUCONAZOLE DR REDDYS LABS INC 50MG	N76658 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76658 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76658 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76658 004 Jul 29, 2004 Jul NEWA
AB	GEDEON RICHTER USA 50MG	N76432 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76432 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76432 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76432 004 Jul 29, 2004 Jul NEWA
AB	GENPHARM 50MG	N76042 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76042 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76042 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76042 004 Jul 29, 2004 Jul NEWA
AB	IVAX PHARMS 50MG	N76077 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76077 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76077 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76077 004 Jul 29, 2004 Jul NEWA
AB	MYLAN 50MG	N76351 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76351 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76351 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76351 004 Jul 29, 2004 Jul NEWA
AB	PLIVA 50MG	N76424 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76424 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76424 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76424 004 Jul 29, 2004 Jul NEWA
AB	RANBAXY 50MG	N76386 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76386 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76386 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76386 004 Jul 29, 2004 Jul NEWA
AB	ROXANE 50MG	N76213 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76213 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76213 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76213 004 Jul 29, 2004 Jul NEWA
AB	SANDOZ 50MG	N76086 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76086 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76086 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76086 004 Jul 29, 2004 Jul NEWA
AB	TARO 50MG	N76507 001 Jul 29, 2004 Jul NEWA
AB	100MG	N76507 002 Jul 29, 2004 Jul NEWA
AB	150MG	N76507 003 Jul 29, 2004 Jul NEWA
AB	200MG	N76507 004 Jul 29, 2004 Jul NEWA

TABLET; ORALFLUCONAZOLE

AB	TEVA	50MG	N74681 001 Jul 29, 2004 Jul NEWA
AB		100MG	N74681 002 Jul 29, 2004 Jul NEWA
AB		150MG	N74681 003 Jul 29, 2004 Jul NEWA
AB		200MG	N74681 004 Jul 29, 2004 Jul NEWA
AB	TORPHARM	50MG	N76665 001 Jul 29, 2004 Jul NEWA
AB		100MG	N76665 002 Jul 29, 2004 Jul NEWA
AB		150MG	N76665 003 Jul 29, 2004 Jul NEWA
AB		200MG	N76665 004 Jul 29, 2004 Jul NEWA

FLUDARABINE PHOSPHATEINJECTABLE; INJECTIONFLUDARABINE PHOSPHATE

+ GENSIA SICOR PHARMS 50MG/2ML (25MG/ML) N76661 001 Apr 28, 2004 Apr NEWA

FLUDEOXYGLUCOSE, F-18INJECTABLE; INJECTIONFLUDEOXYGLUCOSE F 18

@ DOWNSTATE CLINCL 4-90mCi/ML

N20306 002 Sep 25, 2001 May DISC

INJECTABLE; INTRAVENOUSFLUDEOXYGLUCOSE F 18

+ WEILL MEDCL COLL 10-100mCi/ML

N21768 001 Aug 05, 2004 Aug NEWA

FLUMAZENILINJECTABLE; INJECTIONFLUMAZENIL

>A>	AP	AM PHARM	0.5MG/5ML (0.1IMG/ML)	N76955 002 Oct 12, 2004 Oct NEWA
>A>	AP		1IMG/10ML (0.1IMG/ML)	N76955 001 Oct 12, 2004 Oct NEWA
>A>	AP	APOTEX	0.5MG/5ML (0.1IMG/ML)	N76755 002 Oct 12, 2004 Oct NEWA
>A>	AP		1IMG/10ML (0.1IMG/ML)	N76755 001 Oct 12, 2004 Oct NEWA
>A>	AP	BAXTER HLTHCARE	0.5MG/5ML (0.1IMG/ML)	N76787 002 Oct 12, 2004 Oct NEWA
>A>	AP		1IMG/10ML (0.1IMG/ML)	N76787 001 Oct 12, 2004 Oct NEWA
>A>	AP	BEDFORD LABS	0.5MG/5ML (0.1IMG/ML)	N76256 002 Oct 12, 2004 Oct NEWA
>A>	AP		1IMG/10ML (0.1IMG/ML)	N76256 001 Oct 12, 2004 Oct NEWA
>A>	AP	GENSIA SICOR PHARMS	0.5MG/5ML (0.1IMG/ML)	N76589 002 Oct 12, 2004 Oct NEWA
>A>	AP		1IMG/10ML (0.1IMG/ML)	N76589 001 Oct 12, 2004 Oct NEWA
		ROMAZICON		
>D>	+ HLR		0.1IMG/ML	N20073 001 Dec 20, 1991 Oct CFTG
>A>	AP +		1IMG/10ML (0.1IMG/ML)	N20073 001 Dec 20, 1991 Oct CFTG
>A>	AP		0.5MG/5ML (0.1IMG/ML)	N20073 002 Dec 20, 1991 Oct CFTG

FLUNISOLIDESPRAY, METERED; NASALFLUNISOLIDE

+ BAUSCH AND LOMB 0.025MG/SPRAY N74805 001 Feb 20, 2002 Jun CRLD

NASALIDE

@ IVAX RES 0.025MG/SPRAY N18148 001 Jun DISC

FLUOCINONIDECREAM; TOPICALFLUOCINONIDE EMULSIFIED BASE

AB2 ALTANA 0.05% N76586 001 Jun 23, 2004 Jun NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP	BIGMAR BIOPEN PHARMS	50MG/ML 50MG/ML	N40291 001 Mar 24, 1999 Jul CAHN N40379 001 Nov 15, 2000 Jul CAHN
----	----------------------	--------------------	--

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

AB	IVAX PHARMS	EQ 40MG BASE	N75245 003 Sep 28, 2004 Sep NEWA
----	-------------	--------------	----------------------------------

SOLUTION; ORAL

FLUOXETINE HCL

AA	PAR PHARM	EQ 20MG BASE/5ML	N76458 001 May 14, 2004 May NEWA
----	-----------	------------------	----------------------------------

TABLET; ORAL

FLUOXETINE

AB	IVAX PHARMS	EQ 40MG BASE	N75865 003 Aug 30, 2004 Aug NEWA
----	-------------	--------------	----------------------------------

FLUOXETINE HCL

AB	IVAX PHARMS	EQ 10MG BASE	N75865 001 Feb 28, 2002 Aug CAHN
----	-------------	--------------	----------------------------------

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

#	MAYNE PHARMA USA	25MG/ML	N74966 001 Apr 16, 1998 Apr CAHN
---	------------------	---------	----------------------------------

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

PERMITIL

#	SCHERING	5MG/ML	N16008 001 Jun DISC
---	----------	--------	---------------------

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HCL

#	MUTUAL PHARM	15MG	N70454 001 Aug 04, 1986 Aug CAHN
#		30MG	N70455 001 Aug 04, 1986 Aug CAHN

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

GLAXOSMITHKLINE	0.044MG/INH	N21433 003 May 14, 2004 May NEWA
	0.11MG/INH	N21433 002 May 14, 2004 May NEWA
+	0.22MG/INH	N21433 001 May 14, 2004 May NEWA

CREAM; TOPICAL

CUTIVATE

AB	+	GLAXOSMITHKLINE	0.05%	N19958 001 Dec 18, 1990 May CFTG
----	---	-----------------	-------	----------------------------------

FLUTICASONE PROPIONATE

AB	ALTANA	0.05%	N76451 001 May 14, 2004 May NEWA
AB	ATRIX	0.05%	N76633 001 May 14, 2004 May NEWA
AB	CLAY PARK	0.05%	N76793 001 May 14, 2004 May NEWA
AB	KV PHARM	0.05%	N76865 001 Sep 10, 2004 Sep NEWA

OINTMENT; TOPICAL

CUTIVATE

AB	+	GLAXOSMITHKLINE	0.005%	N19957 001 Dec 14, 1990 May CFTG
AB	FLUTICASONE PROPIONATE			
AB	ALTANA	0.005%	N76300 001 May 14, 2004 May NEWA	

CLAY PARK

AB	CLAY PARK	0.005%	N76668 001 May 14, 2004 May NEWA
----	-----------	--------	----------------------------------

FOLLITROPIN ALFA/BETA

INJECTABLE; IM-SC

	FOLLISTIM							
	@ ORGANON USA INC	75 IU/VIAL		N20582	001	Sep 29, 1997	Aug	DISC
BX		75 IU/VIAL		N20582	001	Sep 29, 1997	Mar	CDFR
	+	75 IU/VIAL		N20582	001	Sep 29, 1997	Jun	CTEC
	@	150 IU/VIAL		N20582	002	Sep 29, 1997	Aug	DISC
	+	150 IU/VIAL		N20582	002	Sep 29, 1997	Jun	CTEC
BX		150 IU/VIAL		N20582	002	Sep 29, 1997	Mar	CDFR
	INJECTABLE; SUBCUTANEOUS							
	FOLLISTIM AQ							
	ORGANON USA INC	300 IU/0.525ML		N21211	001	Mar 23, 2004	Mar	NEWA
	+	600 IU/0.885ML		N21211	002	Mar 23, 2004	Mar	NEWA
	GONAL-F							
	@ SERONO INC	37.5 IU/VIAL		N21765	001	Mar 25, 2004	May	DISC
		37.5 IU/VIAL		N21765	001	Mar 25, 2004	Mar	NEWA
BX		75 IU/VIAL		N20378	001	Sep 29, 1997	Mar	CDFR
	@	75 IU/VIAL		N20378	001	Sep 29, 1997	Jun	DISC
	+	75 IU/VIAL		N21765	002	Mar 25, 2004	Jun	CRLO
		75 IU/VIAL		N21765	002	Mar 25, 2004	Mar	NEWA
BX		150 IU/VIAL		N20378	002	Sep 29, 1997	Mar	CDFR
	@	150 IU/VIAL		N20378	002	Sep 29, 1997	Jun	DISC
	+	150 IU/VIAL		N21765	003	Mar 25, 2004	Mar	NEWA
	@	150 IU/VIAL		N21765	003	Mar 25, 2004	May	DISC
		450 IU/VIAL		N20378	005	Mar 26, 2004	Mar	NEWA
	+	1,200 IU/VIAL		N20378	004	Feb 28, 2001	Mar	CAIN
	+	1,050 IU/VIAL		N20378	004	Feb 28, 2001	Apr	CPOT
	GONAL-F RFF PEN							
	SERONO INC	300 IU/0.5ML		N21684	001	May 25, 2004	May	NEWA
		450 IU/0.75ML		N21684	002	May 25, 2004	May	NEWA
	+	900 IU/1.5ML		N21684	003	May 25, 2004	May	NEWA

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE
+ NOVARTIS 6.6MG/ML

N20961 001 Aug 26, 1998 Jan CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA
+ FONDA BV 5MG/0.4ML
+ 7.5MG/0.6ML
+ 10MG/0.8ML
+ GLAXOSMITHKLINE 2.5MG/0.5ML
+ 5MG/0.4ML
+ 7.5MG/0.6ML
+ 10MG/0.8MLN21345 002 May 28, 2004 May NEWA
N21345 003 May 28, 2004 May NEWA
N21345 004 May 28, 2004 May NEWA
N21345 001 Dec 07, 2001 Aug CAHN
N21345 002 May 28, 2004 Aug CAHN
N21345 003 May 28, 2004 Aug CAHN
N21345 004 May 28, 2004 Aug CAHNFOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

>A> AB ANDRX PHARMS 10MG
>A> AB 20MG
>A> AB 40MG
AB EON 10MGN76620 001 Oct 15, 2004 Oct NEWA
N76620 002 Oct 15, 2004 Oct NEWA
N76620 003 Oct 15, 2004 Oct NEWA
N76483 001 Apr 23, 2004 Apr NEWA

TABLET; ORALFOSINOPRIL SODIUM

AB	EON	20MG	N76483 002 Apr 23, 2004 Apr NEWA
AB		40MG	N76483 003 Apr 23, 2004 Apr NEWA
AB	RANBAXY	10MG	N76580 001 Apr 23, 2004 Apr NEWA
AB		20MG	N76580 002 Apr 23, 2004 Apr NEWA
AB		40MG	N76580 003 Apr 23, 2004 Apr NEWA
>A>	AB	SANDOZ	N76188 001 Oct 08, 2004 Oct NEWA
>A>	AB		N76188 002 Oct 08, 2004 Oct NEWA
>A>	AB	20MG	N76188 003 Oct 08, 2004 Oct NEWA
		40MG	

FROVATRIPTAN SUCCINATETABLET; ORAL

FROVA
+ ENDO PHARMS
+ VERNALIS

EQ 2.5MG BASE
EQ 2.5MG BASE

N21006 001 Nov 08, 2001 Aug CAHN
N21006 001 Nov 08, 2001 May CAHN

FUROSEMIDEINJECTABLE; INJECTIONFUROSEMIDE

AP	HOSPIRA	10MG/ML	N18667 001 May 28, 1982 May CAHN
AP		10MG/ML	N70578 001 Jul 08, 1987 May CAHN
AP		10MG/ML	N72080 001 Aug 13, 1991 May CAHN
AP		10MG/ML	N74337 001 Oct 31, 1994 May CAHN
AP		10MG/ML	N75241 001 May 28, 1999 May CAHN

TABLET; ORALFUROSEMIDE

@ MUTUAL PHARM

20MG

N70043 001 Sep 26, 1985 Aug CAHN
N18790 001 Nov 29, 1983 Aug CAHN

@

40MG

N70100 001 Jan 26, 1988 Aug CAHN

@

80MG

N76796 001 Mar 26, 2004 Mar NEWA

AB VINTAGE PHARMS

20MG

N76796 002 Mar 26, 2004 Mar NEWA

AB

40MG

N76796 003 Mar 26, 2004 Mar NEWA

AB @ WATSON LABS

80MG

N70413 001 Feb 26, 1986 Sep DISC

40MG

GABAPENTINCAPSULE; ORALGABAPETIN

TEVA PHARMS

100MG

N75435 001 Oct 08, 2004 Oct NEWA

AB

300MG

N75435 002 Oct 08, 2004 Oct NEWA

AB

400MG

N75435 003 Oct 08, 2004 Oct NEWA

TABLET; ORALGABAPENTIN

IVAX PHARMS

100MG

N76017 001 Apr 28, 2004 Apr NEWA

300MG

N76017 002 Apr 28, 2004 Apr NEWA

400MG

N76017 003 Apr 28, 2004 Apr NEWA

>A> AB PUREPAC PHARM

600MG

N75694 001 Oct 21, 2004 Oct NEWA

>A> AB

800MG

N75694 002 Oct 21, 2004 Oct NEWA

NEURONTIN

>D> PFIZER PHARMS

600MG

N20882 001 Oct 09, 1998 Oct CFTG

>A> AB

600MG

N20882 001 Oct 09, 1998 Oct CFTG

>D> +

800MG

N20882 002 Oct 09, 1998 Oct CFTG

>A> AB +

800MG

N20882 002 Oct 09, 1998 Oct CFTG

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE INJECTION

+ ORGANON USA INC EQ 250UGM BASE/0.5ML

N21057 001 Jul 29, 1999 Jun CTNA

GATIFLOXACIN

SUSPENSION; ORAL

TEQUIN

+ BRISTOL MYERS SQUIBB 200MG/5ML

N21678 001 Aug 27, 2004 Aug NEWA

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ OSCIENT EQ 320MG BASE

N21158 001 Apr 04, 2003 Apr CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	HOSPIRA	EQ 10MG BASE/ML	N62420 001 Aug 15, 1983 May CAHN
AP		EQ 10MG BASE/ML	N62612 004 Feb 20, 1986 May CAHN
AP		EQ 40MG BASE/ML	N62420 002 Aug 15, 1983 May CAHN
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
AP	HOSPIRA	EQ 1.2MG BASE/ML	N62414 001 Aug 15, 1983 May CAHN
	0	EQ 1.2MG BASE/ML	N62588 001 Jan 06, 1986 May CAHN
AP		EQ 1.4MG BASE/ML	N62414 002 Aug 15, 1983 May CAHN
	0	EQ 1.4MG BASE/ML	N62588 002 Jan 06, 1986 May CAHN
AP		EQ 1.6MG BASE/ML	N62414 003 Aug 15, 1983 May CAHN
	0	EQ 1.6MG BASE/ML	N62588 003 Jan 06, 1986 May CAHN
AP		EQ 1.8MG BASE/ML	N62414 004 Aug 15, 1983 May CAHN
	0	EQ 1.8MG BASE/ML	N62588 004 Jan 06, 1986 May CAHN
AP		EQ 2MG BASE/ML	N62414 005 Aug 15, 1983 May CAHN
	0	EQ 2MG BASE/ML	N62588 005 Jan 06, 1986 May CAHN
AP		EQ 60MG BASE/100ML	N62414 006 Aug 15, 1983 May CAHN
	0	EQ 60MG BASE/100ML	N62588 006 Jan 06, 1986 May CAHN
AP		EQ 70MG BASE/100ML	N62414 007 Aug 15, 1983 May CAHN
	0	EQ 70MG BASE/100ML	N62588 007 Jan 06, 1986 May CAHN
AP		EQ 80MG BASE/100ML	N62414 008 Aug 15, 1983 May CAHN
	0	EQ 80MG BASE/100ML	N62588 008 Jan 06, 1986 May CAHN
AP		EQ 90MG BASE/100ML	N62414 009 Aug 15, 1983 May CAHN
	0	EQ 90MG BASE/100ML	N62588 009 Jan 06, 1986 May CAHN
AP		EQ 100MG BASE/100ML	N62414 010 Aug 15, 1983 May CAHN
	0	EQ 100MG BASE/100ML	N62588 010 Jan 06, 1986 May CAHN
OINTMENT; OPHTHALMIC			
GENTAMICIN SULFATE			
AT	+ AKORN	EQ 0.3% BASE	N64093 001 Aug 31, 1995 Jul CFTG
AT	ALTANA	EQ 0.3% BASE	N65024 001 Jul 30, 2004 Jul NEWA
SOLUTION/DROPS; OPHTHALMIC			
GARAMYCIN			
AT	+ SCHERING	EQ 0.3% BASE	N50039 002 Jan CDFR
GENTAMICIN SULFATE			
AT	ALTANA	EQ 3% BASE	N65121 001 Jan 30, 2004 Jan NEWA

GLIPIZIDE

TABLET; ORAL
 GLIPIZIDE
 AB KALI LABS 5MG N74550 001 Sep 11, 1997 Aug CAHN
 AB 10MG N74550 002 Sep 11, 1997 Aug CAHN

GLUTAMINE

FOR SOLUTION; ORAL
 NUTRESTORE
 @ NUTRITIONAL RESTART 5GM/PACKET N21667 001 Jun 10, 2004 Sep DISC
 + 5GM/PACKET N21667 001 Jun 10, 2004 Jul CMS2

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
 GLUCOVANCE
 AB BRISTOL MYERS SQUIBB 1.25MG;250MG N21178 001 Jul 31, 2000 Feb CFTG
 AB 2.5MG;500MG N21178 002 Jul 31, 2000 Feb CFTG
 AB + 5MG;500MG N21178 003 Jul 31, 2000 Feb CFTG
 GLYBURIDE AND METFORMIN HCL
 AB IVAX PHARMS 1.25MG;250MG N76345 001 Feb 18, 2004 Feb NEWA
 AB 2.5MG;500MG N76345 002 Feb 18, 2004 Feb NEWA
 AB 5MG;500MG N76345 003 Feb 18, 2004 Feb NEWA

GLYCINE

SOLUTION; IRRIGATION
 GLYCINE 1.5% IN PLASTIC CONTAINER
 AT HOSPIRA 1.5GM/100ML N17633 001 May CAHN
 AT 1.5GM/100ML N18315 001 May CAHN

GLCOPYRROLATE

INJECTABLE; INJECTION
 GLCOPYRROLATE
 @ HOSPIRA 0.2MG/ML N89393 001 Jun 15, 1988 May CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
 FACTREL
 @ BAXTER HLTHCARE CORP EQ 0.1MG BASE/VIAL N18123 001 Sep 30, 1982 Jun DISC

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION
 KYTRIL
 + ROCHE EQ 0.1MG BASE/ML (EQ 0.1MG N20239 003 Sep 17, 2004 Sep NEWA
 BASE/ML)
 + EQ 1MG BASE/ML (EQ 1MG BASE/ML) N20239 004 Mar 11, 1994 Sep NEWA
 + EQ 4MG BASE/4ML (EQ 1MG BASE /ML) N20239 002 Mar 11, 1994 Sep CPOT

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL
 FULVICIN-U/F
 AB + SCHERING 250MG N60569 002 Sep CRLD

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
 FULVICIN P/G
 @ SCHERING 125MG N61996 001 Jun DISC

TABLET; ORAL

FULVICIN P/G						
# SCHERING	250MG	N61996 002	Jun	DISC	AP	
FULVICIN P/G 165						
# SCHERING	165MG	N61996 003	Apr 06, 1982	Jun	DISC	
FULVICIN P/G 330						
# SCHERING	330MG	N61996 004	Apr 06, 1982	Jun	DISC	
GRIS-PEG						
PEDINOL	125MG	N50475 001	Sep	CTEC	AP	
+	250MG	N50475 002	Jun	CRLD	AP	

HALAZEPAM

TABLET; ORAL						
PAXIPAM						AP
# SCHERING	20MG	N17736 003	Apr	DISC	AP	
#	40MG	N17736 004	Apr	DISC		

HALOPERIDOL

TABLET; ORAL						
HALOPERIDOL						AP
# MUTUAL PHARM	0.5MG	N71156 001	Jan 02, 1987	Aug	CAHN	
#	1MG	N71157 001	Jan 02, 1987	Aug	CAHN	
#	2MG	N71172 001	Jan 02, 1987	Aug	CAHN	
#	5MG	N71212 001	Jan 07, 1988	Aug	CAHN	
#	10MG	N71173 001	Jan 07, 1988	Aug	CAHN	
#	20MG	N71177 001	Jan 07, 1988	Aug	CAHN	
>D> AB SANDOZ	2MG	N71208 001	Nov 17, 1986	Oct	CRLD	
>A> AB +	2MG	N71208 001	Nov 17, 1986	Oct	CRLD	
>D> +	20MG	N71211 001	Mar 11, 1988	Oct	CRLD	
>A>	20MG	N71211 001	Mar 11, 1988	Oct	CRLD	

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION						
HALOPERIDOL DECANOATE						
# MAYNE PHARMA USA	EQ 50MG BASE/ML	N75176 001	Feb 09, 2000	Apr	CAHN	
#	EQ 100MG BASE/ML	N75176 002	Feb 09, 2000	Apr	CAHN	

HALOPERIDOL LACTATE

INJECTABLE; INJECTION						
HALOPERIDOL						AP
AP APOTEX	EQ 5MG BASE/ML	N76774 001	Aug 25, 2004	Aug	NEWA	
AP	EQ 5MG BASE/ML	N76791 001	Aug 25, 2004	Aug	NEWA	AP
AP	EQ 5MG BASE/ML	N76828 001	Aug 25, 2004	Aug	NEWA	
AP SABEX 2002	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Sep	NEWA	

HALOTHANE

LIQUID; INHALATION						
HALOTHANE						
AN + HOSPIRA	99.99%	N83254 001		May	CAHN	

HEPARIN SODIUM

INJECTABLE; INJECTION						
HEPARIN LOCK FLUSH						
AP HOSPIRA	10 UNITS/ML	N05264 001		May	CAHN	
AP	10 UNITS/ML	N40082 001	Feb 28, 1995	May	CAHN	
AP	10 UNITS/ML	N88097 001	Apr 28, 1983	May	CAHN	

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH						
HOSPIRA	10 UNITS/ML	N88346 001	May 18, 1983	May	CAHN	
8	100 UNITS/ML	N05264 010		May	CAHN	
	100 UNITS/ML	N40082 002	Feb 28, 1995	May	CAHN	
	100 UNITS/ML	N88098 001	Apr 28, 1983	May	CAHN	
	100 UNITS/ML	N88347 001	May 18, 1983	May	CAHN	
HEPARIN LOCK FLUSH IN PLASTIC CONTAINER						
HOSPIRA	10 UNITS/ML	N05264 015	May 21, 1985	May	CAHN	
	100 UNITS/ML	N05264 016	May 21, 1985	May	CAHN	
HEPARIN SODIUM						
@ HOSPIRA	2,500 UNITS/ML	N88099 001	Apr 28, 1983	Aug	DISC	
	2,500 UNITS/ML	N88099 001	Apr 28, 1983	May	CAHN	
	5,000 UNITS/ML	N88100 001	Apr 28, 1983	May	CAHN	
8	10,000 UNITS/ML	N40095 001	Jul 26, 1996	May	CAHN	
@ LILLY	10,000 UNITS/ML	N05521 002		Jun	DISC	
@ MARSAM PHARMS LLC	1,000 UNITS/ML	N40007 001	Jun 07, 1996	Sep	DISC	
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
HOSPIRA	200 UNITS/100ML	N18916 010	Jun 23, 1989	May	CAHN	
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%						
@ HOSPIRA	10,000 UNITS/100ML	N18911 006	Jan 30, 1985	May	CAHN	
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
HOSPIRA	10,000 UNITS/100ML	N19339 003	Mar 27, 1985	May	CAHN	
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%						
@ HOSPIRA	10,000 UNITS/100ML	N18911 001	Jan 30, 1985	May	CAHN	
8	10,000 UNITS/100ML	N18916 005	Jan 31, 1984	May	CAHN	
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%						
@ HOSPIRA	10,000 UNITS/100ML	N18911 003	Jan 30, 1985	May	CAHN	
8	10,000 UNITS/100ML	N18916 002	Jan 31, 1984	May	CAHN	
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%						
@ HOSPIRA	5,000 UNITS/100ML	N18911 007	Jan 30, 1985	May	CAHN	
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
HOSPIRA	5,000 UNITS/100ML	N19339 001	Mar 27, 1985	May	CAHN	
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
HOSPIRA	5,000 UNITS/100ML	N18916 006	Jan 31, 1984	May	CAHN	
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%						
@ HOSPIRA	5,000 UNITS/100ML	N18911 005	Jan 30, 1985	May	CAHN	
8	5,000 UNITS/100ML	N18916 003	Jan 31, 1984	May	CAHN	
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
HOSPIRA	200 UNITS/100ML	N18916 011	Jun 23, 1989	May	CAHN	
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
HOSPIRA	4,000 UNITS/100ML	N19805 001	Jan 25, 1989	May	CAHN	
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%						
@ HOSPIRA	5,000 UNITS/100ML	N18911 009	Jan 30, 1985	May	CAHN	
8	10,000 UNITS/100ML	N18911 008	Jan 30, 1985	May	CAHN	
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
HOSPIRA	5,000 UNITS/100ML	N19339 004	Mar 27, 1985	May	CAHN	
	5,000 UNITS/100ML	N19805 002	Jan 25, 1989	May	CAHN	
	10,000 UNITS/100ML	N19339 002	Mar 27, 1985	May	CAHN	
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
HOSPIRA	5,000 UNITS/100ML	N18916 007	Jan 31, 1984	May	CAHN	
	10,000 UNITS/100ML	N18916 008	Jan 31, 1984	May	CAHN	
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%						
@ HOSPIRA	5,000 UNITS/100ML	N18911 004	Jan 30, 1985	May	CAHN	
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
@ HOSPIRA	5,000 UNITS/100ML	N18916 009	Jan 31, 1984	May	CAHN	

INJECTABLE; INJECTION

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%						
@	HOSPIRA	100 UNITS/ML	N18911 002	Jan 30, 1985	May	CAHN
@		100 UNITS/ML	N18916 004	Jan 31, 1984	May	CAHN
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%						
@	HOSPIRA	1,000 UNITS/100ML	N18916 001	Jan 31, 1984	May	CAHN
HEPARIN SODIUM PRESERVATIVE FREE						
+ AP	HOSPIRA	2,000 UNITS/ML	N05264 013	Apr 07, 1986	May	CAHN
+ AP		2,500 UNITS/ML	N05264 014	Apr 07, 1986	May	CAHN
+ AP		10,000 UNITS/ML	N89522 001	May 04, 1987	May	CAHN
	@ MARSAM PHARMS LLC	1,000 UNITS/ML	N89464 001	Jun 03, 1986	Sep	DISC
PANHEPRIN						
@	HOSPIRA	1,000 UNITS/ML	N05264 004		May	CAHN
@		5,000 UNITS/ML	N05264 006		May	CAHN
@		10,000 UNITS/ML	N05264 007		May	CAHN
@		20,000 UNITS/ML	N05264 008		May	CAHN
@		40,000 UNITS/ML	N05264 009		May	CAHN

>A> HISTRELIN ACETATE>A> IMPLANT; SUBCUTANEOUS>A> VANTAS

>A> +	VALERA	50MG	N21732 001	Oct 12, 2004	Oct	NEWA
-------	--------	------	------------	--------------	-----	------

HYALURONIDASEINJECTABLE; INJECTION

>A>	AMPHADASE					
>A> +	AMPHASTAR PHARM	150 UNITS/ML	N21665 001	Oct 26, 2004	Oct	NEWA
VITRASE						
>A> +	ISTA PHARMS	6,200 UNITS/VIAL	N21640 001	May 05, 2004	May	NEWA

HYDRALAZINE HYDROCHLORIDETABLET; ORALHYDRALAZINE HCL

@	MUTUAL PHARM	10MG	N88728 001	Apr 11, 1985	Aug	CAHN
@		25MG	N84106 002		Aug	CAHN
@		50MG	N84107 002		Aug	CAHN
@		100MG	N88729 001	Apr 11, 1985	Aug	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLORTHIAZIDE; RESERPINETABLET; ORALRESERPINE, HYDRALAZINE HCL AND HYDROCHLORTHIAZIDE

@	MUTUAL PHARM	25MG;15MG;0.1MG	N88570 001	Apr 10, 1984	Aug	CAHN
---	--------------	-----------------	------------	--------------	-----	------

HYDROCHLORTHIAZIDETABLET; ORALHYDROCHLORTHIAZIDE

@	MUTUAL PHARM	25MG	N83972 001		Aug	CAHN
@		50MG	N83972 002		Aug	CAHN
@		100MG	N83972 003		Aug	CAHN

HYDROCHLORTHIAZIDE; LISINOPRILTABLET; ORALLISINOPRIL AND HYDROCHLORTHIAZIDE

>A> AB	APOTEX	12.5MG;10MG	N76674 001	Oct 05, 2004	Oct	NEWA
>A> AB		12.5MG;20MG	N76674 002	Oct 05, 2004	Oct	NEWA
>A> AB		25MG;20MG	N76674 003	Oct 05, 2004	Oct	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

	TABLET; ORAL LOPRESSOR HCT NOVARTIS	25MG;50MG 25MG;100MG 50MG;100MG	N18303 001 Dec 31, 1984 Aug CFTG N18303 002 Dec 31, 1984 Aug CFTG N18303 003 Dec 31, 1984 Aug CFTG
AB			
AB			
AB	+ METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE MYLAN	25MG;50MG 25MG;100MG 50MG;100MG	N76792 001 Aug 20, 2004 Aug NEWA N76792 002 Aug 20, 2004 Aug NEWA N76792 003 Aug 20, 2004 Aug NEWA
AB			
AB			

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

	TABLET; ORAL ACCURETIC PFIZER PHARMS	12.5MG;EQ 10MG BASE 12.5MG;EQ 20MG BASE 25MG;EQ 20MG BASE	N20125 001 Dec 28, 1999 Mar CFTG N20125 002 Dec 28, 1999 Mar CFTG N20125 003 Dec 28, 1999 Mar CFTG
AB			
AB			
AB	+ QUINARETIC AMIDE PHARM	12.5MG;EQ 10MG BASE 12.5MG;EQ 20MG BASE 25MG;EQ 20MG BASE	N76374 001 Mar 31, 2004 Mar NEWA N76374 002 Mar 31, 2004 Mar NEWA N76374 003 Mar 31, 2004 Mar NEWA
AB			
AB			

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

	TABLET; ORAL SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE MUTUAL PHARM	25MG;25MG	N87267 001 Aug CAHN
AB			

HYDROCHLOROTHIAZIDE; TELMISARTAN

	TABLET; ORAL MICARDIS HCT BOEHRINGER INGELHEIM	12.5MG;80MG 25MG;80MG	N21162 002 Nov 17, 2000 May CRLD N21162 003 Apr 19, 2004 May NEWA
+			

HYDROCODONE BITARTRATE; IBUPROFEN

	TABLET; ORAL HYDROCODONE BITARTRATE AND IBUPROFEN + INTERPHARM	5MG;200MG 7.5MG;200MG	N76642 002 Mar 18, 2004 Mar NEWA N76642 001 Oct 12, 2004 Oct NEWA
>AB			

HYDROCORTISONE

	CREAM; TOPICAL HYDROCORTISONE AT VINTAGE PHARMS	2.5%	N40503 001 Mar 12, 2004 Mar NEWA
AT			

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

	AEROSOL, METERED; TOPICAL HYDROCORTISONE ACETATE 1% AND PRAMOXINE HCL 1% BX BOCA PHARMA	1%;1%	N89440 001 May 17, 1988 Apr CAHN
BX			

HYDROCORTISONE BUTYRATE

	SOLUTION; TOPICAL HYDROCORTISONE BUTYRATE AT TARO PHARM IND	0.1%	N76364 001 Jan 14, 2004 Jan NEWA
AT			
AT	+ LOCOID FERNDALE LABS	0.1%	N19116 001 Feb 25, 1987 Jan CFTG

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N85929 001	May	CAHN
AP		EQ 250MG BASE/VIAL	N85930 001	May	CAHN
AP		EQ 500MG BASE/VIAL	N85931 001	May	CAHN
AP		EQ 1GM BASE/VIAL	N85932 001	May	CAHN

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PALLADONE

PURDUE PHARMA LP	12MG	N21044 001	Sep 24, 2004	Sep	NEWA
+	16MG	N21044 002	Sep 24, 2004	Sep	NEWA
	24MG	N21044 003	Sep 24, 2004	Sep	NEWA
	32MG	N21044 004	Sep 24, 2004	Sep	NEWA

INJECTABLE; INJECTION
HYDROMORPHONE HCL

AP	HOSPIRA	10MG/ML	N74598 001	Jun 19, 1997	May	CAHN
----	---------	---------	------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDROXYZINE HCL

AP	HOSPIRA	25MG/ML	N87416 001	May	CAHN
	@	50MG/ML	N86821 001	May	CAHN
AP		50MG/ML	N87546 001	May	CAHN

TABLET; ORAL
HYDROXYZINE HCL

AB	ABLE	10MG	N40559 001	Jul 22, 2004	Jul	NEWA
AB		25MG	N40562 001	Jul 22, 2004	Jul	NEWA
AB		50MG	N40563 001	Jul 22, 2004	Jul	NEWA
	@ MUTUAL PHARM	10MG	N88409 001	Nov 15, 1983	Aug	CAHN
	@	25MG	N87857 001	Apr 18, 1983	Aug	CAHN
	@	50MG	N87860 001	Apr 18, 1983	Aug	CAHN
	@	100MG	N87862 001	Apr 18, 1983	Aug	CAHN

IBUPROFEN

SUSPENSION; ORAL
IBUPROFEN

AB	PERRIGO R AND D	100MG/5ML	N76925 001	Sep 23, 2004	Sep	NEWA
----	-----------------	-----------	------------	--------------	-----	------

TABLET; ORAL
IBUPROFEN

	@ MUTUAL PHARM	400MG	N70079 001	Jul 24, 1985	Aug	CAHN
	@	600MG	N70080 001	Jul 24, 1985	Aug	CAHN
	@	800MG	N71448 001	Feb 18, 1987	Aug	CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HCL

+	GENSIA SICOR PHARMS	5MG/VIAL	N65037 003	May 01, 2002	Feb	CTEC
---	---------------------	----------	------------	--------------	-----	------

INAMRINONE LACTATE

INJECTABLE; INJECTION
AMRINONE

AP	+	HOSPIRA	EQ 5MG BASE/ML	N74616 001	Aug 03, 1998	May	CAHN
----	---	---------	----------------	------------	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL
 INDOMETHACIN
 @ MUTUAL PHARM 25MG N70067 001 Oct 03, 1986 Aug CAHN
 @ 50MG N70068 001 Oct 03, 1986 Aug CAHN

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS
 NOVOLOG
 + NOVO NORDISK 100 UNITS/ML N20986 001 Jun 07, 2000 May CAIN

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION
 LANTUS
 + AVENTIS PHARMS 100 UNITS/ML N21081 001 Apr 20, 2000 May CAIN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
 APIDRA
 + AVENTIS PHARMS 100 UNITS/ML N21629 001 Apr 16, 2004 Apr NEWA
 @ 100 UNITS/ML N21629 001 Apr 16, 2004 Jun DISC

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
 HUMALOG MIX 50/50
 + LILLY 50 UNITS/ML;50 UNITS/ML N21018 001 Dec 22, 1999 May CAIN
 HUMALOG MIX 75/25
 + LILLY 75 UNITS/ML;25 UNITS/ML N21017 001 Dec 22, 1999 May CAIN

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION
 HUMALOG
 + LILLY 100 UNITS/ML N20563 001 Jun 14, 1996 May CAIN
 HUMALOG PEN
 + LILLY 100 UNITS/ML N20563 002 Aug 06, 1998 May CAIN

IODIXANOL

INJECTABLE; INJECTION
 VISIPAQUE 270
 GE HEALTHCARE 55% N20808 001 Aug 29, 1997 Jun CMFD
 VISIPAQUE 320
 GE HEALTHCARE 65.2% N20808 002 Aug 29, 1997 Jun CMFD

IOPAMIDOL

INJECTABLE; INJECTION
 IOPAMIDOL-200
 HOSPIRA 41% N74898 001 Dec 30, 1997 May CAHN
 AP IOPAMIDOL-200 IN PLASTIC CONTAINER
 HOSPIRA 41% N74636 001 Dec 30, 1997 May CAHN
 AP IOPAMIDOL-250
 HOSPIRA 51% N74898 002 Dec 30, 1997 May CAHN
 AP 51% N75005 001 Feb 24, 1998 May CAHN
 AP IOPAMIDOL-250 IN PLASTIC CONTAINER
 HOSPIRA 51% N74636 002 Dec 30, 1997 May CAHN

INJECTABLE; INJECTIONIOPAMIDOL-300

AP	HOSPIRA	61%	N74898 003	Dec 30, 1997	May	CAHN
AP		61%	N75005 002	Feb 24, 1998	May	CAHN
IOPAMIDOL-300 IN PLASTIC CONTAINER						
AP	HOSPIRA	61%	N74636 003	Dec 30, 1997	May	CAHN
AP		61%	N74637 001	Apr 03, 1997	May	CAHN
IOPAMIDOL-370						
AP	HOSPIRA	76%	N74898 004	Dec 30, 1997	May	CAHN
AP		76%	N75005 003	Feb 24, 1998	May	CAHN
IOPAMIDOL-370 IN PLASTIC CONTAINER						
AP	HOSPIRA	76%	N74636 004	Dec 30, 1997	May	CAHN

IOPANOIC ACIDTABLET; ORALTELEPAQUE# GE HEALTHCARE

500MG

N08032 001

May DISC

IOPROMIDEINJECTABLE; INJECTIONULTRAVIST (PHARMACY BULK)

+	BERLEX	49.9%	N21425 003	Mar 12, 2004	Mar	NEWA
+		62.3%	N21425 001	Sep 20, 2002	Mar	CPOT
+		76.9%	N21425 002	Sep 20, 2002	Mar	CPOT

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUMINJECTABLE; INJECTIONVASCORAY# MALLINCKRODT

52%:26%

N16783 001

Jun DISC

IPRATROPIUM BROMIDESOLUTION; INHALATIONIPRATROPIUM BROMIDE

AN	HOLOPACK INTL	0.02%	N75693 001	Jan 26, 2001	Apr	CAHN
----	---------------	-------	------------	--------------	-----	------

ISOFLURANELIQUID; INHALATIONISOFLURANE

AN	HOSPIRA	99.9%	N74097 001	Jan 25, 1993	May	CAHN
----	---------	-------	------------	--------------	-----	------

ISONIAZIDINJECTABLE; INJECTIONNYDRAZID

+	SANDOZ	100MG/ML	N08662 001		Feb	CAHN
---	--------	----------	------------	--	-----	------

TABLET; ORALISONIAZID

#	MUTUAL PHARM	100MG	N80136 001		Aug	CAHN
AA		300MG	N83633 001		Aug	CAHN

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTIONISOPROTERENOL HCL

AP	HOSPIRA	0.02MG/ML	N83283 001		May	CAHN	
		0.2MG/ML	N83346 001		May	CAHN	
ISUPREL							
AP	+	HOSPIRA	0.2MG/ML	N10515 001		May	CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE

@ MUTUAL PHARM

5MG

N86166 002 Sep 19, 1986 Aug CAHN

@

10MG

N86169 001 Sep 19, 1986 Aug CAHN

@

20MG

N86167 001 Sep 19, 1986 Aug CAHN

@

30MG

N87564 001 Sep 18, 1986 Aug CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ MUTUAL PHARM

2.5MG

N84204 001 Sep 18, 1986 Aug CAHN

@

5MG

N86168 001 Sep 18, 1986 Aug CAHN

@

10MG

N87545 001 Sep 18, 1986 Aug CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

IMDUR

SCHERING PLOUGH

30MG

N20225 001 Aug 12, 1993 Apr CRLD

AB

60MG

N20225 002 Aug 12, 1993 Apr CRLD

AB

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

EON

100MG

N76104 001 May 28, 2004 May NEWA

AB

SPORANOX

AB

+ JANSSEN PHARMA

100MG

N20083 001 Sep 11, 1992 May CFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETAMINE HCL

HOSPIRA

EQ 50MG BASE/ML

N74549 001 Jun 27, 1996 May CAHN

AP

EQ 100MG BASE/ML

N74549 002 Jun 27, 1996 May CAHN

AP

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

ALTANA

2%

N76294 001 Apr 28, 2004 Apr NEWA

AB

TEVA

2%

N75581 001 Apr 25, 2000 Apr CRLD

NIZORAL

@ JANSSEN PHARMA

2%

N19084 001 Dec 31, 1985 Apr DISC

SHAMPOO; TOPICAL

KETOCONAZOLE

CLAY PARK

2%

N76419 001 Jan 07, 2004 Jan NEWA

AB

NIZORAL

AB

+ MCNEIL CONS SPECLT

2%

N19927 001 Aug 31, 1990 Jan CFTG

SUSPENSION; ORAL

NIZORAL

@ JANSSEN PHARMA

100MG/5ML

N70767 001 Nov 07, 1986 Jul CAHN

TABLET; ORAL

NIZORAL

+ JANSSEN PHARMA

200MG

N18533 001 Jul CAHN

AB

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AMPHASTAR PHARM

15MG/ML

N76209 001 Jul 21, 2004 Jul NEWA

AP

30MG/ML

N76209 002 Jul 21, 2004 Jul NEWA

INJECTABLE; INJECTIONKETOROLAC TROMETHAMINE

AP	APOTEX	15MG/ML	N76722 001	Jul 27, 2004	Jul	NEWA
AP		30MG/ML	N76722 002	Jul 27, 2004	Jul	NEWA
AP	BAXTER HLTHCARE	15MG/ML	N75772 001	Jul 21, 2004	Jul	NEWA
AP		30MG/ML	N75772 002	Jul 21, 2004	Jul	NEWA
AP	+ BEDFORD	15MG/ML	N75222 001	Apr 26, 1999	Jan	CRLD
AP	+ @ HOSPIRA	30MG/ML	N75222 002	Apr 26, 1999	Jan	CRLD
AP		15MG/ML	N74801 001	Jun 05, 1997	May	CAHN
AP		15MG/ML	N74802 001	Jun 05, 1997	May	CAHN
AP		30MG/ML	N74993 001	Jan 27, 1999	May	CAHN
AP		30MG/ML	N74801 002	Jun 05, 1997	May	CAHN
>A>	AP SABEX 2002	15MG/ML	N76271 001	Oct 06, 2004	Oct	NEWA
>A>	AP	30MG/ML	N76271 002	Oct 06, 2004	Oct	NEWA
	TORADOL					
	@ ROCHE PALO	15MG/ML	N19698 001	Nov 30, 1989	Jan	DISC
	@	30MG/ML	N19698 002	Nov 30, 1989	Jan	DISC

KETOTIFEN FUMARATESOLUTION/DROPS; OPHTHALMICZADITOR

+	NOVARTIS	EQ 0.025% BASE
---	----------	----------------

N21066 001 Jul 02, 1999 Feb CAHN

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTIONLABETALOL HCL

AP	HOSPIRA	5MG/ML	N75239 001	Nov 29, 1999	May	CAHN
AP		5MG/ML	N75240 001	Nov 29, 1999	May	CAHN
	NORMODYNE					
	@ SCHERING	5MG/ML	N18686 001	Aug 01, 1984	Sep	DISC
	TABLET; ORAL					
	NORMODYNE					
	@ SCHERING	100MG	N18687 001	Aug 31, 1987	Sep	DISC
	@	200MG	N18687 002	Aug 01, 1984	Sep	DISC
	@	300MG	N18687 003	Aug 01, 1984	Sep	DISC
	TRANDATE					
AB	+ PROMETHEUS LABS	300MG	N18716 003	Aug 01, 1984	Sep	CRLD

LAMIVUDINETABLET; ORALEPIVIR

	GLAXOSMITHKLINE	150MG	N20564 001	Nov 17, 1995	May	CRLD
+		300MG	N20564 003	Jun 24, 2002	May	CRLD

LAMOTRIGINETABLET; ORALLAMICTAL

+	GLAXOSMITHKLINE	25MG	N20241 005	Dec 27, 1994	Apr	CRLD
		200MG	N20241 003	Dec 27, 1994	Apr	CRLD

LANSOPRAZOLEFOR SUSPENSION, DELAYED RELEASE; ORALPREVACID

	TAP PHARM	15MG/PACKET	N21281 001	May 03, 2001	Jul	CDFR
+		30MG/PACKET	N21281 002	May 03, 2001	Jul	CDFR

INJECTABLE; INTRAVENOUS

PREVACID IV
+ TAP PHARM 30MG/VIAL N21566 001 May 27, 2004 May NEWA

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL
PREVACID
+ TAP PHARM 15MG N21428 001 Aug 30, 2002 Jul CDFR
30MG N21428 002 Aug 30, 2002 Jul CDFR

+

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL
FOSRENOL
+ SHIRE PHARM 250MG N21468 001 Oct 26, 2004 Oct NEWA
500MG N21468 002 Oct 26, 2004 Oct NEWA

+

LEFLUNOMIDE

TABLET; ORAL
ARAVA
+ AVENTIS PHARMS 100MG N20905 003 Sep 10, 1998 Jul CMFD

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM
@ PHARMACHEMIE USA EQ 100MG BASE/VIAL N89915 001 Apr 17, 1997 Aug DISC

AP LEUCOVORIN CALCIUM PRESERVATIVE FREE
BIGMAR BIOPEN PHARMS EQ 200MG BASE/VIAL N40258 001 Feb 26, 1999 Jul CAHN

+ EQ 500MG BASE/VIAL N40286 001 Feb 26, 1999 Jul CAHN

AP + HOSPIRA EQ 10MG BASE/ML N40147 001 Jun 25, 1997 May CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE
@ PURDUE PHARMA LP EQ 2.5MG BASE/ML N20997 001 Aug 05, 1999 May DISC

@ EQ 5MG BASE/ML N20997 002 Aug 05, 1999 May DISC

@ EQ 7.5MG BASE/ML N20997 003 Aug 05, 1999 May DISC

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
LIVOSTIN
+ NOVARTIS EQ 0.05% BASE N20219 001 Nov 10, 1993 Feb CAHN

LEVOCARNITINE

SOLUTION; ORAL
CARNITOR
AA + SIGMA TAU 1GM/10ML N19257 001 Apr 10, 1986 Aug CFTG

AA LEVCARNITINE 1GM/10ML N76851 001 Aug 10, 2004 Aug NEWA

LYNE

TABLET; ORAL
CARNITOR
AB + SIGMA TAU 330MG N18948 001 Dec 27, 1985 Sep CFTG

LEVOCARNITINE
AB COREPHARMA 330MG N76858 001 Sep 20, 2004 Sep NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
IQUIX
+ SANTEN 1.5% N21571 001 Mar 01, 2004 Mar NEWA

>A>	SOLUTION; ORAL				
>A>	LEVAQUIN				
>A>	+ ORTHO MCNEIL PHARM	250MG/10ML		N21721 001	Oct 21, 2004 Oct NEWA
	TABLET; ORAL				
	LEVAQUIN				
>D>	ORTHO MCNEIL PHARM	250MG		N20634 001	Dec 20, 1996 Oct CFTG
>A> AB		250MG		N20634 001	Dec 20, 1996 Oct CFTG
>D>		500MG		N20634 002	Dec 20, 1996 Oct CFTG
>A> AB		500MG		N20634 002	Dec 20, 1996 Oct CFTG
>A>	LEVOFLOXACIN				
>A> AB	MYLAN	250MG		N76276 001	Oct 15, 2004 Oct NEWA
>A> AB		500MG		N76276 002	Oct 15, 2004 Oct NEWA

LEVONORGESTREL

	TABLET; ORAL				
	PLAN B				
	+ DURAMED	0.75MG		N21045 001	Jul 28, 1999 Feb CAHN

LEVOTHYROXINE SODIUM *

	TABLET; ORAL				
	LEVOLET				
BX	VINTAGE	0.025MG		N21137 001	Jun 06, 2003 Jul CAHN
BX		0.05MG		N21137 002	Jun 06, 2003 Jul CAHN
BX		0.075MG		N21137 003	Jun 06, 2003 Jul CAHN
BX		0.088MG		N21137 004	Jun 06, 2003 Jul CAHN
BX		0.1MG		N21137 005	Jun 06, 2003 Jul CAHN
BX		0.112MG		N21137 006	Jun 06, 2003 Jul CAHN
BX		0.125MG		N21137 007	Jun 06, 2003 Jul CAHN
BX		0.137MG		N21137 008	Jun 06, 2003 Jul CAHN
BX		0.15MG		N21137 009	Jun 06, 2003 Jul CAHN
BX		0.175MG		N21137 010	Jun 06, 2003 Jul CAHN
BX		0.2MG		N21137 011	Jun 06, 2003 Jul CAHN
BX		0.3MG		N21137 012	Jun 06, 2003 Jul CAHN
	LEVO-T				
AB2,	ALARA PHARM	0.025MG		N21342 001	Mar 01, 2002 Jun CTEC
AB3		0.05MG		N21342 002	Mar 01, 2002 Jun CTEC
AB2,		0.075MG		N21342 003	Mar 01, 2002 Jun CTEC
AB3		0.088MG		N21342 004	Mar 01, 2002 Jun CTEC
AB2,		0.1MG		N21342 005	Mar 01, 2002 Jun CTEC
AB3		0.112MG		N21342 006	Mar 01, 2002 Jun CTEC
AB2,		0.125MG		N21342 007	Mar 01, 2002 Jun CTEC
AB3		0.137MG		N21342 012	Dec 08, 2003 Jun CTEC
AB2,		0.15MG		N21342 008	Mar 01, 2002 Jun CTEC
AB3		0.175MG		N21342 009	Mar 01, 2002 Jun CTEC
AB2,		0.2MG		N21342 010	Mar 01, 2002 Jun CTEC
AB3		0.3MG		N21342 011	Mar 01, 2002 Jun CTEC
	LEVOTHYROXINE SODIUM				
AB1,	MYLAN	0.025MG		N76187 001	Jun 05, 2002 Jun CTEC
AB2,					
AB3					

AB1,	TABLET; ORAL LEVOTHYROXINE SODIUM MYLAN	0.05MG	N76187 002 Jun 05, 2002 Jun CTEC
AB2,		0.075MG	N76187 003 Jun 05, 2002 Jun CTEC
AB3,		0.088MG	N76187 004 Jun 05, 2002 Jun CTEC
AB1,		0.1MG	N76187 005 Jun 05, 2002 Jun CTEC
AB2,		0.112MG	N76187 006 Jun 05, 2002 Jun CTEC
AB3,		0.125MG	N76187 007 Jun 05, 2002 Jun CTEC
AB1,		0.15MG	N76187 008 Jun 05, 2002 Jun CTEC
AB2,		0.175MG	N76187 009 Jun 05, 2002 Jun CTEC
AB3,		0.2MG	N76187 010 Jun 05, 2002 Jun CTEC
AB1,		0.3MG	N76187 011 Jun 05, 2002 Jun CTEC
AB2,			
AB3,			
AB1,	LEVOXYL JONES PHARMA	0.025MG	N21301 001 May 25, 2001 Jun CTEC
AB2,		0.05MG	N21301 002 May 25, 2001 Jun CTEC
AB3,		0.075MG	N21301 003 May 25, 2001 Jun CTEC
AB1,		0.088MG	N21301 004 May 25, 2001 Jun CTEC
AB3,		0.1MG	N21301 005 May 25, 2001 Jun CTEC
AB1,		0.112MG	N21301 006 May 25, 2001 Jun CTEC
AB3,		0.125MG	N21301 007 May 25, 2001 Jun CTEC
AB1,		0.137MG	N21301 008 May 25, 2001 Jun CTEC
AB3,		0.137MG	N21301 009 May 25, 2001 Jul CTEC
AB1,		0.15MG	N21301 010 May 25, 2001 Jun CTEC
AB3,		0.175MG	N21301 011 May 25, 2001 Jun CTEC
AB1,		0.2MG	N21301 012 May 25, 2001 Jun CTEC
AB2,			
AB3,			
AB1, +			
AB3,			
AB2,	SYNTHROID ABBOTT	0.025MG	N21402 001 Jul 24, 2002 Jun CFTG
AB2,		0.05MG	N21402 002 Jul 24, 2002 Jun CFTG
AB2,		0.075MG	N21402 003 Jul 24, 2002 Jun CFTG
AB2,		0.088MG	N21402 004 Jul 24, 2002 Jun CFTG
AB2,		0.1MG	N21402 005 Jul 24, 2002 Jun CFTG
AB2,		0.112MG	N21402 006 Jul 24, 2002 Jun CFTG
AB2,		0.125MG	N21402 007 Jul 24, 2002 Jun CFTG
AB2,		0.137MG	N21402 008 Jul 24, 2002 Jun CFTG
AB2,		0.15MG	N21402 009 Jul 24, 2002 Jun CFTG
AB2,		0.175MG	N21402 010 Jul 24, 2002 Jun CFTG

TABLET; ORAL
SYNTHROID

AB2	ABBOTT	0.2MG	N21402 012 Jul 24, 2002 Jun CFTG
AB2	+	0.3MG	N21402 011 Jul 24, 2002 Jun CFTG
UNITHROID			
AB1,	STEVENS J	0.025MG	N21210 001 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.05MG	N21210 002 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.075MG	N21210 003 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.088MG	N21210 004 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.1MG	N21210 005 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.112MG	N21210 006 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.125MG	N21210 007 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.15MG	N21210 008 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.175MG	N21210 009 Aug 21, 2000 Jun CTEC
AB3			
AB1,		0.2MG	N21210 010 Aug 21, 2000 Jun CTEC
AB3			
AB1, +		0.3MG	N21210 011 Aug 21, 2000 Jun CTEC
AB3			

LIDOCAINE**PATCH; TOPICAL****LIDODERM**

+	TEIKOKU PHARMA USA	5%	N20612 001 Mar 19, 1999 Sep CDFR
---	--------------------	----	----------------------------------

LIDOCAINE HYDROCHLORIDE**INJECTABLE; INJECTION****LIDOCAINE HCL**

Ø	BAXTER HLTHCARE	1%	N80407 001 Aug CAHN
Ø		2%	N80407 002 Aug CAHN
AP	HOSPIRA	0.5%	N88328 001 May 17, 1984 May CAHN
AP		1%	N40013 001 Jun 23, 1995 May CAHN
AP		1%	N83158 001 May CAHN
AP		1%	N88329 001 May 17, 1984 May CAHN
Ø		1.5%	N88330 001 May 17, 1984 May CAHN
AP		2%	N40078 001 Jun 23, 1995 May CAHN
AP		2%	N83158 002 May CAHN
AP		2%	N88294 001 May 17, 1984 May CAHN
AP		2%	N88331 001 May 17, 1984 May CAHN
AP		20%	N83158 003 May CAHN

LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

Ø B BRAUN 200MG/100ML

N18967 001 Mar 30, 1984 Apr DISC

LIDOCAINE HCL 0.2% IN DEXTROSE 5%

AP	HOSPIRA	200MG/100ML	N83158 005 May CAHN
----	---------	-------------	---------------------

LIDOCAINE HCL 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	200MG/100ML	N18388 001 May CAHN
----	---------	-------------	---------------------

LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

Ø B BRAUN 400MG/100ML

N18967 002 Mar 30, 1984 Apr DISC

LIDOCAINE HCL 0.4% IN DEXTROSE 5%

AP	HOSPIRA	400MG/100ML	N83158 006 May CAHN
----	---------	-------------	---------------------

LIDOCAINE HCL 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	400MG/100ML	N18388 002 May CAHN
----	---------	-------------	---------------------

INJECTABLE; INJECTION

LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
 # B BRAUN 800MG/100ML

N18967 003 Mar 30, 1984 Apr DISC

LIDOCAINE HCL 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER
 HOSPIRA 800MG/100ML

N18388 003 Nov 05, 1982 May CAHN

AP LIDOCAINE HCL IN PLASTIC CONTAINER

HOSPIRA 0.5%

N88325 001 Jul 31, 1984 May CAHN

1%

N88299 001 Jul 31, 1984 May CAHN

1.5%

N88326 001 Jul 31, 1984 May CAHN

2%

N88327 001 Jul 31, 1984 May CAHN

10%

N88367 001 Jul 31, 1984 May CAHN

20%

N88368 001 Jul 31, 1984 May CAHN

LIDOCAINE HCL PRESERVATIVE FREE

HOSPIRA 1%

N80408 001 May CAHN

1.5%

N80408 002 May CAHN

4%

N88295 001 May 17, 1984 May CAHN

LIDOCAINE HCL PRESERVATIVE FREE IN PLASTIC CONTAINER

HOSPIRA 1%

N40302 001 Sep 28, 1998 May CAHN

2%

N40302 002 Sep 28, 1998 May CAHN

INJECTABLE; SPINAL

LIDOCAINE HCL 5% AND DEXTROSE 7.5%
 + HOSPIRA 5%

N83914 001 May CAHN

SOLUTION; TOPICAL

LTA II KIT

N80409 001 May CAHN

AT HOSPIRA 4%

N88542 001 Jul 31, 1984 May CAHN

AT 4%

PEDIATRIC LTA KIT

N85995 001 May CAHN

AT HOSPIRA 2%

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINEINJECTABLE; INJECTION

TERRAMYCIN

N60567 001 Feb CRLD

+ PFIZER 2%;50MG/ML

N60567 002 Feb CRLD

+

2%;125MG/ML

LITHIUM CARBONATECAPSULE; ORAL

LITHIUM CARBONATE

N76823 001 Jun 29, 2004 Jun NEWA

AB ABLE 150MG

N76823 002 Jun 29, 2004 Jun NEWA

AB 300MG

N76823 003 Jun 29, 2004 Jun NEWA

AB 600MG

N17812 003 Jan 28, 1987 Jun CFTG

AB + ROXANE 600MG

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

N76832 001 Oct 28, 2004 Oct NEWA

>AB AB ROXANE 300MG

N76691 001 Jan 05, 2004 Jan NEWA

AB 450MG

LITHOBID

N18027 001 Sep CAHN

AB + JDS PHARMS 300MG

LOPERAMIDE HYDROCHLORIDESOLUTION; ORAL

IMODIUM

N19037 001 Jul 31, 1984 Jul CAHN

@ JANSSEN PHARMA 1MG/5ML

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM			
AP	# BAXTER HLTHCARE	2MG/ML	N74496 001 Sep 28, 1998 Sep DISC
AP		2MG/ML	N74496 001 Sep 28, 1998 Aug CAHN
AP		4MG/ML	N74496 002 Sep 28, 1998 Aug CAHN
AP	#	4MG/ML	N74496 002 Sep 28, 1998 Sep DISC
AP	HOSPIRA	2MG/ML	N74243 001 Apr 12, 1994 May CAHN
AP		2MG/ML	N74280 001 May 27, 1994 May CAHN
AP		2MG/ML	N74282 001 May 27, 1994 May CAHN
AP		2MG/ML	N74300 001 Apr 12, 1994 May CAHN
AP		4MG/ML	N74243 002 Apr 12, 1994 May CAHN
AP		4MG/ML	N74280 002 May 27, 1994 May CAHN
AP		4MG/ML	N74282 002 May 27, 1994 May CAHN
AP		4MG/ML	N74300 003 Mar 19, 1997 May CAHN

TABLET; ORAL

LORAZEPAM			
AP	# MUTUAL PHARM	0.5MG	N70472 001 Dec 10, 1985 Aug CAHN
AP	#	1MG	N70473 001 Dec 10, 1985 Aug CAHN
AP	#	2MG	N70474 001 Dec 10, 1985 Aug CAHN

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX		10MG	N21316 001 Jun 26, 2002 Jul CTNA
		20MG	N21316 002 Jun 26, 2002 Jul CTNA
		40MG	N21316 003 Jun 26, 2002 Jul CTNA
+		60MG	N21316 004 Jun 26, 2002 Jul CTNA
	ANDRX LABS LLC	10MG	N21316 001 Jun 26, 2002 Sep CAHN
		20MG	N21316 002 Jun 26, 2002 Sep CAHN
		40MG	N21316 003 Jun 26, 2002 Sep CAHN
+		60MG	N21316 004 Jun 26, 2002 Sep CAHN

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

+	KOS	20MG;500MG	N21249 001 Dec 17, 2001 Feb CRLD
+		20MG;750MG	N21249 002 Dec 17, 2001 Feb CRLD
#		20MG;750MG	N21249 002 Dec 17, 2001 Jul DISC

>A> LUTROPIN ALFA>A> INJECTABLE; SUBCUTANEOUS>A> LUVERIS

>A>	+ SERONO INC	75 IU/VIAL	N21322 001 Oct 08, 2004 Oct NEWA
-----	--------------	------------	----------------------------------

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL

SULFAMYLYN

>A>	+ MYLAN BERTEK	5%	N19832 003 Jun 05, 1998 Aug CAHN
-----	----------------	----	----------------------------------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML;37MG/100ML;222MG/100ML ;526MG/100ML;502MG/100ML	N17586 001	May CAHN
---------	---	------------	----------

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER
 @ HOSPIRA 14MG/100ML;37MG/100ML;222MG/100ML N18406 001 May CAHN
 ;526MG/100ML;502MG/100ML
 30MG/100ML;37MG/100ML;222MG/100ML N17637 002 Jul 08, 1982 May CAHN
 ;526MG/100ML;502MG/100ML

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER
 HOSPIRA 30MG/100ML;37MG/100ML;222MG/100ML N18406 002 Jul 08, 1982 May CAHN
 ;526MG/100ML;502MG/100ML

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE
 AP HOSPIRA 500MG/ML N75151 001 Apr 25, 2000 May CAHN

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
 + HOSPIRA 1GM/100ML N20488 001 Jul 11, 1995 May CAHN
 + 2GM/100ML N20488 002 Jul 11, 1995 May CAHN

MAGNESIUM SULFATE IN PLASTIC CONTAINER
 + HOSPIRA 80MG/ML N20309 002 Jun 24, 1994 May CAHN
 + 4GM/100ML N20309 001 Jun 24, 1994 May CAHN

MALATHION

LOTION; TOPICAL

OVIDE N18613 001 Aug 02, 1982 Jun CAHN
 + TARO PHARMS NORTH 0.5%

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER
 HOSPIRA EQ 0.1MG MANGANESE/ML N18962 001 Jun 26, 1986 May CAHN

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%
 AP @ HOSPIRA 10GM/100ML N16269 002 May CAHN

MANNITOL 10% IN PLASTIC CONTAINER
 AP HOSPIRA 10GM/100ML N19603 002 Jan 08, 1987 May CAHN

MANNITOL 15%
 AP @ HOSPIRA 15GM/100ML N16269 003 May CAHN

MANNITOL 15% IN PLASTIC CONTAINER
 AP HOSPIRA 15GM/100ML N19603 003 Jan 08, 1990 May CAHN

MANNITOL 20%
 AP @ HOSPIRA 20GM/100ML N16269 004 May CAHN

MANNITOL 20% IN PLASTIC CONTAINER
 AP HOSPIRA 20GM/100ML N19603 004 Jan 08, 1990 May CAHN

MANNITOL 25%
 AP @ HOSPIRA 12.5GM/50ML N16269 005 May CAHN
 12.5GM/50ML N16269 006 Aug 25, 1994 May CAHN

MANNITOL 5%
 AP @ HOSPIRA 5GM/100ML N16269 001 May CAHN

MANNITOL 5% IN PLASTIC CONTAINER
 AP HOSPIRA 5GM/100ML N19603 001 Jan 08, 1987 May CAHN

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL
 @ HOSPIRA 540MG/100ML;2.7GM/100ML N80224 001 May CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-72

SOLUTION; IRRIGATION

AT HOSPIRA SORBITOL-MANNITOL IN PLASTIC CONTAINER
 AT 540MG/100ML; 2.7GM/100ML
 AT 540MG/100ML; 2.7GM/100ML

N17636 001
 N18316 001

May CAHN
 May CAHN

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL
 LUDIOMIL
 @ NOVARTIS 25MG
 @ 50MG
 @ 75MG
 MAPROTILINE HCL
 AB + MYLAN 50MG

N17543 001
 N17543 002
 N17543 003 Sep 30, 1982 Jun DISC
 N72285 001 Oct 03, 1988 Jun CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
 DEPO-PROVERA
 AB + PHARMACIA AND UPJOHN 150MG/ML
 >A> AB MEDROXYPROGESTERONE ACETATE
 SICOR PHARMS 150MG/ML
 AB 150MG/ML

N20246 001 Oct 29, 1992 Jul CFTG
 N76552 001 Oct 27, 2004 Oct NEWA
 N76553 001 Jul 28, 2004 Jul NEWA

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL
 MEFLOQUINE HCL
 >A> AB ROXANE 250MG

N76523 001 Oct 01, 2004 Oct NEWA

MELOXICAM

SUSPENSION; ORAL
 MOBIC
 + BOEHRINGER INGELHEIM 7.5MG/5ML

N21530 001 Jun 01, 2004 Jun NEWA

MENOTROPINS (FSH:LH)

>A> INJECTABLE; IM-SC
 >A> REPRONEX
 >A> + FERRING 75 IU/VIAL; 75 IU/VIAL
 INJECTABLE; INJECTION
 PERGONAL
 @ SERONO 75 IU/AMP; 75 IU/AMP
 >D> REPRONEX
 >D> + FERRING 75 IU/VIAL; 75 IU/VIAL
 + 75 IU/VIAL; 75 IU/VIAL
 >A> INJECTABLE; SUBCUTANEOUS
 >A> MENOPUR
 >A> + FERRING 75 IU/VIAL; 75 IU/VIAL

N21047 001 Aug 27, 1999 Oct CDFR

N17646 001 May DISC

N21047 001 Aug 27, 1999 Oct CDFR
 N21047 001 Aug 27, 1999 May CTEC

N21663 001 Oct 29, 2004 Oct NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
 DEMEROL
 AP + HOSPIRA 25MG/ML
 AP + 50MG/ML
 AP + 75MG/ML
 AP + 100MG/ML
 MEPERIDINE HCL PRESERVATIVE FREE
 AP + HOSPIRA 10MG/ML

N21171 001
 N21171 002
 N21171 003
 N21171 004
 N88432 001 Aug 16, 1984 May CAHN

AA	TABLET; ORAL MEPERIDINE HCL MUTUAL PHARM	50MG 100MG	N80448 001 N80448 002	Aug CAHN Aug CAHN
AA				
	<u>MEPIVACAINE HYDROCHLORIDE</u>			
	INJECTABLE; INJECTION CARBOCAINE			
AP	+ HOSPIRA	1%	N12250 001	May CAHN
AP	+	1.5%	N12250 005	May CAHN
AP	+	2%	N12250 002	May CAHN
	<u>MEPROBAMATE</u>			
	TABLET; ORAL MEPROBAMATE # MUTUAL PHARM	200MG 400MG	N80699 001 N80699 002	Aug CAHN Aug CAHN
	<u>MERCAPTOPURINE</u>			
	TABLET; ORAL MERCAPTOPURINE			
AB	PROMETHEUS LABS	50MG	N40461 001 Feb 11, 2004 Feb NEWA	
AB	ROXANE	50MG	N40528 001 Feb 13, 2004 Feb NEWA	
	PURINETHOL			
AB	+ TEVA	50MG	N09053 002	Feb CFTG
	<u>MESALAMINE</u>			
	CAPSULE, EXTENDED RELEASE; ORAL PENTASA			
	SHIRE LABS	250MG	N20049 001 May 10, 1993 Aug CRLD	
	+	500MG	N20049 002 Jul 08, 2004 Aug NEWA	
	ENEMA; RECTAL MESALAMINE			
AB	CLAY PARK	4GM/60ML	N76751 001 Sep 17, 2004 Sep NEWA	
AB	TEVA	4GM/60ML	N76841 001 Sep 30, 2004 Sep NEWA	
	ROWASA			
AB	+ SOLVAY	4GM/60ML	N19618 001 Dec 24, 1987 Sep CFTG	
	<u>MESNA</u>			
	INJECTABLE; INTRAVENOUS MESNA			
AP	BEDFORD	100MG/ML	N75739 001 Jan 09, 2004 Jan NEWA	
	<u>MESORIDAZINE BESYLATE</u>			
	CONCENTRATE; ORAL SERENTIL			
	# NOVARTIS	EQ 25MG BASE/ML	N16997 001	May DISC
	TABLET; ORAL SERENTIL			
	# NOVARTIS	EQ 25MG BASE	N16774 002	May DISC
	#	EQ 100MG BASE	N16774 004	May DISC
	<u>METFORMIN HYDROCHLORIDE</u>			
	TABLET, EXTENDED RELEASE; ORAL FORTAMET			
BY	ANDRX	500MG	N21574 001 Apr 27, 2004 Apr NEWA	

TABLET, EXTENDED RELEASE; ORAL
FORTAMET

BX	+ ANDRX	1GM	N21574 002	Apr 27, 2004	Apr	NEWA
	ANDRX LABS LLC	500MG	N21574 001	Apr 27, 2004	Sep	CAHN
	+ GLUCOPHAGE XR	1GM	N21574 002	Apr 27, 2004	Sep	CAHN
AB	BRISTOL MYERS SQUIBB	500MG	N21202 001	Oct 13, 2000	Jan	CFTG
>D>	+ 750MG		N21202 004	Apr 11, 2003	Oct	CFTG
>A> AB	+ 750MG		N21202 004	Apr 11, 2003	Oct	CFTG
	METFORMIN HCL					
AB	ANDRX PHARMS	500MG	N76172 001	Jun 16, 2004	Jun	NEWA
>A> AB	BARR	750MG	N76863 001	Oct 14, 2004	Oct	NEWA
AB	IMPAK LABS	500MG	N76249 001	Jul 30, 2004	Jul	NEWA
AB	IVAX PHARMS	500MG	N76545 001	Dec 01, 2003	Jan	NEWA
>A> AB	PUREPAC PHARM	500MG	N76450 001	Oct 01, 2004	Oct	NEWA
AB	RANBAXY	500MG	N76413 001	Jun 18, 2004	Jun	NEWA
AB	TEVA	500MG	N76269 001	Jun 18, 2004	Jun	NEWA

METHADONE HYDROCHLORIDE

	TABLET; ORAL					
	METHADONE HCL					
	@ EON	5MG	N40241 001	May 29, 1998	Aug	DISC
AA	MALLINCKRODT	5MG	N40517 001	Apr 27, 2004	Apr	NEWA
AA		10MG	N40517 002	Apr 27, 2004	Apr	NEWA

METHAMPHETAMINE HYDROCHLORIDE

	TABLET; ORAL					
	DESOXYN					
AB	+ OVATION PHARMS	5MG	N05378 002		Feb	CFTG
	METHAMPHETAMINE HCL					
AB	ABLE	5MG	N40529 001	Feb 25, 2004	Feb	NEWA

METHENAMINE HIPPURATE

	TABLET; ORAL					
	UREX					
AB	VATRING PHARMS	1GM	N16151 001		Aug	CAHN

METHIMAZOLE

	TABLET; ORAL					
	TAPAZOLE					
AB	KING PHARMS	5MG	N07517 002		Mar	CAHN
AB		10MG	N07517 004		Mar	CAHN

METHOCARBAMOL

	TABLET; ORAL					
	METHOCARBAMOL					
	@ MUTUAL PHARM	500MG	N84488 001		Aug	CAHN
	@	750MG	N84486 001		Aug	CAHN

METHOTREXATE SODIUM

	INJECTABLE; INJECTION					
	METHOTREXATE					
AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40263 001	Feb 26, 1999	Jul	CAHN
	METHOTREXATE PRESERVATIVE FREE					
AP	BIGMAR BIOREN PHARMS	EQ 25MG BASE/ML	N40265 001	Feb 26, 1999	Jul	CAHN
AP		EQ 1GM BASE/VIAL	N40266 001	Feb 26, 1999	Jul	CAHN

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL
 METHYL AMINOLEVULINATE
 + PHOTOCURE ASA 16.8%

N21415 001 Jul 27, 2004 Jul NEWA

METHYLDOPA

TABLET; ORAL
 METHYLDOPA
 # ACCORD HEALTH 125MG
 AB 250MG
 AB 500MG
 # MUTUAL PHARM 125MG
 # 250MG
 # 500MG

N70070 003 Oct 15, 1985 Jun CAHN
 N70084 001 Oct 15, 1985 Jun CAHN
 N70085 001 Oct 15, 1985 Jun CAHN
 N70073 001 Oct 09, 1986 Aug CAHN
 N70060 001 Oct 09, 1986 Aug CAHN
 N70074 001 Oct 09, 1986 Aug CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
 METHYLDOPATE HCL
 AP HOSPIRA 50MG/ML
 AP 50MG/ML

N70698 001 Jun 15, 1987 May CAHN
 N70699 001 Jun 15, 1987 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
 METADATE CD
 BX CELLTECH PHARMS 10MG
 RITALIN LA
 NOVARTIS 10MG
 BX 10MG

N21259 003 May 27, 2003 May CTEC
 N21284 004 Apr 10, 2004 Apr NEWA
 N21284 004 Apr 10, 2004 May CTEC

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
 A-METHAPRED
 AP HOSPIRA EQ 40MG BASE/VIAL
 AP EQ 125MG BASE/VIAL
 AP EQ 500MG BASE/VIAL
 AP EQ 500MG BASE/VIAL
 AP EQ 1GM BASE/VIAL
 AP EQ 1GM BASE/VIAL
 METHYLPREDNISOLONE SODIUM SUCCINATE
 AP AM PHARM EQ 40MG BASE/VIAL
 AP EQ 125MG BASE/VIAL
 AP EQ 1GM BASE/VIAL

N85853 001 May CAHN
 N85855 001 May CAHN
 N85854 001 May CAHN
 N89173 001 Aug 18, 1987 May CAHN
 N85852 001 May CAHN
 N89174 001 Aug 18, 1987 May CAHN
 N40583 001 Jul 30, 2004 Jul NEWA
 N40583 002 Jul 30, 2004 Jul NEWA
 N40612 001 Aug 12, 2004 Aug NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
 METOCLOPRAMIDE HCL
 AP HOSPIRA EQ 5MG BASE/ML
 AP EQ 5MG BASE/ML
 AP EQ 5MG BASE/ML
 AP EQ 5MG BASE/ML
 AP EQ 5MG BASE/ML
 TABLET; ORAL
 METOCLOPRAMIDE HCL
 # MUTUAL PHARM EQ 10MG BASE

N70505 001 Jun 23, 1989 May CAHN
 N70506 001 Jun 22, 1989 May CAHN
 N73117 001 Jan 17, 1991 May CAHN
 N73118 001 Jan 17, 1991 May CAHN
 N74147 001 Aug 02, 1996 May CAHN

N70660 001 Feb 10, 1987 Aug CAHN

METOLAZONE

TABLET; ORAL				
METOLAZONE				
>A>	AB	MYLAN	5MG	N76698 002 Oct 19, 2004 Oct NEWA
>A>	AB		10MG	N76698 003 Oct 19, 2004 Oct NEWA
	AB	ROXANE	10MG	N76482 002 Apr 29, 2004 Apr NEWA
	AB	TEVA	2.5MG	N76600 001 Jan 06, 2004 Jan NEWA
	AB		5MG	N76833 001 Mar 01, 2004 Mar NEWA
	AB	WATSON LABS	10MG	N76891 001 Jul 21, 2004 Jul NEWA
		MYKROX		
		@ CELLTECH PHARMS	0.5MG	N19532 001 Oct 30, 1987 Jan DISC

METOPROLOL TARTRATE

INJECTABLE; INJECTION			
METOPROLOL TARTRATE			
AP	HOSPIRA	1MG/ML	N74133 001 Dec 21, 1993 May CAHN
AP		1MG/ML	N75160 001 Jul 06, 1998 May CAHN
TABLET; ORAL			
LOPRESSOR			
AB	NOVARTIS	100MG	N17963 002 Mar CRLD
METOPROLOL TARTRATE			
	CARACO	25MG	N76670 001 Jan 15, 2004 Jan NEWA
AB		25MG	N76670 001 Jan 15, 2004 Mar CTEC
+	MYLAN	25MG	N76704 001 Jan 16, 2004 Jan NEWA
AB		25MG	N76704 001 Jan 16, 2004 Mar CTEC
AB		50MG	N76704 002 Jan 16, 2004 Jan NEWA
AB	+	100MG	N76704 003 Jan 16, 2004 Mar CRLD
AB		100MG	N76704 003 Jan 16, 2004 Jan NEWA

METRONIDAZOLE

CAPSULE; ORAL			
METRONIDAZOLE			
AB	KALI LABS	375MG	N76522 001 Jan 29, 2004 Jan NEWA
CREAM; TOPICAL			
METROCREAM			
AB	+ GALDERMA LABS LP	0.75%	N20531 001 Sep 20, 1995 May CFTG
METRONIDAZOLE			
AB	ALTANA	0.75%	N76408 001 May 28, 2004 May NEWA
INJECTABLE; INJECTION			
METRONIDAZOLE IN PLASTIC CONTAINER			
AP	+ HOSPIRA	500MG/100ML	N18890 002 Nov 18, 1983 May CAHN
TABLET; ORAL			
METRONIDAZOLE			
	@ MUTUAL PHARM	250MG	N18818 001 Feb 16, 1983 Aug CAHN
	@	500MG	N18818 002 Feb 16, 1983 Aug CAHN

MICONAZOLE

INJECTABLE; INJECTION			
MONISTAT			
	@ JANSSEN PHARMA	10MG/ML	N18040 001 Jul CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION			
MIDAZOLAM HCL			
	@ HOSPIRA	EQ 1MG BASE/ML	N75293 001 Jun 20, 2000 May DISC
AP		EQ 1MG BASE/ML	N75409 002 Jun 20, 2000 May CAHN

INJECTABLE; INJECTION

MIDAZOLAM HCL				
AP HOSPIRA	EQ 1MG BASE/ML	N75856 001	Jun 13, 2002	May CAHN
AP + @	EQ 1MG BASE/ML	N75857 001	Jul 22, 2002	May CAHN
	EQ 5MG BASE/ML	N75293 002	Jun 20, 2000	May DISC
	EQ 5MG BASE/ML	N75409 001	Jun 20, 2000	May CAHN
	EQ 5MG BASE/ML	N75856 002	Jun 13, 2002	May CAHN
	EQ 5MG BASE/ML	N75857 002	Jul 22, 2002	May CAHN
AP INTL MEDICATION	EQ 1MG BASE/ML	N76020 001	Jul 16, 2004	Jul NEWA
AP	EQ 5MG BASE/ML	N76020 002	Jul 16, 2004	Jul NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL				
MIDODRINE HCL				
AB EON	10MG	N76514 003	Jul 02, 2004	Jul NEWA
AB IMPAX PHARMS	2.5MG	N76449 001	May 27, 2004	May NEWA
AB	5MG	N76449 002	May 27, 2004	May NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION				
MILRINONE LACTATE				
AP APOTEX	EQ 1MG BASE/ML	N76427 001	Sep 21, 2004	Sep NEWA
AP HOSPIRA	EQ 1MG BASE/ML	N75884 001	May 28, 2002	May CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP B BRAUN	EQ 20MG BASE/100ML	N76414 001	Aug 18, 2004	Aug NEWA
AP HOSPIRA	EQ 20MG BASE/100ML	N75885 001	May 28, 2002	May CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL				
MINOCYCLINE HCL				
AB MEDICIS	EQ 50MG BASE	N65131 001	Apr 16, 2003	Jan CFTG
AB	EQ 75MG BASE	N65131 002	Apr 16, 2003	Jan CFTG
AB +	EQ 100MG BASE	N65131 003	Apr 16, 2003	Jan CFTG
AB RANBAXY	EQ 50MG BASE	N65156 001	Jan 06, 2004	Jan NEWA
AB	EQ 75MG BASE	N65156 002	Jan 06, 2004	Jan NEWA
AB	EQ 100MG BASE	N65156 003	Jan 06, 2004	Jan NEWA

MIRTAZAPINE

TABLET; ORAL				
MIRTAZAPINE				
>A> AB AUROBINDO	7.5MG	N76921 001	Oct 22, 2004	Oct NEWA
>A> AB	15MG	N76921 002	Oct 22, 2004	Oct NEWA
>A> AB	30MG	N76921 003	Oct 22, 2004	Oct NEWA
>A> AB	45MG	N76921 004	Oct 22, 2004	Oct NEWA
CARACO	7.5MG	N76541 004	Apr 22, 2004	Apr NEWA
AB	15MG	N76541 001	Apr 22, 2004	Apr NEWA
AB	30MG	N76541 002	Apr 22, 2004	Apr NEWA
AB	45MG	N76541 003	Apr 22, 2004	Apr NEWA

MOLINDONE HYDROCHLORIDE

CONCENTRATE; ORAL				
MOBAN				
@ ENDO PHARMS	20MG/ML	N17938 001		May DISC
TABLET; ORAL				
MOBAN				
@ ENDO PHARMS	100MG	N17111 008		May DISC

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL
DEPODUR

SKYEPHARMA	10MG/ML	N21671 001	May 18, 2004	May	NEWA
+ +	15MG/1.5ML(10MG/ML)	N21671 002	May 18, 2004	May	NEWA
	20MG/2ML(10MG/ML)	N21671 003	May 18, 2004	May	NEWA
INJECTABLE; INJECTION					
MORPHINE SULFATE					
AP + HOSPIRA	0.5MG/ML	N19917 001	Oct 30, 1992	May	CAHN
AP	0.5MG/ML	N71849 001	May 11, 1988	May	CAHN
AP	0.5MG/ML	N73509 001	Sep 30, 1992	May	CAHN
AP +	1MG/ML	N19916 001	Oct 30, 1992	May	CAHN
AP	1MG/ML	N71850 001	May 11, 1988	May	CAHN
AP	1MG/ML	N73510 001	Sep 30, 1992	May	CAHN
TABLET, EXTENDED RELEASE; ORAL					
MORPHINE SULFATE					
AB KV PHARM	15MG	N76733 001	May 19, 2004	May	NEWA
AB	60MG	N76720 001	May 19, 2004	May	NEWA
ORAMORPH SR					
BC + AAIPHARMA	60MG	N19977 002	Aug 15, 1991	Mar	CRLD

MYCOPHENOLIC ACID

TABLET, EXTENDED RELEASE; ORAL
MYFORTIC

NOVARTIS	180MG	N50791 001	Feb 27, 2004	Feb	NEWA
+	360MG	N50791 002	Feb 27, 2004	Feb	NEWA

NABILONE

CAPSULE; ORAL
CESAMET
VALEANT

	1MG	N18677 001	Dec 26, 1985	Jan	CAHN
--	-----	------------	--------------	-----	------

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

+ SANDOZ	EQ 500MG BASE/VIAL	N62527 001	Aug 02, 1984	Jun	CAHN
AP	EQ 1GM BASE/VIAL	N62527 002	Aug 02, 1984	Jun	CAHN
AP	EQ 2GM BASE/VIAL	N62527 003	Aug 02, 1984	Jun	CAHN
AP	EQ 10GM BASE/VIAL	N62527 004	Aug 02, 1984	Jun	CAHN

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL
NAFTIN

MERZ PHARMS	1%	N19599 001	Feb 29, 1988	Jul	CAHN
GEL; TOPICAL					
NAFTIN					
+ MERZ PHARMS	1%	N19356 001	Jun 18, 1990	Jul	CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

AP HOSPIRA	10MG/ML	N70914 001	Feb 03, 1989	May	CAHN
AP	10MG/ML	N70915 001	Feb 03, 1989	May	CAHN
AP	20MG/ML	N70916 001	Feb 03, 1989	May	CAHN
AP	20MG/ML	N70918 001	Feb 03, 1989	May	CAHN

INJECTABLE; INJECTION

NALBUPHINE HCL
@ KING PHARMS 10MG/ML

N74471 001 Mar 19, 1998 Mar DISC

NALIDIXIC ACIDTABLET; ORAL

NALIDIXIC ACID
@ MUTUAL PHARM 250MG
@ 500MG
@ 1GM

N70270 001 Jun 29, 1988 Aug CAHN
N70271 001 Jun 29, 1988 Aug CAHN
N70272 001 Jun 29, 1988 Aug CAHN

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION

NALOXONE
@ BAXTER HLTHCARE 0.4MG/ML
@ 0.4MG/ML

N70298 001 Sep 24, 1986 Aug CAHN
N70299 001 Sep 24, 1986 Aug CAHN

NALOXONE HCL
AP HOSPIRA 0.02MG/ML
AP 0.02MG/ML
AP 0.02MG/ML
AP @ 0.4MG/ML
AP 0.4MG/ML
AP 0.4MG/ML
AP 0.4MG/ML
AP 0.4MG/ML

N70171 001 Sep 24, 1986 May CAHN
N70252 001 Jan 16, 1987 May CAHN
N70253 001 Jan 16, 1987 May CAHN
N70172 001 Sep 24, 1986 May CAHN
N70254 001 Jan 07, 1987 May CAHN
N70255 001 Jan 07, 1987 May CAHN
N70256 001 Jan 07, 1987 May CAHN
N70257 001 Jan 07, 1987 May CAHN

NAPROXENTABLET; ORAL

NAPROXEN
@ BAXTER HLTHCARE 250MG
@ 375MG
@ 500MG
AB WESTWARD 250MG
AB 375MG
AB 500MG

N74105 001 Dec 21, 1993 Aug DISC
N74105 002 Dec 21, 1993 Aug DISC
N74105 003 Dec 21, 1993 Aug DISC
N76494 001 Jan 14, 2004 Jan NEWA
N76494 002 Jan 14, 2004 Jan NEWA
N76494 003 Jan 14, 2004 Jan NEWA

NAPROXEN SODIUMTABLET, EXTENDED RELEASE; ORAL

NAPRELAN
AB + STAT TRADE EQ 375MG BASE
AB + EQ 500MG BASE
@ EQ 750MG BASE

N20353 001 Jan 05, 1996 Jun CAHN
N20353 002 Jan 05, 1996 Jun CAHN
N20353 003 Jan 05, 1996 Jun CAHN

NEDOCROMIL SODIUMAEROSOL, METERED; INHALATION

TILADE
+ KING PHARMS 1.75MG/INH

N19660 001 Dec 30, 1992 Jan CAHN

NEFAZODONE HYDROCHLORIDETABLET; ORAL

NEFAZODONE HCL
@ ROXANE 50MG
@ 100MG
@ 150MG
@ 200MG
@ 250MG

N76196 001 Sep 16, 2003 Jul DISC
N76196 002 Sep 16, 2003 Jul DISC
N76196 003 Sep 16, 2003 Jul DISC
N76196 004 Sep 16, 2003 Jul DISC
N76196 005 Sep 16, 2003 Jul DISC

NIACIN

TABLET; ORAL			
NIACIN			
# MK LABS	500MG	N83525 001	Feb DISC
# TABLICAPS	500MG	N84237 001	Feb DISC
NIACOR			
AA + UPSHER SMITH	500MG	N40378 001	May 03, 2000 Feb CRLD

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL			
NIFEDIPINE			
AB2 MARTEC	90MG	N75414 003	Mar 23, 2004 Mar NEWA
PROCARDIA XL			
AB2 + PFIZER	90MG	N19684 003	Sep 06, 1989 Mar CFTG

NITAZOXANIDE

TABLET; ORAL			
ALINIA			
+ ROMARK	500MG	N21497 001	Jul 21, 2004 Jul NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL			
NITROFURANTOIN			
# MYLAN	100MG	N74967 002	Jul 09, 1997 Aug DISC
AB	100MG	N77025 001	Aug 18, 2004 Aug NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL			
MACROBID			
AB + PROCTER AND GAMBLE	75MG;25MG	N20064 001	Dec 24, 1991 Mar CFTG
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)			
AB MYLAN	75MG;25MG	N76648 001	Mar 22, 2004 Apr CPOT
AB	EQ 75MG BASE;25MG	N76648 001	Mar 22, 2004 Mar NEWA

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL			
NITROGLYCERIN			
AB1 KREMERS URBAN	0.2MG/HR	N75115 001	Aug 10, 2004 Aug NEWA
AB1	0.4MG/HR	N75115 002	Aug 10, 2004 Aug NEWA
INJECTABLE; INJECTION			
NITROGLYCERIN			
AP + HOSPIRA	5MG/ML	N18531 001	May CAHN
NITROGLYCERIN IN DEXTROSE 5%			
AP HOSPIRA	0.1IMG/ML	N74083 001	Oct 26, 1994 May CAHN
AP	10MG/100ML	N71846 001	Aug 31, 1990 May CAHN
AP	20MG/100ML	N71847 001	Aug 31, 1990 May CAHN
AP	40MG/100ML	N71848 001	Aug 31, 1990 May CAHN

NIZATIDINE

SOLUTION; ORAL			
AXID			
+ RELIANT PHARMS	15MG/ML	N21494 001	May 25, 2004 May NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

AP	LEVOPHED + HOSPIRA	EQ 1MG BASE/ML	N07513 001	May CAHN
AP	NOREPINEPHRINE BITARTRATE PHARMAFORCE		N40522 001	Sep 30, 2004 Sep NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HCL @ LILLY	EQ 10MG BASE	N14684 001	Jun DISC
@	EQ 25MG BASE	N14684 002	Jun DISC

NYSTATIN

PASTILLE; ORAL

MYCOSTATIN @ BRISTOL MYERS SQUIBB	200,000 UNITS	N50619 001	Apr 09, 1987 Jun DISC
--------------------------------------	---------------	------------	-----------------------

POWDER; TOPICAL

NYSTATIN AT KALI LABS	100,000 UNITS/GM	N65138 001	Jul 23, 2004 Jul NEWA
TANON	100,000 UNITS/GM	N65203 001	Jul 15, 2004 Jul NEWA

SUSPENSION; ORAL

MYCOSTATIN @ APOTHECON	100,000 UNITS/ML	N61533 001	Aug DISC
---------------------------	------------------	------------	----------

NILSTAT AA + GLENMARK PHARMA	100,000 UNITS/ML	N50299 001	Jul CAHN
---------------------------------	------------------	------------	----------

NYSTATIN @ BAUSCH AND LOMB	100,000 UNITS/ML	N64042 001	Feb 28, 1994 Aug DISC
-------------------------------	------------------	------------	-----------------------

AA + MORTON GROVE	100,000 UNITS/ML	N62512 001	Oct 29, 1984 Aug CRLD
-------------------	------------------	------------	-----------------------

AA VISTAPHARM	100,000 UNITS/ML	N64142 001	Jun 25, 1998 Aug CAHN
---------------	------------------	------------	-----------------------

NYSTEX @ SAVAGE LABS	100,000 UNITS/ML	N62519 001	Jul 06, 1984 Aug DISC
-------------------------	------------------	------------	-----------------------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX AT + ALLERGAN	0.3%	N19921 001	Jul 30, 1993 May CFTG
OFLOXACIN AT ALCON	0.3%	N76231 001	May 14, 2004 May NEWA
BAUSCH AND LOMB	0.3%	N76622 001	May 14, 2004 May NEWA
HI TECH PHARMA	0.3%	N76615 001	May 14, 2004 May NEWA
NOVEX	0.3%	N76513 001	May 14, 2004 May NEWA

SOLUTION/DROPS; OTIC

FLOXIN OTIC + DAIICHI	0.3%	N20799 001	Dec 16, 1997 Jun CTNA
--------------------------	------	------------	-----------------------

SOLUTION; OPHTHALMIC

OFLOXACIN AT PHARMAFORCE	EQ 0.3% BASE	N76830 001	Aug 31, 2004 Aug NEWA
-----------------------------	--------------	------------	-----------------------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

ZYPREXA + LILLY	10MG/VIAL	N21253 001	Mar 29, 2004 Mar NEWA
--------------------	-----------	------------	-----------------------

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ CELLTECH PHARMS 250MG

N19715 001 Jul 31, 1990 Jun CAHN

OMEPRAZOLE

FOR SUSPENSION; ORAL

ZEGERID

+ SANTARUS 20MG/PACKET

N21636 001 Jun 15, 2004 Jun NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP + APOTHECON	EQ 250MG BASE/VIAL	N61490 001	Mar CRLD
AP +	EQ 2GM BASE/VIAL	N61490 004	Mar NEWA
AP	EQ 2GM BASE/VIAL	N62737 002	Dec 23, 1986 Mar CRLD
AP + SANDOZ	EQ 250MG BASE/VIAL	N61490 001	Jun CAHN
AP +	EQ 500MG BASE/VIAL	N61490 002	Jun CAHN
AP +	EQ 1GM BASE/VIAL	N61490 003	Jun CAHN
AP +	EQ 2GM BASE/VIAL	N61490 004	Jun CAHN
AP +	EQ 10GM BASE/VIAL	N61490 006	May 09, 1991 Jun CAHN

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

@ PFIZER 250MG

N18069 001 Mar DISC

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB APOTEX 600MG N75987 001 Sep 02, 2004 Sep NEWA

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

@ GD SEARLE 600MG

N20776 001 Oct 17, 2002 Sep DISC

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

@ MUTUAL PHARM 10MG

N70957 001 Aug 10, 1987 Aug CAHN

@ 15MG

N71025 001 Aug 10, 1987 Aug CAHN

@ 30MG

N71026 001 Aug 10, 1987 Aug CAHN

SERAX

@ ALPHARMA 15MG

N15539 004 Aug DISC

TABLET; ORAL

OXAZEPAM

@ MUTUAL PHARM 15MG

N70683 001 Jan 16, 1987 Aug CAHN

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HCL

AB ENDO PHARMS	10MG	N75923 001 Mar 23, 2004 Mar NEWA
AB	20MG	N75923 002 Mar 23, 2004 Mar NEWA
AB	40MG	N75923 003 Mar 23, 2004 Mar NEWA

TABLET, EXTENDED RELEASE; ORAL

	OXYCODONE HCL						
AB	ENDO PHARMS	80MG	N75923	004	Sep 29, 2004	Sep	NEWA
AB	IMPAK LABS	80MG	N76318	001	Sep 27, 2004	Sep	NEWA
AB	TEVA	80MG	N76168	001	Mar 23, 2004	Mar	NEWA
	OXYCONTIN						
AB	PURDUE PHARMA LP	10MG	N20553	001	Dec 12, 1995	Mar	CFTG
AB		20MG	N20553	002	Dec 12, 1995	Mar	CFTG
AB	+	40MG	N20553	003	Dec 12, 1995	Mar	CFTG
AB	+	80MG	N20553	004	Jan 06, 1997	Mar	CFTG
AB		80MG	N20553	004	Jan 06, 1997	Jun	CRLD
	TABLET; ORAL						
	OXYCODONE HCL						
AB	AMIDE PHARM	15MG	N76636	001	Feb 06, 2004	Feb	NEWA
AB		30MG	N76636	002	Feb 06, 2004	Feb	NEWA
AB	MALLINCKRODT	15MG	N76758	001	Jun 30, 2004	Jun	NEWA
AB		30MG	N76758	002	Jun 30, 2004	Jun	NEWA
	ROXICODONE						
AB	AAIPHARMA	15MG	N21011	001	Aug 31, 2000	Feb	CFTG
AB		30MG	N21011	002	Aug 31, 2000	Feb	CFTG

PANCURONIUM BROMIDE

	INJECTABLE; INJECTION						
	PANCURONIUM BROMIDE						
AP	HOSPIRA	1MG/ML	N72320	001	Jan 19, 1989	May	CAHN
AP		2MG/ML	N72321	001	Jan 19, 1989	May	CAHN

PARICALCITOL

	INJECTABLE; INJECTION						
	ZEMPLAR						
	ABBOTT	0.002MG/ML	N20819	002	Feb 01, 2000	Mar	NEWA

PAROXETINE HYDROCHLORIDE

	TABLET; ORAL						
	PAROXETINE HCL						
AB	ALPHAPHARM	EQ 10MG BASE	N75716	001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75716	002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75716	003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75716	004	Mar 08, 2004	Mar	NEWA
AB	SANDOZ	EQ 10MG BASE	N75566	001	Mar 08, 2004	Mar	NEWA
AB		EQ 20MG BASE	N75566	002	Mar 08, 2004	Mar	NEWA
AB		EQ 30MG BASE	N75566	003	Mar 08, 2004	Mar	NEWA
AB		EQ 40MG BASE	N75566	004	Mar 08, 2004	Mar	NEWA

PEMETREXED DISODIUM

	INJECTABLE; IV (INFUSION)						
+	ALIMTA						
+	LILLY	EQ 500MG BASE/VIAL	N21462	001	Feb 04, 2004	Feb	NEWA

PENTAMIDINE ISETHIONATE

	INJECTABLE; INJECTION						
	PENTAMIDINE ISETHIONATE						
AP	HOSPIRA	300MG/VIAL	N73479	001	Jun 30, 1992	May	CAHN

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N16194 001

May CAHN

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+ HAMELN PHARMS

EQ 1GM/5ML(EQ 200MG/ML)

N21749 001 Aug 11, 2004 Aug NEWA

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+ HAMELN PHARMS

EQ 1GM/5ML(EQ 200MG/ML)

N21751 001 Aug 11, 2004 Aug NEWA

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

@ OVATION PHARMS

30MG

N84095 001

May DISC

@

100MG

N83245 001

May DISC

SODIUM PENTOBARBITAL

+ VALEANT PHARM INTL

100MG

N83264 001

May CRLD

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ ORTHO MCNEIL PHARM

100MG

N20193 001 Sep 26, 1996 Jun CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

BONTRIL PDM

AA

VALEANT

35MG

N85272 001

Aug CAHN

PHENYLBUTAZONE

CAPSULE; ORAL

PHENYLBUTAZONE

@ MUTUAL PHARM

100MG

N88994 001 Dec 04, 1985 Aug CAHN

TABLET; ORAL

PHENYLBUTAZONE

@ MUTUAL PHARM

100MG

N88863 001 Dec 04, 1985 Aug CAHN

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

AB

TARO

125MG/5ML

N40521 001 Mar 08, 2004 Mar NEWA

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

+ PARKE DAVIS

30MG EXTENDED

N84349 001

Aug MAGC

AB

+

100MG EXTENDED

N84349 002

Aug MAGC

DIPHENYLIC SODIUM

@ LANNETT

30MG PROMPT

N80857 001

Aug MAGC

@

100MG PROMPT

N80857 002

Aug MAGC

CAPSULE; ORAL

AB	EXTENDED PHENYTOIN SODIUM						
	BARR	100MG EXTENDED	N40435 001	Jun 20, 2003	Aug	MAGC	
AB	MYLAN	100MG EXTENDED	N40298 001	Dec 28, 1998	Aug	MAGC	
	@ PLIVA	100MG EXTENDED	N89441 001	Dec 18, 1986	Aug	MAGC	
	PHENYTEK						
+	MYLAN	200MG EXTENDED	N40298 002	Dec 06, 2001	Aug	MAGC	
+		300MG EXTENDED	N40298 003	Dec 06, 2001	Aug	MAGC	
	PHENYTEX						
@	WATSON LABS	100MG EXTENDED	N88711 001	Dec 21, 1984	Aug	MAGC	
	PHENYTOIN SODIUM						
@	PHARMERAL	100MG PROMPT	N85435 001		Aug	MAGC	
@	WATSON LABS	100MG PROMPT	N85894 001		Aug	MAGC	
	PROMPT PHENYTOIN SODIUM						
BX	+	IVAX PHARMS	100MG PROMPT	N80259 001		Aug	MAGC
	@ WATSON LABS	100MG PROMPT	N80905 001		Aug	MAGC	
	INJECTABLE; INJECTION						
	PHENYTOIN SODIUM						
@	HOSPIRA	50MG/ML	N89521 001	Mar 17, 1987	May	CAHN	
@		50MG/ML	N89744 001	Dec 18, 1987	May	CAHN	

PHYTONADIONE

	INJECTABLE; INJECTION					
BP	VITAMIN K1					
	HOSPIRA	1MG/0.5ML	N87954 001	Jul 25, 1983	May	CAHN
BP		10MG/ML	N87955 001	Jul 25, 1983	May	CAHN
	@	10MG/ML	N87956 001	Jul 25, 1983	May	CAHN

PIPERACILLIN SODIUM

	INJECTABLE; INJECTION					
	PIPERACILLIN					
+	AM PHARM	EQ 40GM BASE/VIAL	N65157 001	Jul 12, 2004	Jul	NEWA

PIPERAZINE CITRATE

	SYRUP; ORAL					
	MULTIFUGE					
@	BLULINE	EQ 500MG BASE/5ML	N09452 001		Jul	DISC

PODOFILOX

	SOLUTION; TOPICAL						
	CONDYLOX						
AT	+	OCLASSEN	0.5%	N19795 001	Dec 13, 1990	Sep	CAHN

POLYETHYLENE GLYCOL 3350

	FOR SOLUTION; ORAL						
	GLYCOLAX						
AA	SCHWARZ PHARMA	17GM/SCOOPFUL	N76652 001	Jul 02, 2004	Jul	NEWA	
	MIRALAX						
AA	+	BRAINTREE	17GM/SCOOPFUL	N20698 001	Feb 18, 1999	Jul	CFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

	FOR SOLUTION; ORAL						
	NULYTLY						
AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 001	Apr 22, 1991	Feb	CFTG

FOR SOLUTION; ORAL
NULYTELY-FLAVORED

AA	+	BRAINTREE	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N19797 002 Nov 18, 1994 Feb CFTG
		TRILYTE		
AA		SCHWARZ PHARMA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;1 1.2GM/BOT	N76491 001 Feb 05, 2004 Feb NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL
OCL

+ HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML; 146MG/100ML;1.29GM/100ML	N19284 001 Apr 30, 1986 May CAHN
-----------	---	----------------------------------

POTASSIUM ACETATE

INJECTABLE; INJECTION
POTASSIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA	2MEQ/ML	N18896 001 Jul 20, 1984 May CAHN
-----------	---------	----------------------------------

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

@ HOSPIRA	1MEQ/ML	N80205 003 May CAHN
@	1MEQ/ML	N83345 003 May CAHN
+	1.5MEQ/ML	N83345 001 May CAHN
AP +	2MEQ/ML	N80205 001 May CAHN
AP	2MEQ/ML	N83345 002 May CAHN
@	2.4MEQ/ML	N80205 004 May CAHN
@	3.2MEQ/ML	N80205 005 May CAHN
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER		
@ HOSPIRA	14.9MG/ML	N20161 005 Nov 30, 1992 May CAHN
@	745MG/100ML	N20161 001 Nov 30, 1992 May CAHN
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER		
AP + HOSPIRA	29.8MG/ML	N20161 006 Aug 11, 1998 May CAHN
@	1.49GM/100ML	N20161 002 Nov 30, 1992 May CAHN
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER		
AP + HOSPIRA	2.24GM/100ML	N20161 003 Aug 11, 1998 May CAHN
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER		
AP + HOSPIRA	2.98GM/100ML	N20161 004 Aug 11, 1998 May CAHN
TABLET, EXTENDED RELEASE; ORAL		
POTASSIUM CHLORIDE		
AB EURAND	20MEQ	N76368 001 Aug 18, 2004 Aug NEWA

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP HOSPIRA	149MG/100ML;900MG/100ML	N19686 001 Oct 17, 1988 May CAHN
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER		
AP HOSPIRA	298MG/100ML;900MG/100ML	N19686 002 Oct 17, 1988 May CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION
THAM-E

@ HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N13025 001 May CAHN
-----------	----------------------------------	---------------------

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE				
@ EVERYLIFE	2.5MG	N84439 002	May	DISC
@	5MG	N84439 003	May	DISC
@ SPERTI	1MG	N80358 001	May	DISC
@	2.5MG	N80358 002	May	DISC
@	5MG	N80358 003	May	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE				
MORTON GROVE	EQ 15MG BASE/5ML	N76895 001	Oct 04, 2004	Oct NEWA
PREDNISOLONE SODIUM PHOSPHATE		N75988 001	May 25, 2004	May NEWA
PADDOCK	EQ 5MG BASE/5ML			

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

AT	+	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N18988 001	Aug 26, 1988	Aug CAHN
----	---	----------	------------------------	------------	--------------	----------

PREDNISONE

TABLET; ORAL

DELTASONE					
@ PHARMACIA AND UPJOHN	2.5MG	N09986 005	Sep	DISC	
@	5MG	N09986 002	Oct	DISC	
@	5MG	N09986 002	Oct	DISC	
@	10MG	N09986 006	Sep	DISC	
@	20MG	N09986 007	Jul	DISC	
@	50MG	N09986 008	Oct	DISC	
@	50MG	N09986 008	Oct	DISC	
PREDNISONE					
@ MUTUAL PHARM	5MG	N80701 001	Aug	CAHN	
@	10MG	N86595 001	Aug	CAHN	
@	20MG	N84634 001	Aug	CAHN	
@	50MG	N86596 001	Aug	CAHN	
ROXANE	2.5MG	N87801 001	Apr 22, 1982	Oct CRLD	
AB	2.5MG	N87801 001	Apr 22, 1982	Oct CRLD	
AB	5MG	N80352 001	Oct	CRLD	
AB	5MG	N80352 001	Oct	CRLD	
AB	5MG	N84122 001	Oct	CRLD	
AB	10MG	N84122 001	Oct	CRLD	
AB	10MG	N87342 001	Jul	CRLD	
AB	20MG	N84283 001	Oct	CRLD	
AB	50MG	N84283 001	Oct	CRLD	
AB	50MG	N85813 001	Aug	DISC	
@ SANDOZ	20MG				
WEST WARD	2.5MG	N40538 001	Jan 08, 2004	Jan NEWA	

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL				
HOSPIRA	100MG/ML	N89069 001	Feb 12, 1986	May CAHN
	500MG/ML	N89070 001	Feb 12, 1986	May CAHN
	500MG/ML	N89537 001	Aug 25, 1987	May CAHN

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NOVOCAIN

AP	*	HOSPIRA	1%	N85362 003	May CAHN
AP	+		2%	N85362 004	May CAHN
	+		10%	N86797 001	May CAHN
		PROCaine HCl			
AP		HOSPIRA	1%	N80416 001	May CAHN
AP			2%	N80416 002	May CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

AP		BAXTER HLTHCARE	EQ 5MG BASE/ML	N89903 001	Aug 29, 1989 Aug CAHN
AP		BEDFORD	EQ 5MG BASE/ML	N40540 001	May 28, 2004 May NEWA
AP		HOSPIRA	EQ 5MG BASE/ML	N89703 001	Apr 07, 1988 May CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCl

AP		BEDFORD LABS	25MG/ML	N40524 001	Mar 17, 2004 Mar NEWA
AP			50MG/ML	N40524 002	Mar 17, 2004 Mar NEWA
AP		BIONICHE PHARMA	25MG/ML	N40471 001	Nov 21, 2002 Sep CAHN
AP		HOSPIRA	25MG/ML	N40372 001	Jun 08, 2000 May CAHN
AP			50MG/ML	N40372 002	Jun 08, 2000 May CAHN
AP			50MG/ML	N83838 002	May CAHN

SYRUP; ORAL
PROMETH PLAIN
ALPHARMA

			6.25MG/5ML	N85953 001	Feb DISC
--	--	--	------------	------------	----------

PROMETHAZINE HCl

AA		HI TECH PHARMA	6.25MG/5ML	N40026 001	Sep 25, 1998 May CRLD
AA	+		6.25MG/5ML	N40026 001	Sep 25, 1998 Feb CRLD

PROMETHAZINE PLAIN

AA	+	MORTON GROVE	6.25MG/5ML	N87953 001	Nov 15, 1982 May CRLD
----	---	--------------	------------	------------	-----------------------

TABLET; ORAL
PHENERGAN

AB		# WYETH PHARMS INC	12.5MG	N07935 002	Sep DISC
AB			12.5MG	N07935 002	Jul CPTG
AB	+		25MG	N07935 003	Jul CTEC
AB			50MG	N07935 004	Jul CTEC

PROMETHAZINE HCl

AB		ABLE	12.5MG	N40558 001	Jul 01, 2004 Jul NEWA
AB			25MG	N40558 002	Jul 01, 2004 Jul NEWA
AB			50MG	N40558 003	Jul 01, 2004 Jul NEWA

MUTUAL PHARM

			12.5MG	N84555 001	Aug CAHN
			25MG	N84554 001	Aug CAHN
			50MG	N84557 001	Aug CAHN

PROPafenone HYDROCHLORIDE

TABLET; ORAL
PROPafenone HCl

AB		PLIVA	150MG	N76550 001	Apr 23, 2004 Apr NEWA
AB			225MG	N76550 002	Apr 23, 2004 Apr NEWA
AB			300MG	N76550 003	Apr 23, 2004 Apr NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
 DARVON
 # AAIPHARMA LLC 32MG N10997 001 Aug DISC
 PROPOXYPHENE HCL
 # MUTUAL PHARM 65MG N83186 001 Aug CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
 PROPRANOLOL
 AP TABLET; ORAL AM PHARM PARTNERS 1MG/ML N75826 001 Aug 31, 2001 Jan NEWA
 PROPRANOLOL HCL
 # MUTUAL PHARM 10MG N70319 001 Oct 22, 1985 Aug CAHN
 # 20MG N70320 001 Oct 22, 1985 Aug CAHN
 # 40MG N70103 001 Oct 22, 1985 Aug CAHN
 # 60MG N70321 001 Sep 24, 1986 Aug CAHN
 # 80MG N70322 001 Aug 04, 1986 Aug CAHN

PROPYLTHIOURACIL

TABLET; ORAL
 PROPYLTHIOURACIL
 # MUTUAL PHARM 50MG N83982 001 Aug CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION
 PROTAMINE SULFATE
 + AM PHARM PARTNERS 10MG/ML N89454 001 Apr 07, 1987 Mar CRLD
 # LILLY 10MG/ML N06460 002 Mar DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL
 VIVACTIL
 # ODYSSEY PHARMS 5MG N16012 001 Jun CAHN
 # 10MG N16012 002 Jun CAHN

PANTITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT; ORAL
 ZANTAC 25
 GLAXOSMITHKLINE EQ 25MG BASE N20251 003 Apr 01, 2004 Apr NEWA

RIBAVIRIN

CAPSULE; ORAL
 REBETOL
 AB + SCHERING PLOUGH RES 200MG N20903 002 Jul 25, 2001 Apr CFTG
 RIBASPHERE
 AB THREE RIVERS PHARMS 200MG N76203 001 Apr 06, 2004 Apr NEWA
 AB RIBAVIRIN
 SANDOZ 200MG N76192 001 Apr 06, 2004 Apr NEWA
 AB TEVA 200MG N76277 001 Oct 04, 2004 Oct NEWA

RIFAXIMIN

TABLET; ORAL
 XIFAXAN
 + SALIX PHARMS 200MG N21361 001 May 25, 2004 May NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

JANSSEN PHARMA	25MG/VIAL	N21346 001 Oct 29, 2003 Jul CAHN
	37.5MG/VIAL	N21346 002 Oct 29, 2003 Jul CAHN
+	50MG/VIAL	N21346 003 Oct 29, 2003 Jul CAHN
TABLET, ORALLY DISINTEGRATING; ORAL		
RISPERDAL		
JANSSEN PHARMA	0.5MG	N21444 001 Apr 02, 2003 Jun CAHN
+	1MG	N21444 002 Apr 02, 2003 Jun CAHN
	2MG	N21444 003 Apr 02, 2003 Jun CAHN

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HCL

+	HOSPIRA	10MG/ML	N71618 001 Feb 28, 1991 May CAHN
+		15MG/ML	N71619 001 Feb 28, 1991 May CAHN
	RITODRINE HCL IN DEXTROSE 5% IN PLASTIC CONTAINER		
+	HOSPIRA	30MG/100ML	N71438 001 Jan 22, 1991 May CAHN

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

@	ORGANON USA INC	10MG/ML	N20214 002 Mar 17, 1994 Jul DISC
		10MG/ML	N20214 002 Mar 17, 1994 Jun CMFD
	ZEMURON (P/F)		
+	ORGANON USA INC	50MG/5ML(10MG/ML)	N20214 001 Mar 17, 1994 Jul CPOT
+		100MG/10ML(10MG/ML)	N20214 003 Mar 17, 1994 Jul NEWA

ROFECOXIB

SUSPENSION; ORAL

VIOXX

@ MERCK	12.5MG/5ML	N21052 001 May 20, 1999 Sep DISC
@	25MG/5ML	N21052 002 May 20, 1999 Sep DISC

TABLET; ORAL

VIOXX

@ MERCK	12.5MG	N21042 001 May 20, 1999 Sep DISC
@	25MG	N21042 002 May 20, 1999 Sep DISC
@	50MG	N21042 003 Feb 25, 2000 Sep DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

GLAXOSMITHKLINE	EQ 5MG BASE	N20658 005 Sep 19, 1997 May CRLD
-----------------	-------------	----------------------------------

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

+	HOSPIRA	5%;5% (5GM/100ML)	N18997 001 Aug 27, 1984 May CAHN
+	HOSPIRA	10%;10% (10GM/100ML)	N18991 001 Aug 27, 1984 May CAHN

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+ CHIRHOCLIN

16UGM/VIAL

N21256 001 Apr 09, 2004 Sep CTNA

HUMAN SECRETIN

+ CHIRHOCLIN

16UGM/VIAL

N21256 001 Apr 09, 2004 Apr NEWA

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREMAX

+ CHIRHOCLIN

16UGM/VIAL

N21136 001 Apr 04, 2002 Jul CAIN

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HCL

@ SOMERSET

5MG

N19334 001 Jun 05, 1989 Aug DISC

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

@ GENZYME

403MG

N20926 001 Oct 30, 1998 Jun DISC

SIROLIMUS

TABLET; ORAL

RAPAMUNE

WYETH PHARMS INC

2MG

N21110 002 Aug 22, 2002 Feb CRLD

+

5MG

N21110 003 Feb 23, 2004 Feb NEWA

SODIUM ACETATE, ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA

2MEQ/ML

N18893 001 May 04, 1983 May CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP

9MG/ML

N18800 001 Oct 29, 1982 May CAHN

+ HOSPIRA

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP

450MG/100ML

N18090 001 May CAHN

AP

450MG/100ML

N19759 001 Jun 08, 1988 May CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>>>

900MG/100ML

N76316 001 Oct 27, 2004 Oct NEWA

AP HAEMONETICS

9MG/ML

N18803 001 Oct 29, 1982 May CAHN

HOSPIRA

9MG/ML

N19217 001 Jul 13, 1984 May CAHN

AP

9MG/ML

N19217 001 Jul 13, 1984 Jul CRLD

+

9MG/ML

N19465 002 Jul 15, 1985 May CAHN

AP

9MG/ML

N16366 001 May CAHN

AP

900MG/100ML

N19465 001 Jul 15, 1985 May CAHN

AP

900MG/100ML

N19480 001 Sep 17, 1985 May CAHN

AP

900MG/100ML

N18897 001 Jul 20, 1984 May CAHN

SODIUM CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

2.5MEQ/ML

N17670 001 May CAHN

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AT

450MG/100ML

N18380 001 May CAHN

HOSPIRA

450MG/100ML

8

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AT	HOSPIRA	900MG/100ML	N17514 001	May CAHN
AT		900MG/100ML	N18314 001	May CAHN

SODIUM FERRIC GLUCONATE COMPLEXINJECTABLE; INJECTION

FERRLECIT

+ WATSON PHARMS	62.5MG/5ML	N20955 001 Feb 18, 1999 Feb CAHN
-----------------	------------	----------------------------------

SODIUM IODIDE, I-131SOLUTION; ORAL

SODIUM IODIDE I 131

@ CIS	50mCi/ML	N17315 001	Apr DISC
-------	----------	------------	----------

SODIUM LACTATEINJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP	HOSPIRA	1.87GM/100ML	N18249 001	May CAHN
SODIUM LACTATE IN PLASTIC CONTAINER				
	HOSPIRA	5MEQ/ML	N18947 001 Sep 05, 1984 May CAHN	

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION

NITROPRESS

AP	+ HOSPIRA	25MG/ML	N71961 001 Aug 01, 1988 May CAHN
	+	50MG/VIAL	N70566 001 Jun 09, 1986 May CAHN

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUSINJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

HOSPIRA	142MG/ML;276MG/ML	N18892 001 May 10, 1983 May CAHN
---------	-------------------	----------------------------------

SOMATROPIN RECOMBINANTINJECTABLE; INJECTION

>A>	NORDITROPIN NORDIFLEX		
>A>	NOVO NORDISK	5MG/1.5ML	N21148 004 Oct 01, 2004 Oct NEWA
>A>		10MG/1.5ML	N21148 005 Oct 01, 2004 Oct NEWA
>A>		15MG/1.5ML	N21148 006 Oct 01, 2004 Oct NEWA
SAIZEN			
	@ SERONO	6MG/VIAL	N19764 001 Oct 08, 1996 May DISC
SEROSTIM			
BX	SERONO	4MG/VIAL	N20604 003 Jul 25, 1997 Jan CTBC
	@	8.8MG/VIAL	N20604 004 Sep 06, 2001 Jan DISC
ZORBTIVE			
	@ SERONO INC	4MG/VIAL	N21597 001 Dec 01, 2003 May DISC
	@	5MG/VIAL	N21597 002 Dec 01, 2003 May DISC
	@	6MG/VIAL	N21597 003 Dec 01, 2003 May DISC

SOTALOL HYDROCHLORIDETABLET; ORAL

SOTALOL HCL

AB2	MUTUAL PHARM	80MG	N76576 001 Apr 08, 2004 Apr NEWA
AB2		120MG	N76576 002 Apr 08, 2004 Apr NEWA
AB2		160MG	N76576 003 Apr 08, 2004 Apr NEWA
AB2	TEVA	80MG	N76883 001 Jul 26, 2004 Jul NEWA

TABLET; ORAL
 SOTALOL HCL
 AB2 TEVA 120MG N76883 002 Jul 26, 2004 Jul NEWA
 AB2 TEVA 160MG N76883 003 Jul 26, 2004 Jul NEWA

SOYBEAN OIL

INJECTABLE; INJECTION
 LIPOSYN III 10%
 AP + HOSPIRA 10% N18969 001 Sep 24, 1984 May CAHN
 LIPOSYN III 20%
 AP + HOSPIRA 20% N18970 001 Sep 25, 1984 May CAHN
 LIPOSYN III 30%
 AP + HOSPIRA 30% N20181 001 Jan 13, 1998 May CAHN

SPARFLOXACIN

TABLET; ORAL
 ZAGAM
 @ MYLAN 200MG N20677 001 Dec 19, 1996 Mar DISC

SPIRONOLACTONE

TABLET; ORAL
 SPIRONOLACTONE
 AB MUTUAL PHARM 25MG N87265 001 Aug CAHN

STAVUDINE

CAPSULE, EXTENDED RELEASE; ORAL
 ZERIT XR
 @ BRISTOL MYERS SQUIBB 37.5MG N21453 001 Dec 31, 2002 Jun DISC
 @ 50MG N21453 002 Dec 31, 2002 Jun DISC
 @ 75MG N21453 003 Dec 31, 2002 Jun DISC
 @ 100MG N21453 004 Dec 31, 2002 Jun DISC

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
 ANECTINE
 AP + SABEX 2002 20MG/ML N08453 002 Jul CAHN
 @ 50MG/ML N08453 003 Jul CAHN
 + 500MG/VIAL N08453 001 Jul CAHN
 + 1GM/VIAL N08453 004 Jul CAHN
 QUELICIN
 AP + HOSPIRA 20MG/ML N08845 006 May CAHN
 QUELICIN PRESERVATIVE FREE
 AP + HOSPIRA 20MG/ML N08845 001 May CAHN
 @ 50MG/ML N08845 002 May CAHN
 + 100MG/ML N08845 004 May CAHN

SUCRALFATE

TABLET; ORAL
 CARAFATE
 AB + AXCAN SCANDIPHARM 1GM N18333 001 Feb CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION
 SUFENTANIL CITRATE
 AP BAXTER HLTHCARE EQ 0.05MG BASE/ML N74413 001 Dec 15, 1995 Aug CAHN

INJECTABLE; INJECTION

SULFENTANIL CITRATE

AP HOSPIRA EQ 0.05MG BASE/ML N74534 001 Dec 11, 1996 May CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULF-10

AT NOVARTIS 10% N80025 001 Mar CMFD

SULFACYTINE

TABLET; ORAL

RENOQUID

@ GLENWOOD 250MG N17569 001 Aug DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ BAXTER HLTHCARE 80MG/ML;16MG/ML

N70627 001 Dec 29, 1987 Sep DISC

AP 80MG/ML;16MG/ML N70627 001 Dec 29, 1987 Aug CAHN

AP 80MG/ML;16MG/ML N70628 001 Dec 29, 1987 Aug CAHN

AP HOSPIRA 80MG/ML;16MG/ML N73199 001 Sep 11, 1992 May CAHN

TABLET; ORAL

SULFAMETHOPRIM-DS

@ PAR PHARM 800MG;160MG N70032 001 Feb 15, 1985 Sep DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ MUTUAL PHARM 400MG;80MG N70006 001 Nov 14, 1984 Aug CAHN

@ SANDOZ 400MG;80MG N70889 001 Nov 13, 1986 Sep DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

@ MUTUAL PHARM 800MG;160MG N70007 001 Nov 14, 1984 Aug CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

BERLEX LABS N/A N20887 001 Sep 14, 1998 Jun CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

+ BERLEX LABS N/A N21012 001 Aug 03, 1999 Jun CAHN

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

DRAXIMAGE MDP

AP + DRAXIMAGE N/A N18035 001 May CTNA

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+ MALLINCKRODT N/A N18321 001 Sep CRLD

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

+ BRISTOL MYERS SQUIBB N/A N19785 001 Dec 21, 1990 Jul CRLD

TELITHROMYCIN

TABLET; ORAL
KETEK
+ AVENTIS PHARMS 400MG N21144 001 Apr 01, 2004 Apr NEWA

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM
@ MUTUAL PHARM 15MG N71174 001 Jul 10, 1986 Aug CAHN
@ 30MG N71175 001 Jul 10, 1986 Aug CAHN

TERRINAFINE

GEL; TOPICAL
LAMISIL
NOVARTIS 1% N20846 001 Apr 29, 1998 Jan CMFD

TERBUTALINE SULFATE

INJECTABLE; INJECTION
BRETHINE
AP + AAIPHARMA LLC 1MG/ML N18571 001 Apr CFTG
TERBUTALINE SULFATE
AP AM PHARM 1MG/ML N76887 001 May 26, 2004 May NEWA
AP BEDFORD 1MG/ML N76770 001 Apr 23, 2004 Apr NEWA
AP SICOR PHARMS 1MG/ML N76853 001 Jul 20, 2004 Jul NEWA

TERCONAZOLE

CREAM; VAGINAL
TERAZOL 3
AB + ORTHO MCNEIL PHARM 0.8% N19964 001 Feb 21, 1991 Apr CFTG
TERCONAZOLE
DA EX + ALTANA 0.8% N21735 001 Oct 01, 2004 Oct NEWA
AB TARO 0.8% N75953 001 Apr 06, 2004 Apr NEWA

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM
+ WATSON LABS 5MG/24HR N20489 002 May 02, 1997 Aug CTEC
TESTODERM
@ ALZA 4MG/24HR N19762 001 Oct 12, 1993 Aug DISC
@ 6MG/24HR N19762 002 Oct 12, 1993 Aug DISC
TESTODERM TTS
@ ALZA 5MG/24HR N20791 001 Dec 18, 1997 Aug DISC

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB MUTUAL PHARM 250MG N60736 001 Aug CAHN
500MG N60736 002 Aug CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
AEROLATE III
@ FLEMING PHARMS 65MG N85075 003 Nov 24, 1986 Jun DISC
AEROLATE JR
@ FLEMING PHARMS 130MG N85075 002 Nov 24, 1986 Jun DISC

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE SR

@ FLEMING PHARMS

260MG

N85075 001 Nov 24, 1986 Jun DISC

THEOPHYLLINE

>D>	AB	INWOOD LABS	100MG	N40052 001 Feb 14, 1994 Oct CTEC
>A>	BC		100MG	N40052 001 Feb 14, 1994 Oct CTEC
>D>	AB		125MG	N40052 002 Feb 14, 1994 Oct CTEC
>A>	BC		125MG	N40052 002 Feb 14, 1994 Oct CTEC
>D>	AB		200MG	N40052 003 Feb 14, 1994 Oct CTEC
>A>	BC		200MG	N40052 003 Feb 14, 1994 Oct CTEC
>D>	AB		300MG	N40052 004 Feb 14, 1994 Oct CTEC
>A>	BC	+	300MG	N40052 004 Feb 14, 1994 Oct CTEC

INJECTABLE; INJECTION

THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	HOSPIRA	4MG/ML	N19211 007 Dec 14, 1984 May CAHN
AP	+		40MG/100ML	N19211 001 Dec 14, 1984 May CAHN
AP	+		80MG/100ML	N19211 002 Dec 14, 1984 May CAHN
AP	+		160MG/100ML	N19211 003 Dec 14, 1984 May CAHN
AP	+		200MG/100ML	N19211 004 Dec 14, 1984 May CAHN
AP	+		320MG/100ML	N19211 006 Jan 20, 1988 May CAHN
AP	+		400MG/100ML	N19211 005 Dec 14, 1984 May CAHN

SOLUTION; ORAL

AEROLATE

@ FLEMING PHARMS 150MG/15ML

N89141 001 Dec 03, 1986 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

THEOLAIR-SR

@ 3M		200MG	N88369 001 Jul 16, 1987 Jun DISC
@		250MG	N86363 002 Jul 16, 1987 Jun DISC
@		300MG	N88364 001 Jul 16, 1987 Jun DISC
@		500MG	N89132 001 Jul 16, 1987 Jun DISC

THEOPHYLLINE

AB		ABLE	300MG	N40548 001 Apr 30, 2004 Apr NEWA
AB			400MG	N40543 001 Apr 27, 2004 Apr NEWA
AB			450MG	N40546 001 Apr 30, 2004 Apr NEWA
AB			600MG	N40539 001 Apr 27, 2004 Apr NEWA

UNIPHYL

AB	+	PURDUE FREDERICK	400MG	N87571 001 Sep 01, 1982 Apr CFTG
AB	+		600MG	N40086 001 Apr 15, 1996 Apr CFTG

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

AP		BAXTER HLTHCARE	100MG/ML	N80575 001 Aug CAHN
AP		HOSPIRA	100MG/ML	N40079 001 May 03, 1996 May CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HCL

@	MUTUAL PHARM	10MG	N88375 001 Nov 18, 1983 Aug CAHN
@		15MG	N88461 001 Nov 18, 1983 Aug CAHN
@		25MG	N87264 001 Nov 18, 1983 Aug CAHN
AB		50MG	N88370 001 Nov 18, 1983 Aug CAHN
@		100MG	N88379 001 Nov 16, 1983 Aug CAHN
@		150MG	N88737 001 Sep 26, 1984 Aug CAHN
@		200MG	N88738 001 Oct 16, 1984 Aug CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

BT	+	ISTALOL	EQ 0.5% BASE	N21516 001 Jun 04, 2004 Sep CTEC
	+	ISTA PHARMS	EQ 0.5% BASE	N21516 001 Jun 04, 2004 Jun NEWA
	+	SENJU	EQ 0.5% BASE	
AT		TIMOLOL MALEATE	EQ 0.5% BASE	N75163 001 Sep 10, 2002 Jun CDER
		HI TECH PHARMA	EQ 0.5% BASE	

TINIDAZOLE

TABLET; ORAL

TINDAMAX

PRESUTTI LABS

250MG

N21618 001 May 17, 2004 May NEWA
N21618 002 May 17, 2004 May NEWA

+

500MG

TIOTROPIUM BROMIDE MONOHYDRATE

CAPSULE; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM EQ 0.018MG BASE

N21395 001 Jan 30, 2004 Jan NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

ZANAFLEX

ACORDA

EQ 2MG BASE

N21447 001 Aug 29, 2002 Aug CAHN
N21447 002 Aug 29, 2002 Aug CAHN
N21447 003 Aug 29, 2002 Aug CAHN

+

EQ 4MG BASE

EQ 6MG BASE

TABLET; ORAL

TIZANIDINE HCL

IVAX PHARMS

EQ 2MG BASE

N76321 001 Sep 30, 2004 Sep NEWA
N76321 002 Sep 30, 2004 Sep NEWA

AB

EQ 4MG BASE

AB

EQ 2MG BASE

AB

EQ 4MG BASE

N76533 001 Jan 16, 2004 Jan NEWA
N76533 002 Jan 16, 2004 Jan NEWA

AB

ZANAFLEX

ACORDA

EQ 2MG BASE

N20397 002 Feb 04, 2000 Aug CAHN
N20397 001 Nov 27, 1996 Aug CAHN

AB

EQ 4MG BASE

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

@ LILLY

EQ 10MG BASE/ML

N50477 005 Jun DISC

@

EQ 10MG BASE/ML

N62008 004 Jun DISC

@

EQ 10MG BASE/ML

N62707 001 Apr 29, 1987 Jun DISC

@

EQ 40MG BASE/ML

N62008 001 Jun DISC

@

EQ 1.2GM BASE/VIAL

N50519 001 Jun DISC

TOBRAMYCIN

AM PHARM

EQ 1.2GM BASE/VIAL

N50789 001 Jul 13, 2004 Jul NEWA

AP

+ PHARMA TEK

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jun CRLD

+

EQ 1.2GM BASE/VIAL

N65013 001 Aug 17, 2001 Jul CTEC

TOBRAMYCIN SULFATE

HOSPIRA

EQ 10MG BASE/ML

N63080 001 Apr 30, 1991 May CAHN

AP

EQ 10MG BASE/ML

N63080 001 Apr 30, 1991 Jun CRLD

AP

EQ 10MG BASE/ML

N63112 001 Apr 30, 1991 May CAHN

AP

EQ 40MG BASE/ML

N63111 001 Apr 30, 1991 May CAHN

AP

EQ 40MG BASE/ML

N63116 001 May 18, 1992 May CAHN

AP

EQ 40MG BASE/ML

N63161 001 May 29, 1991 May CAHN

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
+ HOSPIRA EQ 1.2MG BASE/ML N63081 003 Jul 31, 1990 May CAHN

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ HOSPIRA	EQ 1.6MG BASE/ML	N63081 006 Jun 02, 1993 May CAHN
+	EQ 80MG BASE/100ML	N63081 001 Jul 31, 1990 May CAHN

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ WATSON LABS

100MG

N70513 001 Jan 09, 1986 Aug DISC

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT

100MG

N20697 001 Jan 29, 1998 Aug CAHN

+

200MG

N20697 002 Jan 29, 1998 Aug CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ TEVA

EQ 400MG BASE

N73519 001 May 29, 1992 Sep DISC

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

ORTHO MCNEIL PHARM

15MG

N20844 001 Oct 26, 1998 Jul CAHN

+

25MG

N20844 002 Oct 26, 1998 Jul CAHN

@

50MG

N20844 003 Oct 26, 1998 Jul CAHN

TABLET; ORAL

TOPAMAX

ORTHO MCNEIL PHARM

50MG

N20505 005 Dec 24, 1996 Jun CMFD

TORSEMIDE

TABLET; ORAL

TORSEMIDE

>A> AB

PLIVA PHARM IND

100MG

N76346 004 Oct 19, 2004 Oct NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

+ ALCON

0.004%

N21257 001 Mar 16, 2001 May CAHN

TRETINOIN

CREAM; TOPICAL

AVITA

AB

MYLAN BERTEK

0.025%

N20404 003 Jan 14, 1997 Aug CAHN

GEL; TOPICAL

AVITA

BT

MYLAN BERTEK

0.025%

N20400 001 Jan 29, 1998 Aug CAHN

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

BP

+ FUJISAWA HLTHCARE

4MG

N11161 007

Jun CRLD

KENACORT

@ BRISTOL MYERS SQUIBB

8MG

N11283 010

Jun DISC

TABLET; ORAL
TRIAMCINOLONE
@ WATSON LABS 4MG

N84270 001

Jun DISC

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT
+ KOS 0.1MG/INH

N18117 001 Apr 23, 1982 Apr CAHN

SPRAY, METERED; NASAL
NASACORT HFA
+ AVENTIS PHARMS 0.055MG/SPRAY

N20784 001 Apr 07, 2004 Apr NEWA

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT
@ SABEX 2002 25MG/ML
@ 40MG/ML

N11685 003

Jun DISC

N12802 001

Jun DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HCL
HOSPIRA 100MG/ML

N88804 001 Apr 03, 1987 May CAHN

AP

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM
@ MUTUAL PHARM 100MG
@ 200MG

N70494 001 Jan 22, 1986 Aug CAHN

N70495 001 Sep 24, 1986 Aug CAHN

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL
ODYSSEY PHARMS EQ 25MG BASE
EQ 50MG BASE
+ EQ 100MG BASE

N16792 001

Jun CAHN

N16792 002

Jun CAHN

N16792 003 Sep 15, 1982 Jun CAHN

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR
+ WATSON PHARMS 11.25MG/VIAL
TRELSTAR DEPOT
+ WATSON PHARMS EQ 3.75MG BASE/VIAL

N21288 001 Jun 29, 2001 Sep CAHN

N20715 001 Jun 15, 2000 Sep CAHN

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX
@ PURDUE FREDERICK 10%

N11340 002

May DISC

TROMETHAMINE

INJECTABLE; INJECTION

THAM
+ HOSPIRA 3.6GM/100ML

N13025 002

May CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-100

TROSPiUM CHLORIDE

TABLET; ORAL
SANCTURA
+ INDEVUS 20MG

N21595 001 May 28, 2004 May NEWA

TROVAFLOXACIN MESYLATE

TABLET; ORAL
TROVAN
@ PFIZER EQ 100MG BASE
@ EQ 200MG BASE

N20759 001 Dec 18, 1997 Jun DISC
N20759 002 Dec 18, 1997 Jun DISCTUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
@ BRISTOL MYERS SQUIBB 3MG/ML
+ 3MG/ML
@ HOSPIRA 3MG/ML
AP + 3MG/ML

N05657 001 Jul DISC
N05657 001 Jun CTEC
N06095 001 Jun DISC
N06095 001 May CAHNUNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ NOVARTIS 0.15%

N21214 001 Aug 03, 2000 Aug CAHN

UREA

INJECTABLE; INJECTION
STERILE UREA
@ HOSPIRA 40GM/VIAL
UREAPHIL
+ HOSPIRA 40GM/VIAL

N17698 001 May CAHN
N12154 001 May CAHNUROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS
BRAVELLE
>D> BX + FERRING 75 IU/VIAL
>A> + 75 IU/VIAL
INJECTABLE; SUBCUTANEOUS
>D> FERTINEX
>D> BX + SERONO 75 IU/AMP
>A> @ 75 IU/AMP

N21289 001 May 06, 2002 Oct CTEC
N21289 001 May 06, 2002 Oct CTEC
N19415 005 Aug 23, 1996 Oct DISC
N19415 005 Aug 23, 1996 Oct DISCURSODIOL

TABLET; ORAL
URSO 250
AXCAN SCANDIPHARM 250MG
URSO FORTE
+ AXCAN SCANDIPHARM 500MG
URSODIOL
+ AXCAN SCANDIPHARM 500MG

N20675 001 Dec 10, 1997 Jul CTNA
N20675 002 Jul 21, 2004 Sep CTNA
N20675 002 Jul 21, 2004 Jul NEWAVALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL
VALTREX
+ GLAXOSMITHKLINE EQ 1GM BASE

N20487 002 Jun 23, 1995 Feb CRLD

AP
AP
AP
AP
APAP
AP
AP>D>
>A>>D>
>A>>D>
>A>AP
AP
AP
APAB
AB
AB

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HCL

# LILLY	EQ 250MG BASE/5ML	N61667 002	Jul 13, 1983	Jun	DISC
#	EQ 500MG BASE/6ML	N61667 001		Jun	DISC

INJECTABLE; INJECTION

VANCOCIN HCL

# LILLY	EQ 500MG BASE/VIAL	N60180 001		Jun	DISC
#	EQ 500MG BASE/VIAL	N62476 001	Mar 15, 1984	Jun	DISC
#	EQ 500MG BASE/VIAL	N62716 001	Mar 13, 1987	Jun	DISC
#	EQ 500MG BASE/VIAL	N62812 001	Nov 17, 1987	Jun	DISC
#	EQ 1GM BASE/VIAL	N60180 002	Mar 21, 1986	Jun	DISC
#	EQ 1GM BASE/VIAL	N62476 002	Mar 21, 1986	Jun	DISC
#	EQ 1GM BASE/VIAL	N62716 002	Mar 13, 1987	Jun	DISC
#	EQ 1GM BASE/VIAL	N62812 002	Nov 17, 1987	Jun	DISC
#	EQ 10GM BASE/VIAL	N62812 003	Nov 17, 1987	Jun	DISC

VANCOMYCIN HCL

AP	HOSPIRA	EQ 500MG BASE/VIAL	N62911 001	Aug 04, 1988	May	CAHN
AP		EQ 500MG BASE/VIAL	N62931 001	Oct 29, 1992	May	CAHN
AP		EQ 1GM BASE/VIAL	N62912 001	Aug 04, 1988	May	CAHN
AP		EQ 1GM BASE/VIAL	N62933 001	Oct 29, 1992	May	CAHN
AP		EQ 5GM BASE/VIAL	N63076 001	Dec 21, 1990	May	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

+	ABBOTT	4MG/VIAL	N75558 001	Sep 11, 2001	Apr	CAHN
+	HOSPIRA	4MG/VIAL	N75558 001	Sep 11, 2001	May	CAHN
AP		10MG/VIAL	N75164 001	Oct 21, 1999	May	CAHN
AP		20MG/VIAL	N75164 002	Oct 21, 1999	May	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

EFFEXOR

>D>	WYETH PHARMS INC	EQ 50MG BASE	N20151 003	Dec 28, 1993	Oct	CRLD
>A>	+	EQ 50MG BASE	N20151 003	Dec 28, 1993	Oct	CRLD
>D>	+	EQ 50MG BASE	N20151 003	Dec 28, 1993	May	CRLD
>A>	+	EQ 100MG BASE	N20151 005	Dec 28, 1993	Oct	CRLD
	+	EQ 100MG BASE	N20151 005	Dec 28, 1993	Oct	CRLD
	+	EQ 100MG BASE	N20151 005	Dec 28, 1993	May	CRLD

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

AP	HOSPIRA	2.5MG/ML	N70577 001	Feb 02, 1987	May	CAHN
AP		2.5MG/ML	N70737 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70738 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70739 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N70740 001	May 06, 1987	May	CAHN
AP		2.5MG/ML	N75136 001	Oct 20, 1998	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HCL

AB	BARR	120MG	N75072 001	May 25, 1999	May	CMFD
AB		240MG	N75072 003	May 25, 1999	May	CMFD
AB	KALI LABS	120MG	N75072 001	May 25, 1999	Aug	CAHN

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

1-102

TABLET, EXTENDED RELEASE; ORAL
VERAPAMIL HCLAB KALI LABS 240MG
TABLET; ORAL
VERAPAMIL HCL
MUTUAL PHARM 80MG
120MGN75072 003 May 25, 1999 Aug CAHN
N70482 001 Sep 24, 1986 Aug CAHN
N70483 001 Sep 24, 1986 Aug CAHNVINCRISTINE SULFATEINJECTABLE; INJECTION
ONCOVIN
LILLY 1MG/ML

N14103 003 Mar 07, 1984 Mar DISC

VINOSELBINE TARTRATEINJECTABLE; INJECTION
VINOSELBINE TARTRATE
AP BAXTER HLTHCARE EQ 10MG BASE/ML

N75992 001 Jun 10, 2003 Aug CAHN

VITAMIN A PALMITATEINJECTABLE; INJECTION
AQUASOL A
+ MAYNE PHARMA USA EQ 50,000 UNITS BASE/ML

N06823 001 Apr CAHN

WARFARIN SODIUMTABLET; ORAL
WARFARIN SODIUMAB GENPHARM 1MG
AB 2MG
AB 2.5MG
AB 3MG
AB 4MG
AB 5MG
AB 6MG
AB 7.5MG
AB 10MGN40415 001 Sep 27, 2004 Sep NEWA
N40415 002 Sep 27, 2004 Sep NEWA
N40415 003 Sep 29, 2004 Sep NEWA
N40415 004 Sep 27, 2004 Sep NEWA
N40415 005 Sep 27, 2004 Sep NEWA
N40415 006 Sep 27, 2004 Sep NEWA
N40415 007 Sep 27, 2004 Sep NEWA
N40415 008 Sep 27, 2004 Sep NEWA
N40415 009 Sep 27, 2004 Sep NEWAWATER FOR INJECTION, STERILE

LIQUID; N/A

AP BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER
HOSPIRA 100%
AP STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
B BRAUN 100%
AP HOSPIRA 100%
AP 100%
AP 100%N18802 001 Oct 27, 1982 May CAHN
N19077 001 Mar 02, 1984 May DISC
N18233 001 May CAHN
N18801 001 Oct 27, 1982 May CAHN
N19869 001 Dec 26, 1989 May CAHNWATER FOR IRRIGATION, STERILE

LIQUID; IRRIGATION

AT STERILE WATER IN PLASTIC CONTAINER
HOSPIRA 100%
AT 100%N17513 001 May CAHN
N18313 001 May CAHNXENON, XE-133GAS; INHALATION
XENON XE 133
GEN ELECTRIC 5-100 CI/CYLINDER

N17550 001 Sep DISC

GAS; INHALATION
XENON XE 133
@ GEN ELECTRIC

0.25-5 CI/AMP

N17550 003

Sep DISC

ZIDOVUDINE

SYRUP; ORAL
RETROVIR

+ GLAXOSMITHKLINE

50MG/5ML

N19910 001 Sep 28, 1989 Jul CRLD

ZILEUTON

TABLET; ORAL
ZYFLO

+ CRITICAL

300MG

N20471 001 Dec 09., 1996 Jul CAHN

600MG

N20471 003 Dec 09, 1996 Jul CAHN

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 1MG ZINC/ML

N18959 001 Jun 26, 1986 May CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

+ PFIZER

20MG

N20825 001 Feb 05, 2001 Sep CRLD

80MG

N20825 004 Feb 05, 2001 Sep CRLD

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

SANOFI SYNTHELABO

5MG

N19908 001 Dec 16, 1992 Apr CAHN

10MG

N19908 002 Dec 16, 1992 Apr CAHN

PREScription DRUG PRODUCT LIST - 24TH EDITION
OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2004

2-1

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

+ NOVARTIS 0.5%;0.05%

N18746 002 Jul 11, 1994 Feb CAHN

>A> AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

>A> + SCHERING PLOUGH 3%;7.5%;3%

N20045 001 Dec 07, 1992 Oct CAIN

>D> AVOBENZONE; OCTYL METHOXYCINNAMATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

>D> + SCHERING PLOUGH 3%;7.5%;3%

N20045 001 Dec 07, 1992 Oct CAIN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER 2%

N20421 001 Dec 21, 1995 Jun CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

HIBICLENS

+ REGENT 4%

N17768 001 Sep CAHN

HIBISTAT

+ REGENT 0.5%

N18300 001 Sep CAHN

SPONGE; TOPICAL

HIBICLENS

+ REGENT 4%

N18423 001 Sep CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP FREPP

+ MEDI FLEX HOSP 2%;70%

N20832 001 Jul 14, 2000 Jun CTNA

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ MEDI FLEX HOSP 2%;70%

N21555 001 Oct 07, 2002 Jun CAIN

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ 12MG

N70797 001 Aug 12, 1988 Apr DISC

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

SCHERING PLOUGH 8MG

N07638 001 Sep DISC

EFIDAC 24 CHLORPHENIRAMINE MALEATE

+ ALZA 16MG

N19746 002 Nov 18, 1994 Mar CRLD

@ 16MG

N19746 002 Nov 18, 1994 Sep DISC

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ WYETH CONS 1MG/5ML;100MG/5ML;15MG/5ML

N21587 001 Feb 24, 2004 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

ADAMS LABS

30MG;600MG

60MG;1.2GM

N21620 002 Apr 29, 2004 Apr NEWA

N21620 001 Apr 29, 2004 Apr NEWA

+

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK

25MG

N40564 001 Aug 27, 2004 Aug NEWA

EPINEPHRINE

AEROSOL, METERED; INHALATION

EPINEPHRINE

ALPHARMA

ARMSTRONG PHARMS

0.2MG/INH

0.2MG/INH

N87907 001 May 23, 1984 Oct CAHN

N87907 001 May 23, 1984 Oct CAHN

>D
>AGUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MUCINEX D

ADAMS

600MG;60MG

1.2GM;120MG

N21585 001 Jun 22, 2004 Jun NEWA

N21585 002 Jun 22, 2004 Jun NEWA

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

TARO

100MG/5ML

N21604 001 Jan 07, 2004 Jan NEWA

TABLET, CHEWABLE; ORAL

IBUPROFEN

PERRIGO

50MG

100MG

N76359 001 Jan 16, 2004 Jan NEWA

N76359 002 Jan 16, 2004 Jan NEWA

TABLET; ORAL

IBUPROFEN

LNK

100MG

N76741 001 Jun 17, 2004 Jun NEWA

@ MUTUAL PHARM

200MG

N70493 001 Dec 24, 1985 Aug CAHN

@

200MG

N70908 001 Sep 26, 1986 Aug CAHN

@

200MG

N71462 001 Oct 02, 1986 Aug CAHN

IBUPROFEN POTASSIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ WYETH CONS

200MG;30MG

N21374 001 May 30, 2002 Mar CAIN

LORATADINE

SYRUP; ORAL

LORATADINE

APOTEX

MORTON GROVE

PERRIGO

RANBAXY

TARO

1MG/ML

1MG/ML

1MG/ML

1MG/ML

1MG/ML

N75565 001 Oct 05, 2004 Oct NEWA

N75815 001 Aug 20, 2004 Aug NEWA

N75728 001 Aug 20, 2004 Aug NEWA

N76529 001 Aug 20, 2004 Aug NEWA

N76805 001 Aug 20, 2004 Aug NEWA

TABLET; ORAL

LORATADINE

PERRIGO

10MG

10MG

N21512 001 Jun 24, 2004 Jun NEWA

N76301 001 Jun 25, 2004 Jun NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

@ SCHERING	5MG;120MG	N19670 002	Nov 27, 2002	Aug	DISC
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
ANDRX PHARMS	5MG;120MG	N76208 001	Jan 28, 2004	Jan	NEWA
+ IMPAX LABS	5MG;120MG	N76050 001	Jan 30, 2003	Aug	CRLD
	10MG;240MG	N75989 001	Mar 04, 2004	Mar	NEWA
RANBAXY	10MG;240MG	N76557 001	Sep 22, 2004	Sep	NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

G AND W LABS 2%,100MG

N76585 001 Mar 26, 2004 Mar NEWA

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%,4%

N76357 001 Mar 30, 2004 Mar NEWA

MONISTAT 3 COMBINATION PACK

PERSONAL PRODS 2%,4%

N21261 003 Jun 17, 2003 Aug CRLD

MINOXIDIL

SOLUTION; TOPICAL

THEROXIDIL

HARMONY LABS 5%

N76239 001 Aug 24, 2004 Aug NEWA

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HCL

PERRIGO EQ 200MG BASE;120MG

N76518 001 Mar 17, 2004 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

PERRIGO	EQ 2MG BASE	N76775 001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76789 001	Sep 16, 2004	Sep	NEWA
WATSON LABS	EQ 2MG BASE	N76568 001	Jul 29, 2004	Jul	NEWA
	EQ 2MG BASE	N76569 001	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76568 002	Jul 29, 2004	Jul	NEWA
	EQ 4MG BASE	N76569 002	Jul 29, 2004	Jul	NEWA

NICOTINE POLACRILEX (MINT)

PERRIGO	EQ 2MG BASE	N76777 001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76779 001	Sep 16, 2004	Sep	NEWA

NICOTINE POLACRILEX (ORANGE)

PERRIGO	EQ 2MG BASE	N76776 001	Sep 16, 2004	Sep	NEWA
	EQ 4MG BASE	N76778 001	Sep 16, 2004	Sep	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

ZANTAC 150

+ PFIZER CONS HLTHCARE EQ 150MG BASE

N21698 001 Aug 31, 2004 Aug NEWA

ZANTAC 75

WARNER LAMBERT EQ 75MG BASE

N20520 001 Dec 19, 1995 Aug CRLD

TERBINAFINE HYDROCHLORIDE

SPRAY; TOPICAL
LAMISIL AT
+ NOVARTIS

1%

N21124 002 Mar 17, 2000 Feb NEWA



DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2004

NO OCTOBER 2004 APPROVALS



This data is provided to the Office of Generic Drugs from
the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
October 2004

Generic Name:

Indication Designated:
Treatment for patients with brain stem glioma

Trade Name (if present):
A10 & AS2-1 Antineoplaston

Sponsor and Address
Burzynski Research Institute, Inc.
9432 Old Katy Road
Houston TX 77055

Date Designated: 9/3/2004

Marketing Exclusivity Date:

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride

Indication Designated:
Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/10/2004

Marketing Exclusivity Date:

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride

Indication Designated:
Treatment of acute lymphoblastic leukemia

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Generic Name:
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride

Indication Designated:
Treatment of T-cell non-Hodgkin's lymphoma

Trade Name (if present):

Sponsor and Address
BioCryst Pharmaceuticals, Inc.
2190 Parkway Lake Drive
Birmingham AL 35244

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
(3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid

Indication Designated:
For use in the treatment of cystic fibrosis resulting from a nonsense (premature stopcodon) mutation in the cystic fibrosis transmembrane conductance regulatory gene.

Trade Name (if present):

Orphan Products Designations and Approvals List
October 2004

Date Designated:	9/1/2004	Sponsor and Address PTC Therapeutics 100 Corporate Court South Plainfield NJ 07080
Marketing Exclusivity Date:		*****
Generic Name:	(6R,S)5,10-methylene-tetrahydrofolic acid	Indication Designated: For use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer
Trade Name (if present):	CoFactor	Sponsor and Address Adventrx Pharmaceuticals, Inc. 6725 Mesa Ridge Road Suite 100
Date Designated:	8/13/2004	San Diego CA 92121
Marketing Exclusivity Date:		*****
Generic Name:	17-alltalamino-17-demethoxygeldanamycin (17-AGG)	Indication Designated: Treatment of multiple myeloma.
Trade Name (if present):		Sponsor and Address Kosan Biosciences, Inc. 3832 Bay Center Place Hayward CA 94545
Date Designated:	9/9/2004	*****
Marketing Exclusivity Date:		
Generic Name:	17-allylamino-17-demethoxygeldanamycin (17-AGG)	Indication Designated: For the treatment of Chronic Myelogenous Leukemia
Trade Name (if present):		Sponsor and Address Kosan Biosciences, Inc. 3832 Bay Center Place Hayward CA 94545
Date Designated:	9/3/2004	*****
Marketing Exclusivity Date:		
Generic Name:	1-Deoxygalactonojirimycin	Indication Designated: Treatment of Fabry Disease
Trade Name (if present):		Sponsor and Address Amicus Therapeutics, Inc. 675 US Route 1 North Brunswick NJ 08902
Date Designated:	2/25/2004	*****
Marketing Exclusivity Date:		
Generic Name:	3-carboxy-2,3-dihydroxy-propionate 2-(3,5-dimethyl-	Indication Designated: Treatment of chronic lymphocytic leukemia

Orphan Products Designations and Approvals List
October 2004

1H-pyrrol-2-ylmethylene)-5-(1H-indol-2-yl)-3-methoxy-2H-pyrronium

Trade Name (if present):

Sponsor and Address
Gemin X, Inc.
5 Great Valley Parkway
Malvern PA 19355

Date Designated: 10/8/2004

Marketing Exclusivity Date:

Indication Designated:
Treatment of idiopathic pulmonary fibrosis

Generic Name:
5-methyl-1-phenyl-2-(1H)-pyridone(CAS 53179-13-8)

Trade Name (if present):
Pirfenidone

Sponsor and Address
InterMune, Inc.
3280 Bayshore Blvd
Brisbane CA 94005

Date Designated: 3/5/2004

Marketing Exclusivity Date:

Indication Designated:
Treatment of pancreatic cancer

Generic Name:

90Y-hPAMA4

Sponsor and Address
Immunomedics, Inc.
300 American Road
Morris Plains NJ 07950

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Indication Designated:
Treatment of retinitis pigmentosa

Generic Name:
Allogeneic retinal epithelial cells transfected with
plasmid vector expressing ciliary neurotrophic
growth factor

Trade Name (if present):

Sponsor and Address
Neurotech USA, Inc.
6 Blackstone Valley Place
Lincoln RI 02865

Date Designated: 9/1/2004

Marketing Exclusivity Date:

Indication Designated:
Treatment of cocaine overdose

Generic Name:
Alpha-1-acid glycoprotein

Sponsor and Address
Bio Products Laboratory
Dagger Lane, Elstree
WD6 3BX

Date Designated: 3/5/2004

Marketing Exclusivity Date:

UNITED KINGDOM

Orphan Products Designations and Approvals List
October 2004

Generic Name:	Indication Designated:
Alpha-1-acid glycoprotein	Treatment of tricyclic antidepressant poisoning

Trade Name (if present):	Sponsor and Address
	Bio Products Laboratory
	Dagger Lane
Date Designated: 3/17/2004	Elstree, Hertfordshire
Marketing Exclusivity Date:	UNITED KINGDOM

Generic Name:	Indication Designated:
Alpha1-Proteinase Inhibitor (Human) [API]	Treatment of Cystic Fibrosis

Trade Name (if present):	Sponsor and Address
ARC-API	Kamada Ltd.
	Kiryat Weizmann
Date Designated: 9/1/2004	ISRAEL
Marketing Exclusivity Date:	

Generic Name:	Indication Designated:
Ambrisentan	Treatment of pulmonary arterial hypertension

Trade Name (if present):	Sponsor and Address
	Myogen, Inc.
Date Designated: 7/16/2004	7575 West 103rd Avenue
Marketing Exclusivity Date:	Suite 102
	Westminster CO 80021-5426

Generic Name:	Indication Designated:
Antivenin crotaline (pit-viper) equine immune F(ab)2	Treatment of envenomation by Crotaline snakes

Trade Name (if present):	Sponsor and Address
Antivipmyn	Rare Disease Therapeutics, Inc.
	1101 Kermit Drive,
Date Designated: 1/29/2004	Suite 608
Marketing Exclusivity Date:	Nashville TN 37217

Generic Name:	Indication Designated:
Aplidin	Treatment of Acute Lymphoblastic Leukemia

Trade Name (if present):	Sponsor and Address
	PharmaMar USA, Inc
	320 Putnam Avenue
Date Designated: 6/18/2004	Cambridge MA 02139

Orphan Products Designations and Approvals List
October 2004

Marketing Exclusivity Date:

Generic Name:
Autologous incubated macrophage
in

Indication Designated:
Therapy to improve the motor and sensory neurological outcome
acute cases of spinal cord injury

Trade Name (if present):

Sponsor and Address
Proneuron Biotechnologies, Inc.
Weizmann Science Park
P. O. Box 277
Ness-Ziona 74101
ISRAEL

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
Bevacizumab

Indication Designated:
Treatment of pancreatic cancer

Trade Name (if present):
Avastin

Sponsor and Address
Genentech, Inc.
1 DNA Way, MS #242
South San Francisco CA 94080-4990

Date Designated: 10/20/2004
Marketing Exclusivity Date:

Generic Name:
Buffered Ursodeoxycholic Acid

Indication Designated:
For the treatment of pruritus in patients with Alagille Syndrome

Trade Name (if present):
Ursocarb

Sponsor and Address
Digestive Care, Inc.
1120 Win Drive
Bethlehem PA 18017

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
C1 esterase inhibitor (human)

Indication Designated:
Treatment of Angioedema

Trade Name (if present):

Sponsor and Address
Lev Pharmaceuticals, Inc.
236 Old Lancaster Road
Merion Station PA 19066

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name:
Chenodeoxycholic acid

Indication Designated:
Treatment of cerebrotendinous xanthomatosis

Trade Name (if present):

Orphan Products Designations and Approvals List

October 2004

Chenofalk

Sponsor and Address

Dr. Falk Pharma GmbH

Leinenweberstrasse 5

9041 Freiburg, GERMANY

Date Designated: 1/29/2004

Marketing Exclusivity Date:

GERMANY

Generic Name:

Indication Designated:

Coagulation factor VIIa (recombinant)

Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Trade Name (if present):

NovoSeven

Sponsor and Address

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton NJ 08540

Date Designated: 7/21/2004

Marketing Exclusivity Date:

Generic Name:

Indication Designated:

Coagulation factor VIIa (recombinant)

Prevention of bleeding episodes in Glanzmann's thrombasthenia

Trade Name (if present):

NovoSeven

Sponsor and Address

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:

Indication Designated:

Coagulation factor VIIa (recombinant)

Prevention of bleeding episodes in patients with congenital Factor VII deficiency

Trade Name (if present):

NovoSeven

Sponsor and Address

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton NJ 08540

Date Designated: 9/10/2004

Marketing Exclusivity Date:

Generic Name:

Indication Designated:

Coagulation Factor VIIa (Recombinant)

Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX

Trade Name (if present):

NovoSeven

Sponsor and Address

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton NJ 08540

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name:

Indication Designated:

Orphan Products Designations and Approvals List

October 2004

Coagulation factor VIIa (recombinant) B,	Prevention of bleeding episodes in patients with hemophilia A or with or without inhibitors
Trade Name (if present): NovoSeven	Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540
Date Designated: 6/18/2004	Indication Designated:
Marketing Exclusivity Date:	Treatment of bleeding episodes in Glanzmann's thrombasthenia
*****	*****
Generic Name: Coagulation factor VIIa (Recombinant)	
Trade Name (if present): NovoSeven	Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540
Date Designated: 6/18/2004	Indication Designated:
Marketing Exclusivity Date:	Treatment of bleeding episodes in patients with congenital factor VII deficiency
*****	*****
Generic Name: Coagulation factor VIIa (recombinant)	
Trade Name (if present): NovoSeven	Sponsor and Address Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton NJ 08540
Date Designated: 9/10/2004	Indication Designated:
Marketing Exclusivity Date:	Treatment of amyotrophic lateral sclerosis and its variants
*****	*****
Generic Name: Cyclosporin A	
Trade Name (if present): Cyclosporin	Sponsor and Address Maas BiolAB 1934 Quail Run Loop NE Albuquerque NM 87122
Date Designated: 10/29/2004	Indication Designated:
Marketing Exclusivity Date:	Treatment of multiple myeloma
*****	*****
Generic Name: Cytoxan	
Trade Name (if present): Aplidin	Sponsor and Address PharmaMar USA, Inc. 320 Putnam Avenue Cambridge MA 02139-4616
Date Designated: 9/30/2004	Indication Designated:
Marketing Exclusivity Date:	

Orphan Products Designations and Approvals List

October 2004

Generic Name:
DEAE-rebeccamycin

Indication Designated:
Treatment of bile duct tumors

Trade Name (if present):

Sponsor and Address
Exelixis, Inc.
170 Harbor Way
South San Francisco CA 94083-0511

Date Designated: 3/1/2004

Marketing Exclusivity Date:

Generic Name:
Deferitriptin

Indication Designated:
Treatment of iron overload

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 4/14/2004

Marketing Exclusivity Date:

Generic Name:
Depsipeptide

Indication Designated:
Treatment of cutaneous T-cell lymphoma

Trade Name (if present):

Sponsor and Address
Gloucester Pharmaceuticals, Inc.
One Broadway
Cambridge MA 02142

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Generic Name:
Desmoglein 3 synthetic peptide (PI-0824)

Indication Designated:
Treatment of pemphigus vulgaris

Trade Name (if present):

Sponsor and Address
Peptimmune, Inc.
64 Sidney Street
Cambridge MA 02139-4170

Date Designated: 10/26/2004

Marketing Exclusivity Date:

Generic Name:
dexanabinol

injury

Indication Designated:
For the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain

Trade Name (if present):

Sponsor and Address
Pharmos Corporation
99 Wood Avenue

Orphan Products Designations and Approvals List
October 2004

Date Designated: 8/11/2004
Marketing Exclusivity Date:

Suite 311
Iselin NJ 08830

Generic Name:
Dexrazoxane

Indication Designated:
Treatment of anthracycline extravasation during chemotherapy

Trade Name (if present):

Sponsor and Address
Topo Target A/S
Fruebjergvej 3, 2100
Copenhagen

Date Designated: 3/25/2004
Marketing Exclusivity Date:

DENMARK

Generic Name:
diethylenetriaminepentaacetate (DPTA)

Indication Designated:
For treatment of patients with known or suspected internal
contamination with plutonium, americium or curium to increase
the rates of elimination.

Trade Name (if present):

Sponsor and Address
CIS-US
10 DeAngelo Drive
Bedford MA 01730

Date Designated: 4/14/2004
Marketing Exclusivity Date:

Indication Designated:
Treatment of patients with known or suspected internal
contamination with plutonium, americium, or curium to increase
the rates of elimination.

Trade Name (if present):

Sponsor and Address
Hameln Pharmaceuticals gmbh
Langes Feld 13
Hameln
8/11/2004
GERMANY

Date Designated: 4/28/2004
Marketing Exclusivity Date:

Indication Designated:
Treatment for hepatocellular carcinoma

Trade Name (if present):

Sponsor and Address
Genzyme Corporation
153 Second Avenue
Waltham MA 02451

Date Designated: 5/25/2004
Marketing Exclusivity Date:

Indication Designated:
Treatment of bronchopulmonary infection in patients with cystic
fibrosis who are colonized with Pseudomonas aeruginosa or

Generic Name:
Doripenem

Orphan Products Designations and Approvals List
October 2004

Trade Name (if present):	Burkholderia cepacia.
Date Designated:	7/16/2004
Marketing Exclusivity Date:	
<hr/>	
Generic Name: Efaproxiral	Indication Designated: Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer
Trade Name (if present):	Sponsor and Address Allos Therapeutics, Inc. 11080 CirclePoint Road Suite 200 Westminster CO 80020
Date Designated:	7/28/2004
Marketing Exclusivity Date:	
<hr/>	
Generic Name: heat killed Mycobacterium w immunomodulator	Indication Designated: To be used as an adjuvant to chemotherapy for multi drug resistant tuberculosis.
Trade Name (if present): CADI Mw	Sponsor and Address CPL, Inc. 16020 Swingley Ridge Road Chesterfield MO 63017
Date Designated:	9/3/2004
Marketing Exclusivity Date:	
<hr/>	
Generic Name: Human anti-CD30 monoclonal antibody	Indication Designated: Treatment of Hodgkin's Disease
Trade Name (if present):	Sponsor and Address Medarex, Inc. 519 Route 173 West Bloomsbury NJ 08804
Date Designated:	9/27/2004
Marketing Exclusivity Date:	
<hr/>	
Generic Name: human anti-CD4 monoclonal antibody	Indication Designated: Treatment of mycosis fungoides
Trade Name (if present): HuMax-CD4	Sponsor and Address Genmab A/S Tolbodgade 33 DK-1253 Copenhagen K
Date Designated:	8/13/2004
Marketing Exclusivity Date:	DENMARK
<hr/>	

Orphan Products Designations and Approvals List
October 2004

Generic Name: human anti-transforming growth factor-B1,2,3	Indication Designated: Treatment of idiopathic pulmonary fibrosis
Trade Name (if present):	Sponsor and Address Genzyme Corporation 500 Kendall Street Cambridge MA 02142
Date Designated: 7/9/2004	
Marketing Exclusivity Date:	*****
Generic Name: Human immunoglobulin (IgG1k)antiCTLA-4 monoclonal antibody	Indication Designated: Treatment of high risk Stage II, Stage III, and Stage IV melanoma
Trade Name (if present):	Sponsor and Address Medarex, Inc. 519 Route 173 West Bloomsbury NJ 08804
Date Designated: 6/3/2004	
Marketing Exclusivity Date:	*****
Generic Name: Hydralazine	Indication Designated: Treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure less than or equal to 160) associated with severe preeclampsia/eclampsia
Trade Name (if present):	of pregnancy
Date Designated: 4/9/2004	Sponsor and Address Esp Pharma, Inc. 2035 Lincoln Hwy. Suite 2150 Edison NJ 08817
Marketing Exclusivity Date:	*****
Generic Name: Icatibant acetate	Indication Designated: Treatment of burn patients hospitalized with burn-induced edema
Trade Name (if present):	Sponsor and Address Jerini AG Invalidenstr. 130 10115 Berlin
Date Designated: 5/5/2004	GERMANY
Marketing Exclusivity Date:	*****
Generic Name: Idebenone (INN)	Indication Designated: Treatment of cardiomyopathy associated with Friedreich's ataxia
Trade Name (if present):	Sponsor and Address Santhera Pharmaceuticals LLC Hammerstrasse 25 CH-4410 Liestal
Date Designated: 3/25/2004	

Orphan Products Designations and Approvals List

October 2004

Marketing Exclusivity Date:

SWITZERLAND

Generic Name:
Iloprost inhalation solution

Indication Designated:
Treatment of pulmonary arterial hypertension

Trade Name (if present):
Ventavis

Sponsor and Address

CoTherix, Inc.
5000 Shoreline Court
South San Francisco CA 94080

Date Designated: 8/12/2004

Marketing Exclusivity Date:

Generic Name:
Immortalized human liver cells found in the
extracorporeal liver assist device

Indication Designated:
Treatment of fulminant hepatic failure (acute liver failure)

Trade Name (if present):
ELAD

Sponsor and Address
Vital Therapies, Inc.
15222 Avenue of Science
Suite C
San Diego CA 92128

Date Designated: 7/16/2004

Marketing Exclusivity Date:

Generic Name:
Immune Globulin (Human)

Indication Designated:
Treatment of chronic inflammatory demyelinating polyneuropathy

Trade Name (if present):
Gamunex

Sponsor and Address
Bayer Corporation
800 Dwight Way
Berkley CA 94701-1986

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Generic Name:
Immune Globulin (Human) containing high titers of
West Nile virus antibodies

Indication Designated:
Treatment of the West Nile virus infection

Trade Name (if present):
Omr-IgG-am (tm) 5% (WNV)

Sponsor and Address
OMRIX Biopharmaceuticals, Ltd.
Plasma Fractionation Institute
Ramat Gan 52621

Date Designated: 3/17/2004

Marketing Exclusivity Date:

ISRAEL

Generic Name:
Immune Globulin Intravenous (human)

Indication Designated:
Treatment for Guillain Barre Syndrome

Trade Name (if present):
Carimune NF

Sponsor and Address

Orphan Products Designations and Approvals List
October 2004

Date Designated: 5/4/2004

Marketing Exclusivity Date:

ZLB Bioplasma AG
Wankdorffstrasse 10
CH-3000 Bern 22

SWITZERLAND

Generic Name:
Immune Globulin Subcutaneous (Human)

Indication Designated:
Treatment of patients with primary immune deficiency (PID) that are intolerant to immune globulin intravenous (IGIV) due to severe adverse events or poor venous access

Trade Name (if present):
Vivaglobin P (proposed)

Sponsor and Address
Aventis Behring, L.L.C.
1020 First Avenue
P.O. Box 61501
King of Prussia PA 19406-0901

Date Designated: 9/22/2004
Marketing Exclusivity Date:

Generic Name:
Implitapide

Indication Designated:
Treatment of homozygous familial hypercholesterolemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/13/2004
Marketing Exclusivity Date:

Generic Name:
Implitapide

Indication Designated:
Treatment of patients with Fredrickson type I or V hyperlipoproteinemia

Trade Name (if present):

Sponsor and Address
Medical Research Laboratories International
2 Tesseneer Drive
Highland Heights KY 41076

Date Designated: 8/18/2004
Marketing Exclusivity Date:

Generic Name:
Lenalidomide

Indication Designated:
Treatment of myelodysplastic syndromes

Trade Name (if present):
Revimid

Sponsor and Address
Celgene Corporation
7 Powder Horn Drive
Warren NJ 07059

Date Designated: 1/29/2004
Marketing Exclusivity Date:

Generic Name:
Liarozole

Indication Designated:
The treatment of congenital ichthyosis

Orphan Products Designations and Approvals List
October 2004

Trade Name (if present):

Sponsor and Address
Barrier Therapeutics, Inc
600 College Road East
Princeton NJ 08540

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:

L-tyrosine-L-serine-L-leucine

Indication Designated:

Treatment of hepatocellular carcinoma.

Trade Name (if present):

CMS-024

Sponsor and Address
Pepharin R&D Limited
Room 1404, 14th Floor
#39 Healthy Street East
North Point
HONG KONG

Date Designated: 9/10/2004

Marketing Exclusivity Date:

Generic Name:

mannopentaose phosphate sulfate

Indication Designated:

Treatment of high-risk Stage II, Stage III, and Stage IV melanoma

Trade Name (if present):

Sponsor and Address
Progen Industries Limited
P. O. Box 28
Richlands 4077

Date Designated: 4/27/2004

Marketing Exclusivity Date:

AUSTRALIA

Generic Name:

meclorethamine or nitrogen mustard

Indication Designated:

Treatment of mycosis fungoides.

Trade Name (if present):

Sponsor and Address
Yaupon Therapeutics, Inc.
259 Radnor Chester Road
Radnor PA 19087

Date Designated: 8/12/2004

Marketing Exclusivity Date:

Generic Name:

Melatonin

Indication Designated:

Treatment of non-24-hour sleep-wake disorder in blind individuals without light perception

Trade Name (if present):

Circadin

Sponsor and Address

Neurim Pharmaceuticals, Ltd.
8 Hanechoshet St.
Tel-Aviv

Date Designated: 7/9/2004

Marketing Exclusivity Date:

ISRAEL

Orphan Products Designations and Approvals List
October 2004

Trade Name (if present):

Sponsor and Address
GlaxoSmithKline Pharmaceuticals
P.O. Box 7929
Philadelphia PA 19101

Date Designated: 5/28/2004

Marketing Exclusivity Date:

Generic Name:

Multi-ligand somatostatin analogue

Indication Designated:

Treatment of patients with functional gastroenteropancreatic (GEP) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, GRFoma, VIPoma and glucagonoma.

Trade Name (if present):

Sponsor and Address
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover NJ 07936-1080

Date Designated: 7/27/2004

Marketing Exclusivity Date:

Generic Name:

multi-vitamin infusion without vitamin K complications

Indication Designated:
Prevention of vitamin deficiency and thromboembolic

in people receiving home parenteral nutrition and warfarin-type

Trade Name (if present):

M.V.I.-12

Sponsor and Address
Mayne Pharma (USA) Inc.
Mack-Cali Centre II
Second Floor

Date Designated: 3/8/2004

Marketing Exclusivity Date:

9/9/2004 Paramus NJ 07652

Generic Name:

N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide

Indication Designated:
Treatment of neuroblastoma

Trade Name (if present):

Sponsor and Address
Abbott Laboratories
Pharmaceuticals Products Division
D-491, AP30-1E
Abbott Park IL 60064-6157

Date Designated: 9/30/2004

Marketing Exclusivity Date:

Generic Name:

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide

Indication Designated:
Treatment of stages IIB-IV melanoma

Trade Name (if present):

Sponsor and Address
3M Pharmaceuticals
3M Center
Building 270-3A-08
St. Paul MN 55144-1000

Date Designated: 8/13/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List
October 2004

Date Designated:	8/13/2004	Building 270-3A-08
Marketing Exclusivity Date:		St. Paul MN 55144-1000
<hr/>		
Generic Name:		Indication Designated:
nelarabine		Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma
Trade Name (if present):		Sponsor and Address
		GlaxoSmithKline
		One Franklin Plaza
Date Designated:	8/10/2004	Philadelphia PA 19101
Marketing Exclusivity Date:		
<hr/>		
Generic Name:		Indication Designated:
Nitric oxide		To reduce the risk of chronic lung disease in premature neonates
Trade Name (if present):		Sponsor and Address
INOmax		INO Therapeutics
		6 Route 173
Date Designated:	9/27/2004	Clinton NJ 08809
Marketing Exclusivity Date:		
<hr/>		
Generic Name:		Indication Designated:
Nucleic acid aptamer binding to tumor cell nucleolin		Treatment of pancreatic cancer
Trade Name (if present):		Sponsor and Address
		Aptamera, Inc.
		640 S. Fourth Street
Date Designated:	8/11/2004	Louisville KY 40202
Marketing Exclusivity Date:		
<hr/>		
Generic Name:		Indication Designated:
oral unfractionated heparin		Treatment of sickle cell disease
Trade Name (if present):		Sponsor and Address
		TRF Technologies, Inc.
		108 Eagle Trace Drive
Date Designated:	1/29/2004	Half Moon Bay CA 94019
Marketing Exclusivity Date:		
<hr/>		
Generic Name:		Indication Designated:
pentetate trisodium		Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.
Trade Name (if present):		Sponsor and Address
diethylenetriaminepentaacetate		

Orphan Products Designations and Approvals List
October 2004

Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co.
Goerzallee 253
Federal of Republic of Germany

Date Designated: 4/12/2004
Marketing Exclusivity Date:

GERMANY

Generic Name:
posaconazole

Indication Designated:
Treatment of zygomycosis

Trade Name (if present):
Posoril

Sponsor and Address
Schering Corporation
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 7/16/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine
therapy.

Indication Designated:
Treatment of myelodysplastic syndromes (MDS) requiring

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of acute myelogenous leukemia

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
PR1 Vaccine

Indication Designated:
Treatment of chronic myelogenous leukemia.

Trade Name (if present):

Sponsor and Address
The Vaccine Company
P. O. Box 93921
Carmel CA 93921

Date Designated: 9/3/2004
Marketing Exclusivity Date:

Generic Name:
Quinine Sulfate

Indication Designated:
Treatment of malaria

Orphan Products Designations and Approvals List
October 2004

Trade Name (if present):

Sponsor and Address
Mutual Pharmaceutical Company, Inc.
1100 Orthodox Street
Philadelphia PA 19124

Date Designated: 6/3/2004

Marketing Exclusivity Date:

Generic Name:
recombinant human fibroblast growth factor-20

Indication Designated:
Treatment of radiation induced oral mucositis

Trade Name (if present):

Sponsor and Address
CuraGen Corporation
322 East Main Street
Branford CT 06405

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Generic Name:
Recombinant Porcine Factor VIII, B-domain Deleted

Indication Designated:
Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII

Trade Name (if present):

Sponsor and Address
Ipsen Limited
190 Bath Road
Berkshire S11 3XE

Date Designated: 3/16/2004

Marketing Exclusivity Date:

UNITED KINGDOM

Generic Name:
rh-microplasmin

Indication Designated:
Adjunct to surgery in cases of pediatric vitrectomy

Trade Name (if present):

Sponsor and Address
ThromboGenics Ltd
Unit 14
Bridgecourt Office Park
Dublin 12
IRELAND

Date Designated: 3/16/2004

Marketing Exclusivity Date:

Generic Name:
Rituximab

Indication Designated:
Treatment of chronic lymphocytic leukemia

Trade Name (if present):

Sponsor and Address
Biogen IDEC, Inc.
5200 Research Place
San Diego CA 92122

Rituxan

Date Designated: 1/29/2004

Marketing Exclusivity Date:

Orphan Products Designations and Approvals List
October 2004

Generic Name: rofecoxib	Indication Designated: Treatment of juvenile rheumatoid arthritis
Trade Name (if present): VIOXX	Sponsor and Address MERCK & Co., Inc. 126 East Lincoln Ave. Rahway NJ 07065
Date Designated: 3/16/2004	
Marketing Exclusivity Date:	*****
Generic Name: Rufinamide	Indication Designated: For the treatment of Lennox-Gastaut Syndrome.
Trade Name (if present):	Sponsor and Address Eisai Medical Research, Inc. 55 Challenger Road Ridgefield NJ 07660
Date Designated: 10/8/2004	
Marketing Exclusivity Date:	*****
Generic Name: sarsasapogenin	Indication Designated: Treatment of amyotrophic lateral sclerosis (ALS)
Trade Name (if present):	Sponsor and Address Phytopharm plc Corpus Christi House Godmanchester, Cambridgeshire PE29 2HY
Date Designated: 6/18/2004	
Marketing Exclusivity Date:	UNITED KINGDOM
Generic Name: SGN-30 (anti-CD30 antibody)	Indication Designated: Treatment of CD30 positive T-cell lymphomas
Trade Name (if present):	Sponsor and Address Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021
Date Designated: 2/18/2004	
Marketing Exclusivity Date:	*****
Generic Name: SGN-40 (anti-CD40 antibody)	Indication Designated: Treatment of multiple myeloma.
Trade Name (if present):	Sponsor and Address Seattle Genetics, Inc. 21823 30th Drive Southeast Bothell WA 98021
Date Designated: 8/13/2004	
Marketing Exclusivity Date:	*****

Orphan Products Designations and Approvals List
October 2004

Generic Name: Sodium thiosulfate	Indication Designated: Prevention of platinum-induced ototoxicity in pediatric patients
Trade Name (if present):	Sponsor and Address Adherex Technologies, Inc. 600 Peter Morand Crescent Ottawa, Ontario
Date Designated: 3/17/2004	
Marketing Exclusivity Date:	CANADA
<hr/>	
Generic Name: Somatropin	Indication Designated: Treatment of patients with HIV-associated adipose redistribution syndrome
Trade Name (if present): Serostim	Sponsor and Address Serono, Inc. One Technology Place Rockland MA 02370
Date Designated: 3/16/2004	
Marketing Exclusivity Date:	
<hr/>	
Generic Name: Sorafenib	Indication Designated: Treatment of renal cell carcinoma.
Trade Name (if present):	Sponsor and Address Bayer Pharmaceutical Corporation 400 Morgan Lane West Haven CT 06516
Date Designated: 10/8/2004	
Marketing Exclusivity Date:	
<hr/>	
Generic Name: Staphylococcus aureus Immune Globulin (Human)	Indication Designated: Prophylaxis against Staphylococcus aureus infections in low birth weight neonates
Trade Name (if present): Altastaph	Sponsor and Address Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville MD 20852
Date Designated: 1/29/2004	
Marketing Exclusivity Date:	
<hr/>	
Generic Name: Suberoylanilide hydroxamic acid	Indication Designated: Treatment of T-cell non-Hodgkin's lymphoma
Trade Name (if present):	Sponsor and Address Merck & Co., Inc. P. O. Box 2000, RY 32-605

Orphan Products Designations and Approvals List October 2004

Date Designated: 3/16/2004 Rahway NJ 07065-0900

Marketing Exclusivity Date:

Generic Name:
Suberoylanilide hydroxamic acid

Indication Designated:
Treatment of mesothelioma

Trade Name (if present):

Sponsor and Address
Merck & Co., Inc.
P. O. Box 2000, RY 32-605
Rahway NJ 07065-0900

Date Designated: 3/17/2004

Marketing Exclusivity Date:

Generic Name:
temocillin sodium

Indication Designated:
Treatment of pulmonary infections caused by *Burkholderia cepacia*

Trade Name (if present):
Negaban

Sponsor and Address
Belpharma N.V.
67 Winston Churchill Avenue
Brussels

Date Designated: 4/21/2004

Marketing Exclusivity Date:

BELGIUM

Generic Name:
Temozolomide

Indication Designated:

Trade Name (if present):
Temodal

Sponsor and Address
Schering-Plough Research Institute
2000 Galloping Hill Road
Kenilworth NJ 07033

Date Designated: 10/18/2004

Marketing Exclusivity Date:

Generic Name:
Terlipressin (INN)

Indication Designated:
Treatment of Hepatorenal Syndrome

Trade Name (if present):

Sponsor and Address
Orphan Therapeutics, LLC
3 Werner Way
Round Valley Executive Ctr.
Lebanon, NJ 08833

Date Designated: 10/29/2004
Marketing Exclusivity Date:

Generic Name:
tetrahydrobiopterin

Indication Designated:
For treatment of hyperphenylalaninemia

Trade Name (if present):

Sponsor and Address

Orphan Products Designations and Approvals List
October 2004

Date Designated:	1/29/2004	Biomarin Pharmaceutical Inc. 371 Bel Marin Blvd. Novato CA 94949
Marketing Exclusivity Date:		
*****	*****	*****
Generic Name:	Thalidomide	Indication Designated: Treatment of Myelodysplastic Syndrome
Trade Name (if present):	Thalomid	Sponsor and Address Celgene Corporation 7 Powder Horn Drive Warren NJ 07059
Date Designated:	9/27/2004	
Marketing Exclusivity Date:		
*****	*****	*****
Generic Name:	Thymosin beta 4	Indication Designated: Treatment of epidermolysis bullosa
Trade Name (if present):		Sponsor and Address RegeneRx Biopharmaceuticals, Inc. 3 Bethesda Metro Center Suite 700 Bethesda MD 20814
Date Designated:	5/28/2004	
Marketing Exclusivity Date:		
*****	*****	*****
Generic Name:	Tipifarnib	Indication Designated: Treatment of acute myeloid leukemia
Trade Name (if present):	Zarnestra	Sponsor and Address Johnson & Johnson Pharmaceutical Research & Dev. 920 U.S. Highway 202 Raritan NJ 08869
Date Designated:	7/6/2004	
Marketing Exclusivity Date:		
*****	*****	*****
Generic Name:	Trabectedin	Indication Designated: Treatment of soft tissue sarcoma.
Trade Name (if present):	Yondelis	Sponsor and Address Johnson & Johnson Pharmaceutical Research & Dev. 920 US Highway 202 Raritan NJ 08869
Date Designated:	9/30/2004	
Marketing Exclusivity Date:		
*****	*****	*****
Generic Name:	Trisodium zinc Diethylenetriaminepentaacetate	Indication Designated: Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.

Orphan Products Designations and Approvals List
October 2004

Trade Name (if present):

Sponsor and Address
CustomCare Pharmacy
5710 Hoover Blvd
Tampa FL 33634

Date Designated: 2/27/2004

Marketing Exclusivity Date:

Generic Name:
Ubiquinol

Indication Designated:
Treatment of Huntington's Disease

Trade Name (if present):
Ubi-Q-Nol, Li-Q-Nol

Sponsor and Address
Gel-Tec
Division of Tishcon Corp
P. O. Box 331
Westbury NY 11590

Date Designated: 4/12/2004

Marketing Exclusivity Date:

Generic Name:
Ubiquinol, coenzyme Q10, ubiquinone

Indication Designated:
Treatment of pediatric congestive heart failure

Trade Name (if present):
UBI-Q-NOL

Sponsor and Address
Gel-Tec, Division of TISHCON Corporation
30 New York Avenue
P.O. Box 331
Westbury NY 11590

Date Designated: 4/12/2004

Marketing Exclusivity Date:

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Indication Designated:
Treatment of complications of vaccinia vaccination

Trade Name (if present):
CNJ-016

Sponsor and Address
Cangene Corporation
104 Chancellor Matheson Road
Winnipeg, Manitoba R3T 5Y3

Date Designated: 6/18/2004

Marketing Exclusivity Date:

CANADA

Generic Name:
Vaccinia Immune Globulin (Human) Intravenous

Indication Designated:
Treatment of severe complications from the smallpox vaccine

Trade Name (if present):

Sponsor and Address
DynPort Vaccine Company LLC
64 Thomas Johnson Drive
Frederick MD 21702

Date Designated: 6/18/2004

Marketing Exclusivity Date:

Generic Name:

Indication Designated:

Orphan Products Designations and Approvals List
October 2004

Vapreotide

Treatment of symptomatic carcinoid tumors

Trade Name (if present):
Sanvar

Sponsor and Address

H3 Pharma, Inc.
666 Sherbrooke Street West Suite 1400
Montreal, Quebec,

Date Designated: 4/6/2004
Marketing Exclusivity Date:

CANADA

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2004 ADDITIONS

2025 RELEASE UNDER E.O. 14176

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021652 001	ABACAVIR SULFATE; EPZICOM	5034394 5089500 6294540 5047407 5905082 6417191 6180639	DEC 18, 2011 JUN 26, 2009 MAY 14, 2018 NOV 17, 2009 MAY 18, 2016 MAR 28, 2016 JAN 30, 2018	DS DP DS DP U257 DS DP U257 DS DP U257 DS DP DS DP DP U257	D-40 D-40	AUG 02, 2007 AUG 02, 2007
020977 001	ABACAVIR SULFATE; ZIAGEN	5968895	DEC 11, 2016	DP		
020978 001	ABACAVIR SULFATE; ZIAGEN	6180608	DEC 11, 2016	DP U549		
021120 001	ABARELIX; PLENAXIS	6423686 6423686 6455499 5843901 6699833	JUN 07, 2015 JUN 07, 2015 DEC 01, 2015 DEC 11, 2016	DS U549 DS DP		
021431 001	ACAMPYROSATE CALCIUM; CAMPRAL	6451340	JUL 23, 2018	DS DP U470		
021539 001	ACETYLCYSTEINE; ACETADOTE ADEFOVIR DIPIVOXIL; HEP SERA	5663159 6635278 6723303 6702997	SEP 02, 2014 DEC 15, 2018 APR 20, 2021 DEC 28, 2021	DS DP U470 DS DP DP DP		
020899 001	ALBUMIN HUMAN; OPTISON	6702997	DEC 28, 2021	U558		
020949 001	ALBUTEROL SULFATE; ACCUNEB	6315173	DEC 23, 2017	DP		
020949 002	ALBUTEROL SULFATE; ACCUNEB	6510969	DEC 23, 2017	DP		
>ADD>	ALBUTEROL SULFATE; VENTOLIN HFA	6131566	APR 14, 2015	DP U589		
020983 001	ALBUTEROL SULFATE; VENTOLIN HFA	6532955	APR 14, 2015	DP U590	D-87 D-87	APR 16, 2007 APR 16, 2007
020560 005	ALENDRONATE SODIUM; FOSAMAX	5932622	AUG 03, 2016	U562		
021575 001	ALENDRONATE SODIUM; FOSAMAX	6710066	JUL 28, 2009	U289	NDF	SEP 29, 2007
020886 001	ALITRETNINOIN; PANRETIN	5223995*PED	JUN 28, 2011	DS DP U162	NC	JAN 30, 2007
020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE; LEVULAN	64455574	AUG 11, 2018	U552		
021727 001	AMLEXANOX; AMLEXANOX	5969156*PED	JUL 08, 2017	DS		
021540 001	AMLODIPINE BENZYLATE; CADUET	5686104*PED	NOV 11, 2014	DP U213		
>ADD>	AMLODIPINE BENZYLATE; CADUET	6126971	MAY 11, 2015			
021540 002	AMLODIPINE BENZYLATE; CADUET	6126971*PED	JAN 19, 2013	DP		
		4681893	JUL 19, 2013			
		4681893*PED	SEP 24, 2009	DS DP U161		
		4681893*PED	MAR 24, 2010			
		4879303*PED	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			
		4572909	JUL 31, 2006	DS DP U3		
		4572909*PED	JAN 31, 2007			
		4681893	SEP 24, 2009	DS DP U161	NC	
		4681893*PED	MAR 24, 2010			
		4879303	MAR 25, 2007	DS DP		
		4879303*PED	SEP 25, 2007			</td

PRESCRIPTION AND OTC DRUG PRODUCT

PRINTED IN U.S.A. PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

PREScription AND OTC DRUGS FROM PATENT AND EXCLUSIVITY DATA
INFORMATION REGARDING REPORT CONTENT

Footnotes for Introduction

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY

See report footnotes for information regarding recent patent and exclusivity data.

INGREDIENT NAME; TRADE NAME

APPL./PROD
NUMBER

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

See report footnotes for information regarding report content.

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	011522 011 AMPHETAMINE ASPARTATE; ADDERALL 7.5 AMPRENAVR; AGENERASE AMPRENAVR; AGENERASE ANAGRELIDE HYDROCHLORIDE; AGRYLIN	6384020+PED 6730679 6730679	JAN 06, 2021 NOV 11, 2017 NOV 11, 2017	DP DP		
>ADD>	021264 001 APOMORPHINE HYDROCHLORIDE; APOKYN				ODE	MAR 14, 2004
>ADD>	021264 002 APOMORPHINE HYDROCHLORIDE; APOKYN				PED	SEP 14, 2004
>ADD>	021436 001 ARIPIPRAZOLE; ABILIFY 021436 002 ARIPIPRAZOLE; ABILIFY 021436 003 ARIPIPRAZOLE; ABILIFY 021436 004 ARIPIPRAZOLE; ABILIFY 021436 005 ARIPIPRAZOLE; ABILIFY 021436 006 ARIPIPRAZOLE; ABILIFY 021248 001 ASCORBIC ACID; M.V.I.-12 (WITHOUT V 008809 006 ATAZANAVIR SULFATE; REYATAZ 021567 001 ATAZANAVIR SULFATE; REYATAZ 021567 002 ATAZANAVIR SULFATE; REYATAZ 021567 003 ATORVASTATIN CALCIUM; LIPITOR	6723351	NOV 10, 2018	U573		
>ADD>	020702 001 ATORVASTATIN CALCIUM; LIPITOR	4681893 5273995 5686104 5969156 6126971 4681893 5273995 5686104 5969156 6126971 4681893 5273995 5686104 5969156 6126971 4681893 5273995 5686104 5969156 6126971	SEP 24, 2009 DEC 28, 2010 NOV 11, 2014 JUL 08, 2016 JAN 19, 2013 SEP 24, 2009 DEC 28, 2010 NOV 11, 2014 JUL 08, 2016 JAN 19, 2013 SEP 24, 2009 DEC 28, 2010 NOV 11, 2014 JUL 08, 2016 JAN 19, 2013 SEP 24, 2009 DEC 28, 2010 NOV 11, 2014 JUL 08, 2016 JAN 19, 2013	DS DP U161 DS DP U162 DS DP U213 DS DP DS DP U161 DS DP U162 DS DP U213 DS DP U161 DS DP U162 DS DP U213	D-89 D-89 M-36 I-434 I-434 M-36 I-434 I-434 M-36 I-434 I-434 M-36 I-434 I-434 M-36 I-434 I-434 M-36 I-434 I-434 M-36 I-434 I-434 M-36	SEP 09, 2011 JUL 06, 2007 JUL 06, 2007 JUL 30, 2007 JUL 30, 2007
>ADD>	020702 002 ATORVASTATIN CALCIUM; LIPITOR				ODE	
>ADD>	020702 003 ATORVASTATIN CALCIUM; LIPITOR				ODE	
>ADD>	020702 004 ATORVASTATIN CALCIUM; LIPITOR				ODE	
>ADD>	050794 001 AZACITIDINE; VIDAZA AZELASTINE HYDROCHLORIDE; ASTELIN	5164194 5164194+PED 4412992	NOV 01, 2010 MAY 01, 2011 JUL 08, 2006	U207		
>ADD>	020610 001 BALSALAZIDE DISODIUM; COLAZAL 019851 001 BENAZEPRIL HYDROCHLORIDE; LOTENSIN				M-30 PED	MAR 02, 2007
>ADD>	019851 002 BENAZEPRIL HYDROCHLORIDE; LOTENSIN				M-30 PED	MAR 02, 2007
>ADD>	019851 003 BENAZEPRIL HYDROCHLORIDE; LOTENSIN				M-30 PED	MAR 02, 2007

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
019851 004	BENAZEPRIL HYDROCHLORIDE; LOTENSTIN	6713446	JAN 25, 2022	M-30	MAR 02, 2007	
021551 001	BISACODYL; HALFLYTELY	6747150	OCT 28, 2014	PED	SEP 02, 2007	
021602 001	BORTEZOMB; VELCADE	6686346	APR 29, 2017	NP	MAY 10, 2007	
020746 001	BUDESONIDE; RHINOCORT	6686346	APR 29, 2017	DP	DP	
020746 002	BUDESONIDE; RHINOCORT	5989588*PED	APR 29, 2017	DP	DP	
>ADD> 020958 001	CALCIUM CARBONATE, PRECIPITATED; PEPCID COMPLETE	4657927	MAR 30, 2016	U557	DP	
019880 001	CARBOPLATIN; PARAPLATIN	4657927*PED	APR 14, 2004	U349	U175	
019880 002	CARBOPLATIN; PARAPLATIN	4657927	OCT 14, 2004	U175	DP	
019880 003	CARBOPLATIN; PARAFLATIN	4657927*PED	APR 14, 2004	U175	DP	
020452 001	CARBOPLATIN; PARAFLATIN	4657927*PED	APR 14, 2004	U175	DP	
020452 002	CARBOPLATIN; PARAFLATIN	4657927	OCT 14, 2004	U175	DP	
020452 003	CARBOPLATIN; PARAFLATIN	4657927*PED	APR 14, 2004	U175	DP	
020452 004	CARBOPLATIN; PARAFLATIN	4657927*PED	OCT 14, 2004	U175	DP	
>ADD> 020637 001	CARMUSTINE; GLIADEL	4657927*PED	APR 14, 2004	U175	DP	
>ADD> 021227 001	CASPOFUNGIN ACETATE; CANCIDAS	5952300	OCT 14, 2004	U175	DP	
>ADD>		5378804	MAR 28, 2017	DP	FEB 25, 2010	
>ADD>		5514650	MAR 16, 2013	DS	SEP 29, 2007	
>ADD>		5792746	MAR 16, 2013	DS	DP	
>ADD>		6136783	MAR 16, 2013	DP	U607	
>ADD>		5952300	MAR 28, 2017	DP	U607	
>ADD>		5378804	MAR 16, 2013	DS	I-438	SEP 29, 2007
>ADD>		5514650	MAR 16, 2013	DS	DP	
>ADD>		5792746	MAR 16, 2013	DS	DP	
>ADD>		6136783	MAR 28, 2017	DS	U607	
>ADD>		4525358	JUN 25, 2007	DS	DP	
>ADD>		4525358*PED	DEC 25, 2007	DS	U565	
>ADD>		6455533	JUL 02, 2018	DP	DP	
>ADD>		4525358	JUN 25, 2007	DS	DP	
>ADD>		4525358*PED	DEC 25, 2007	DS	DP	
>ADD>		6455533	JUL 02, 2018	DP	DP	
021621 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	5340821	JUL 07, 2013	U309	NP	FEB 24, 2007
021621 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	5767251	JUN 16, 2015	DS		
020989 002	CEVIMELINE HYDROCHLORIDE; EVOXAC	6706681	MAR 16, 2021	DP		
021587 001	CHLORPHENIRAMINE MALEATE; CHILDREN'S ADVIL ALL.	6031003	DEC 14, 2016	U559	ODE	MAR 08, 2011
021149 002	CHORILOGANDOTROPIN ALFA; QVIDREL	6211244	OCT 23, 2015	DS	DP	MAR 08, 2009
021688 001	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	OCT 23, 2015	DS	DP	
021688 002	CINACALCET HYDROCHLORIDE; SENSIPAR	6031068	DEC 14, 2016	DS	DP	
021688 003	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	DS	DP	
021688 004	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 005	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 006	CINACALCET HYDROCHLORIDE; SENSIPAR	6031068	DEC 14, 2016	DS	DP	
021688 007	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 008	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 009	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	DS	DP	
021688 010	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 011	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 012	CINACALCET HYDROCHLORIDE; SENSIPAR	6031068	DEC 14, 2016	DS	DP	
021688 013	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 014	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 015	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	DS	DP	
021688 016	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 017	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 018	CINACALCET HYDROCHLORIDE; SENSIPAR	6031068	DEC 14, 2016	DS	DP	
021688 019	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 020	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 021	CINACALCET HYDROCHLORIDE; SENSIPAR	6031003	DEC 14, 2016	DS	DP	
021688 022	CINACALCET HYDROCHLORIDE; SENSIPAR	6211244	OCT 23, 2015	DS	DP	
021688 023	CINACALCET HYDROCHLORIDE; SENSIPAR	6313146	DEC 14, 2016	DS	DP	
021688 024	CINACALCET HYDROCHLORIDE; SENSIPAR	6031068	DEC 14, 2016	DS	DP	

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL. EXPIRES	PATENT CODE(S)	EXCLUS. CODE	EXCLUS. EXPIRES
019537 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO			I-421		MAR 25, 2007
020805 001	CIPROFLOXACIN HYDROCHLORIDE; CIPRO HC			PED		SEP 25, 2007
075593 002	CIPROFLOXACIN HYDROCHLORIDE; CIPROFLOXACIN; CIPRO			I-421		MAR 25, 2007
019537 003	CIPROFLOXACIN HYDROCHLORIDE; CIPRO			PED		SEP 25, 2007
019537 004	CIPROFLOXACIN HYDROCHLORIDE; CIPRO			I-421		MAR 25, 2007
020780 001	CIPROFLOXACIN HYDROCHLORIDE; CIPROFLOXACIN; CIPRO	5965549	JUN 06, 2015	DP	PC	FEB 05, 2005
019847 001	CIPROFLOXACIN; CIPRO			I-421		MAR 25, 2007
020780 001	CIPROFLOXACIN; CIPRO			PED		SEP 25, 2007
020780 002	CIPROFLOXACIN; CIPRO			I-421		MAR 25, 2007
019857 001	CIPROFLOXACIN; CIPRO IN DEXTROSE 5%			PED		SEP 25, 2007
019858 001	CIPROFLOXACIN; CIPRO IN SODIUM CHLO			I-421		MAR 25, 2007
021473 002	CIPROFLOXACIN; CIPRO XR			PED		SEP 25, 2007
021644 001	CLOBETASOL PROPIONATE; CLOBEX			I-421		MAR 25, 2007
021165 001	DESLORATADINE; CLARINEX			PED		SEP 25, 2007
021312 001	DESLORATADINE; CLARINEX			I-421		MAR 25, 2007
021038 001	DEXMETHETOIMIDINE; PRECEDEX			PED		SEP 25, 2007
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN			I-421		MAR 25, 2007
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN			PED		SEP 25, 2007
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE; FOCALIN			I-421		MAR 25, 2007
021392 001	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			PED		SEP 25, 2007
021392 002	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-421		MAR 25, 2007
021392 003	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			PED		SEP 25, 2007
021392 004	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-421		MAR 25, 2007
021392 005	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			PED		SEP 25, 2007
021392 006	DILTIAZEM HYDROCHLORIDE; CARDIZEM LA			I-421		MAR 25, 2007
021168 001	DIVALPROEX SODIUM; DEPAKOTE ER			PED		SEP 25, 2007
021168 002	DIVALPROEX SODIUM; DEPAKOTE ER			I-421		MAY 19, 2007
020449 001	DOCETAXEL; TAXOTERE			I-436		AUG 18, 2007

PREScription AND oTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020931 001	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007			
020931 002	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007			
020931 003	DOFETILIDE; TIKOSYN	4959366	SEP 25, 2007			
020869 001	DORZOLAMIDE HYDROCHLORIDE; COSOPT	6316443	APR 17, 2011	DP U561		
020408 001	DORZOLAMIDE HYDROCHLORIDE; TRUSOPT	4797413	APR 28, 2008	DS DP U103		
020862 001	DOXERCALCIFEROL; HECTOROL	4619939	OCT 28, 2003	DS DP U104	I-424	APR 23, 2007
020862 002	DOXERCALCIFEROL; HECTOROL	5869473	AUG 02, 2008	U278	I-424	APR 23, 2007
018651 001	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
018651 002	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
018651 003	DRONABINOL; MARINOL	6703418	FEB 26, 2011	U563		
021098 001	DROSPIRENONE; YASMIN	6787531	AUG 31, 2008	DP		
021427 001	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
021427 002	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
021427 004	DULOXETINE HYDROCHLORIDE; CYMBALTA	5508276	JUL 18, 2014	DP		
021733 001	DULOXETINE HYDROCHLORIDE; CYMBALTA	5023269	JUN 11, 2008	DS DP U605	NCE	AUG 03, 2009
021733 002	DULOXETINE HYDROCHLORIDE; CYMBALTA	5508276	JUL 18, 2014	DP		
021733 004	DULOXETINE HYDROCHLORIDE; CYMBALTA	5508276	JUL 18, 2014	DP		
021500 001	EMTRICITABINE; EMTRIVA	6703396	MAR 09, 2021	DS DP	NP	OCT 26, 2007
021486 001	EPINEPHRINE; LIODOCAINE HCL AND EP	5246418	SEP 30, 2013	DS DP	NP	MAY 04, 2007
021504 001	EPINEPHRINE; LIODSITE TOPICAL SYS	5873850	SEP 30, 2013	DS DP		
021633 001	ESTRADIOL ACETATE; FEMTRACE	6377847	SEP 30, 2013	DS DP		
021633 002	ESTRADIOL ACETATE; FEMTRACE	6385488	SEP 30, 2013	DS DP		
021633 003	ESTRADIOL ACETATE; FEMTRACE	6629968	JUN 30, 2020	DS DP		
021437 001	EPLERENONE; INSPRA	6635045	JUN 29, 2021	DS DP		
021437 002	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587		
021437 003	EPLERENONE; INSPRA	6747020	NOV 05, 2019	U587		
021674 001	ESTRADIOL; ESTROGEL	6747020	NOV 05, 2019	U587		
021040 001	ESTRADIOL; PREFEST					
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTITIN				D-85	FEB 05, 2007
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTITIN				D-85	FEB 05, 2007
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTITIN				D-85	FEB 05, 2007
020992 006	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTITIN				NS	FEB 05, 2007
021443 003	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				D-85	FEB 05, 2007
021443 004	ESTROGENS, CONJUGATED SYNTHETIC B; ENJUVIA				NP	MAY 10, 2007
021490 001	ETHINYL ESTRADIOL; OVCON-35	6667050	JUN 12, 2021	DP U1	NP	MAY 10, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME: TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021687 001	EZETIMIBE; VYTORIN	4444784 5846966 RE37721	DEC 23, 2005 SEP 21, 2013 JUN 16, 2015	DS DP U592 DP U593	NCE	OCT 25, 2007
021687 002	EZETIMIBE; VYTORIN	4444784 5846966 RE37721	DEC 23, 2005 SEP 21, 2013 JUN 16, 2015	DS DP U592 DP U593	NCE	OCT 25, 2007
021687 003	EZETIMIBE; VYTORIN	4444784 5846966 RE37721	DEC 23, 2005 SEP 21, 2013 JUN 16, 2015	DS DP U592 DP U593	NCE	OCT 25, 2007
021687 004	EZETIMIBE; VYTORIN	4444784 5846966 RE37721	DEC 23, 2005 SEP 21, 2013 JUN 16, 2015	DS DP U592 DP U593	NCE	OCT 25, 2007
020363 001	FAMCICLOVIR; FAMVIR	5840763 58866581 5916893 6124304	SEP 01, 2015 OCT 04, 2014 SEP 01, 2015 OCT 04, 2014	U96 U96 U96 U96	U96 U96 U96 U96	OCT 01, 2007
020363 002	FAMCICLOVIR; FAMVIR	5840763 58866581 5916893 6124304	SEP 01, 2015 OCT 04, 2014 SEP 01, 2015 OCT 04, 2014	U96 U96 U96 U96	U96 U96 U96 U96	OCT 01, 2007
020363 003	FAMCICLOVIR; FAMVIR	5840763 58866581 5916893 6124304	SEP 01, 2015 OCT 04, 2014 SEP 01, 2015 OCT 04, 2014	U96 U96 U96 U96	U96 U96 U96 U96	OCT 01, 2007
019922 001 020180 001	FENOLDOPAM MESYLATE; CORLOPAM FINASTERIDE; PROSCAR	4760071 5886184 6046183	JUN 19, 2006 NOV 19, 2012 MAR 20, 2011	DS DP U262 DS DS DS DP U577		
019949 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
019949 002	FLUCONAZOLE; DIFLUCAN	4404216* PED	JUL 29, 2004			
019949 003	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
019949 004	FLUCONAZOLE; DIFLUCAN	4404216* PED	JUL 29, 2004			
020090 001	FLUCONAZOLE; DIFLUCAN	4404216	JAN 29, 2004			
020090 002	FLUCONAZOLE; DIFLUCAN	4404216* PED	JUL 29, 2004			
019950 003	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216* PED	JUL 29, 2004			
019950 005	FLUCONAZOLE; DIFLUCAN IN DEXTROSE	4404216* PED	JUL 29, 2004			
019950 001	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216* PED	JUL 29, 2004			
019950 002	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216* PED	JUL 29, 2004			
019950 004	FLUCONAZOLE; DIFLUCAN IN SODIUM C	4404216* PED	JUL 29, 2004			
020985 001	FLUOROURACIL; CARAC	6670335	JUN 02, 2021	DP U68		
021235 001	FLUOXETINE HYDROCHLORIDE; PROZAC WEEKLY	5910319 5985322	MAY 29, 2017 MAY 29, 2017	U396 U397		

PREScription AND OTC DRUG PRODUCT

See report footnotes for information regarding report content.

PRESCRIBING AND EXCLUSIVITY DATA

See report footnotes for information.

PREScription AND OTC DRUG PRODUCT

APPL/ PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS EXPIRES
020758 002	HYDROCHLORTIAZIDE; AVALIDE	5270317 5994348 5270317* PED 5994348* PED	SEP 30, 2011 JUN 07, 2015 MAR 30, 2012 DEC 07, 2015 SEP 30, 2011 JUN 07, 2015 MAR 30, 2012 DEC 07, 2015		
020758 003	HYDROCHLORTIAZIDE; AVALIDE	5270317 5994348 5270317* PED 5994348* PED	JUN 07, 2015 MAR 30, 2012 DEC 07, 2015 SEP 30, 2011 JUN 07, 2015 MAR 30, 2012 DEC 07, 2015		
>ADD> >ADD> >ADD>	001 HYDROCHLORTIAZIDE; QUINARETIC 002 HYDROCHLORTIAZIDE; QUINARETIC 003 HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE 001 HYDROCODONE BITARTRATE; HYDROCODONE BITARTRATE 002 HYDROMORPHONE HYDROCHLORIDE; PALLADONE 001 HYDROMORPHONE HYDROCHLORIDE; PALLADONE 003 HYDROMORPHONE HYDROCHLORIDE; PALLADONE 004 HYDROMORPHONE HYDROCHLORIDE; PALLADONE 001 IBUPROFEN; CHILDREN'S ELIXISURE 001 IBUPROFEN; IBUPROFEN AND PSEUDO 001 IMIQUIMOD; ALDARA	5270317 5994348 5270317* PED 5994348* PED	JUN 07, 2015 MAR 30, 2012 DEC 07, 2015 SEP 30, 2011 JUN 07, 2015 MAR 30, 2012 DEC 07, 2015		
020685 001	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554	
020685 003	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554	
020685 005	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554	
020685 006	INDINAVIR SULFATE; CRIXIVAN	6689761	FEB 10, 2021	U554	
021629 001	INSULIN GLULISINE RECOMBINANT; API DRA	6221633	JUN 18, 2018	DS DP U471	NCE APR 16, 2009 D-86 JUN 02, 2007 D-86 JUN 02, 2007
020563 001	INSULIN LISPRO RECOMBINANT; HUMALOG	4364921	MAR 06, 2005		
020563 002	INSULIN LISPRO RECOMBINANT; HUMALOG PEN	5270317 6342247	SEP 30, 2011 JUN 07, 2015	DS DP U113	I-373 PED MAR 17, 2005
021425 003	TOPROMIDE; ULTRAVIST (PHARMACY IPBESARTAN; AVAPRO	5270317* PED 5270317* PED 5270317* PED	MAR 30, 2012 MAR 30, 2015 MAR 30, 2012		
020757 001	IPBESARTAN; AVAPRO	6342247* PED 5270317* PED 6342247* PED	DEC 07, 2015 MAR 30, 2012 DEC 07, 2015		
020757 002	IPBESARTAN; AVAPRO	5270317* PED	MAR 30, 2012		
020757 003	IPBESARTAN; AVAPRO				
>ADD> >ADD>	001 IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	6794370 4604463 6403569 4604463 6403569* PED	MAY 01, 2020 NOV 01, 2020 AUG 20, 2007 APR 28, 2020 FEB 20, 2008 OCT 28, 2020 JAN 13, 2019 JAN 13, 2019	U606 DP U449 DP U599	
021066 001	KETOTIFEN FUMARATE; ZADITOR	6774137 6776982	JAN 13, 2019 JAN 13, 2019	DP	
021281 001	LANSOPRAZOLE; PREVACID	021281 002	LANSOPRAZOLE; PREVACID	M-12 AUG 30, 2005	
021428 001	LANSOPRAZOLE; PREVACID	021428 002	LANSOPRAZOLE; PREVACID	M-12 AUG 30, 2005	
021428 002	LANSOPRAZOLE; PREVACID	021566 001	LANSOPRAZOLE; PREVACID IV LANTHANUM CARBONATE; FOSRENOL	M-12 AUG 30, 2005 M-12 MAY 27, 2007	
>ADD>	001	021468 001		NCE OCT 26, 2009	

**PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

Footnotes for information regarding report content

see report footnotes for information regarding

APPL / PROD NUMBER	INGREDIENT NAME ; TRADE NAME	PATENT NUMBER	PATENT / PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE
>ADD> 021468 002	LANTHANUM CARBONATE ; FOSRENOL			NCE	OCT 26, 2009 M-32 MAR 05, 2007 PED
020905 001	LEFLUNOMIDE ; ARAVA			SEP 05, 2007 M-32 MAR 05, 2007 PED	
020905 002	LEFLUNOMIDE ; ARAVA			SEP 05, 2007 M-32 MAR 05, 2007 PED	
020905 003	LEFLUNOMIDE ; ARAVA	6083993	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
020837 004	LEVALUTEROL HYDROCHLORIDE ; XOPENEX				
020182 001	LEVOCARNITINE ; CARNITOR	6451289	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021275 001	LEVOFLOXACIN ; IQUIX	5362755	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021225 001	LEVONORGESTREL ; MIRENA	5547994	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021451 001	LIDOCAINE ; QRAQIX	5766090	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021130 001	LINEZOLID ; ZYVOX	5844002	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021130 002	LINEZOLID ; ZYVOX	6696493	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021131 001	LINEZOLID ; ZYVOX	5053407	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021132 001	LINEZOLID ; ZYVOX	6031007	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021226 001	LOPINAVIR ; KALETRA	5785053	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
021251 001	LOPINAVIR ; KALETRA	65688792	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
075505 001	LORATADINE ; LORATADINE	6559305	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
020386 001	LOSARTAN POTASSIUM ; COZAAR	5688792	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
020386 002	LOSARTAN POTASSIUM ; COZAAR	6559305	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
020386 003	LOSARTAN POTASSIUM ; COZAAR	6703403	JAN 05, 2010 MAR 21, 2021 NOV 08, 2011 AUG 20, 2013	U332 DP U332 U332	
020803 001	LOTEPREDNOL ETABONATE ; ALREX	5747061	OCT 25, 2013 OCT 25, 2013 SEP 20, 2013 SEP 20, 2013	DP U576 DP U575	
020583 001	LOTEPREDNOL ETABONATE ; LOTEMAX	6676967	OCT 25, 2013 OCT 25, 2013 SEP 20, 2013 SEP 20, 2013	DP U548 DP U586	
021249 001	LOVASTATIN ; ADVICOR	6746691	OCT 25, 2013 OCT 25, 2013 SEP 20, 2013 SEP 20, 2013	DP U548 DP U548	
021249 002	LOVASTATIN ; ADVICOR	6676967	OCT 25, 2013 OCT 25, 2013 SEP 20, 2013 SEP 20, 2013	DP U586 DP U548	
021249 003	LOVASTATIN ; ADVICOR	6746691	OCT 25, 2013 OCT 25, 2013 SEP 20, 2013 SEP 20, 2013	DP U586 DP U548	
>ADD>	021663 001	MONOTROPINS (FSH ; LH) ; MENOPUR		NP	OCT 29, 2000 ODE
>ADD>	021322 001	LUTROPIN ALFA ; LUVERIS			OCT 08, 2000 JUL 16, 2000
020938 001	MELoxicAM ; MOBIC	6184220	MAR 25, 2019	DP	I-430 I-430 I-430 I-430
020938 002	MELoxicAM ; MOBIC				NCE
021530 001	MELoxicAM ; MOBIC				
013217 001	METAXALONE ; SKELAXIN	6683102	DEC 03, 2021	U189	
013217 003	METAXALONE ; SKELAXIN	6683102	DEC 03, 2021	U189	
021574 001	METFORMIN HYDROCHLORIDE ; FORTAMET	6790459	MAR 17, 2021	NP	APR 27, 2000
		6495162	MAR 20, 2018	DP	
		6099859	MAR 20, 2018	DP	

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

API#/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL. EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021574 002	METFORMIN HYDROCHLORIDE; FORTAMET	6790459 6495162 6099859	MAR 17, 2021 MAR 20, 2018 MAR 20, 2018	U604 DP DP	NP	APR 27, 2007
076172 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL					
076545 001	METFORMIN HYDROCHLORIDE; METFORMIN HCL					
021415 001	METHYL AMINOLEVULINATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	PC	DEC 14, 2004
021284 001	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	PC	MAY 29, 2004
021284 002	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	NE	JUL 27, 2007
021284 003	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	6635284	DEC 04, 2015	DP	PC	DEC 14, 2004
021284 004	METHYLPHENIDATE HYDROCHLORIDE; RITALIN LA	5837284	DEC 04, 2015	DP	PC	MAY 29, 2004
021308 001	MICONAZOLE NITRATE; MONISTAT 1 COMBINATI	6635284	DEC 04, 2015	DP	PC	JUN 29, 2004
076307 001	MIRTAZAPINE; MIRTAZAPINE	6723713	JAN 27, 2014	U574	D-90	OCT 01, 2007
076307 002	MIRTAZAPINE; MIRTAZAPINE	6723713* PED	JUL 27, 2014		PC	JUN 14, 2004
020762 001	MOMETASONE FUROATE MONOHYDRATE; NASONEX					
021671 001	MORPHINE SULFATE; DEPODUR	5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997099	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6249999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997099	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6249999	SEP 01, 2016	DP		
		5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997099	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6249999	SEP 01, 2016	DP		
021671 003	MORPHINE SULFATE; DEPODUR	5723147	MAR 03, 2015	DP	U584	
		5807572	SEP 15, 2015	DP		
		5891467	JAN 31, 2017	DP		
		5931089	JUL 14, 2015	DP	U584	
		5997099	SEP 01, 2016	DP		
		5962016	JAN 31, 2017	DP	U584	
		6071534	FEB 18, 2008	DP		
		6171613	OCT 01, 2016	DP		
		6193998	SEP 01, 2016	DP		
		6249999	SEP 01, 2016	DP		
021598 001	MOXIFLOXACIN HYDROCHLORIDE; VIGAMOX	6716830* PED	SEP 20, 2019	DP	NCE	DEC 10, 2004
		6716830	MAR 29, 2020	DP		JUN 10, 2005

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME, TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
020381 001	NIACIN; NIASPAN	6746691	SEP 20, 2013	US86		
020381 002	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
020381 003	NIACIN; NIASPAN	6746691	SEP 20, 2013	U586		
020381 004	NIACIN; NIASPAN	6676967	SEP 20, 2013	U548		
020381 005	NIACIN; NIASPAN TITRATION ST	6746691	SEP 20, 2013	U548		
021497 001	NITAZOXAMIDE; ALINIA	6746691	SEP 20, 2013	U586		
021498 001	NITAZOXANIDE; ALINIA					
076648 001	NITROFURANTOIN; NITROFURANTOIN (MONO)	5229382	APR 23, 2011	DS DP U149	NDF	NOV 22, 2007
021494 001	NIZATIDINE; AXID	5229382	APR 23, 2001	U547	I-417	JAN 14, 2007
020592 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	NPP	NOV 22, 2009
020592 002	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	ODE	JUL 21, 2007
020592 003	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	ODE	NOV 22, 2009
020592 004	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	PC	SEP 19, 2004
020592 005	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	NDF	MAY 25, 2007
020592 006	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	I-417	JAN 14, 2007
021253 001	OLANZAPINE; ZYPREXA	5229382	APR 23, 2011	DS DP U149	NDF	NOV 22, 2009
021086 001	OLANZAPINE; ZYPREXA ZYDIS	5840737	JUL 16, 2016	US88		
021086 002	OLANZAPINE; ZYPREXA ZYDIS	6645988	JUL 16, 2016	DS DP		
021086 003	OLANZAPINE; ZYPREXA ZYDIS	6489346	JUL 16, 2016	DS DP	U588	
021086 004	OLANZAPINE; ZYPREXA ZYDIS	6699885	JUL 16, 2016	DS DP	U588	
021636 001	CME PRAZOLE; ZEGERID	6780882	NOV 20, 2015	DP U610		
>ADD>	020605 001 021087 001	ONDANSETRON HYDROCHLORIDE; ZOFTRAN OSELTAMIVIR PHOSPHATE; Tamiflu	5854270 5763483 5866601 592375 5763483*PED 5866601*PED 5952375*PED 5866601 5952375	DEC 27, 2016 FEB 02, 2016 FEB 02, 2016 JUN 27, 2017 DEC 27, 2016 JUN 27, 2017 AUG 02, 2016 FEB 02, 2016 FEB 02, 2016 AUG 02, 2016	NCE PED	OCT 27, 2004 APR 27, 2005
021246 001	OSELTAMIVIR PHOSPHATE; Tamiflu					U376

PREScription AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL / PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS CODE	EXCLUS EXPIRES
021492 001	OXALIPLATIN; ELOXATIN	5872147	DEC 05, 2017	U585	I-425	JAN 09, 2007
021492 002	OXALIPLATIN; ELOXATIN	6670351	OCT 20, 2012	U585	I-425	JAN 09, 2007
013718 001	OXANDROLONE; OXANDRIN	6576659	DEC 05, 2017	U585		
013718 002	OXANDROLONE; OXANDRIN	6090799	JUL 18, 2017	U585		
021351 002	OXYBUTYNIN; OXYTROL	5872147	DEC 05, 2017	U585		
076168 001	OXYCODONE HYDROCHLORIDE; OXYCODONE HCL	6670351	OCT 20, 2012	U585		
020988 001	PANTOPRAZOLE SODIUM; PRONONIX IV	6576659	DEC 05, 2017	U585		
020819 001	PARICALCITOL; ZEMPLAR	6090799	JUL 18, 2017	U585		
020819 002	PARICALCITOL; ZEMPLAR	6743441	APR 26, 2020	DP U318		
>ADD ₂		6780881	NOV 17, 2021	DP	PC	SEP 26, 2004
>ADD ₂		5246925	APR 17, 2012	U314	M-31	MAR 31, 2007
>ADD ₂		5246925*PED	OCT 17, 2012		M-31	OCT 01, 2007
>ADD ₂		558497	DEC 24, 2013		M-31	MAR 31, 2007
>ADD ₂		558497*PED	JUN 24, 2014		M-31	OCT 01, 2007
020629 001	PENCICLOVIR SODIUM; DENAVIR	6136799	APR 08, 2018	DP		
020629 002	PENTETATE CALCIUM TRISODIUM; PENTETATE CALCIUM TRISODIUM; PENTETATE ZINC TRISO	6361758	APR 08, 2018	DP	D-91	JAN 27, 2007
>ADD ₂		6361758*PED	OCT 08, 2018		D-91	JAN 27, 2007
>ADD ₂		5217974	MAR 29, 2011	U551	D-91	JAN 27, 2007
>ADD ₂		5344932	SEP 06, 2011	DS DP	NCE	FEB 04, 2009
021462 001	PEMETRExed DISODIUM; ALIMTA	5840763	SEP 01, 2015	U501	ODE	FEB 04, 2011
020629 001	PENCICLOVIR SODIUM; DENAVIR	5866581	SEP 04, 2014	U501		
021749 001	PENTETATE CALCIUM TRISODIUM; PENTETATE CALCIUM TRISODIUM; PENTETATE ZINC TRISO	5916893	SEP 01, 2015	U501		
>ADD ₂		6124304	SEP 04, 2014	U501		
>ADD ₂					NCE	AUG 11, 2009
021751 001	PIOGLItAZONE HYDROCHLORIDE; ACTOS	4879288	SEP 26, 2011	DS DP U550	ODE	AUG 11, 2011
>ADD ₂		021073 001	PIOGLItAZONE HYDROCHLORIDE; ACTOS		NCE	AUG 11, 2009
>ADD ₂		021073 002	PIOGLItAZONE HYDROCHLORIDE; ACTOS		ODE	AUG 11, 2011
021073 003	PIOGLItAZONE HYDROCHLORIDE; ACTOS	4879288	SEP 26, 2011	DS DP U550	M-35	NOV 26, 2006
020639 001	QUIETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	M-35	NOV 26, 2006
020639 002	QUIETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020639 003	QUIETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020639 004	QUIETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020639 005	QUIETIAPINE FUMARATE; SEROQUEL	4879288	SEP 26, 2011	DS DP U550	I-418	JAN 12, 2007
020815 001	RALOXIFENE HYDROCHLORIDE; EVISTA	6797719	MAR 10, 2017	DP	I-418	JAN 12, 2007
021698 001	RANITIDINE HYDROCHLORIDE; ZANTAC 150	6677358	JUN 12, 2018	DS DP U546	NP	AUG 31, 2007
020741 001	REPAGLINIDE; FRANDIN					

PRESCRIPTION AND OTC DRUG PRODUCT

PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE(S)	EXCLUS EXPIRES
020741 002	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546	
020741 003	REPAGLINIDE; PRANDIN	6677358	JUN 12, 2018	DS DP U546	
020903 002	RIBAVIRIN; REBETOL	6177074	NOV 01, 2016	U454	
		6177074*PED	MAY 01, 2017	U454	
		6461605	NOV 01, 2016	U478	
		6461605*PED	MAY 01, 2017	U478	
		6473373	SEP 21, 2017	U479	
		6473373*PED	MAR 21, 2018	U479	
		6524570	NOV 01, 2016	U499	
		6524570*PED	MAY 01, 2017	U499	
076203 001	RIBAVIRIN; RIBASPHERE	6465443	AUG 14, 2018	DP	0595
076192 001	RIBAVIRIN; RIBAVIRIN	6432932	JUL 17, 2018	U564	
021361 001	RIFAXIMIN; XIFAXAN	6703403	JUN 26, 2016	U564	
020835 003	RISEDRONATE SODIUM; ACTONEL	6703403	JUN 26, 2016	U564	
020659 001	RITONAVIR; NORVIR	5474995	JUN 24, 2013	DS DP U602	
020945 001	RITONAVIR; NORVIR	5691374	MAY 18, 2015	I-353	
021042 001	ROFECOXIB; VIOXX	6063811	MAY 06, 2017	M-27	
		6239173	JUN 24, 2013	U602	
		5474995*PED	DEC 24, 2013	PED	
		5691374*PED	NOV 18, 2015	PED	
		6063811*PED	NOV 06, 2017	I-423	
		6239173*PED	DEC 24, 2013	NCE	
		5474995	JUN 24, 2013	DS DP U602	
		5691374	MAY 18, 2015	I-353	
021042 002	ROFECOXIB; VIOXX	5691374	MAY 06, 2017	M-27	
		6063811	JUN 24, 2013	U602	
		6239173	DEC 24, 2013	PED	
		5474995*PED	NOV 18, 2015	PED	
		5691374*PED	NOV 06, 2017	I-423	
		6063811*PED	NOV 06, 2017	NCE	
		6239173*PED	DEC 24, 2013	DS DP U602	
		5474995	JUN 24, 2013	DS DP U602	
		5691374	MAY 18, 2015	I-353	
		6063811	MAY 06, 2017	M-27	
021042 003	ROFECOXIB; VIOXX	5474995*PED	DEC 24, 2013	U602	
		5691374*PED	NOV 18, 2015	PED	
		6063811*PED	NOV 06, 2017	I-353	
		6239173*PED	JUN 24, 2013	U602	
		5474995	MAY 06, 2017	M-27	
021052 001	ROFECOXIB; VIOXX	5691374	JUN 24, 2013	PED	
		6063811	MAY 06, 2017	N-27	
		6239173	DEC 24, 2013	PED	
		5474995*PED	NOV 18, 2015	PED	
		5691374*PED	NOV 06, 2017	I-353	
021052 002	ROFECOXIB; VIOXX	6063811	JUN 24, 2013	U266	

PREScription AND OTC DRUG PRODUCT

See report footnotes for information regarding report content
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
021256 001	SECRETIN SYNTHETIC HUMAN; CHIHOSTIM	6239173*PED	DEC 24, 2013		ODE NCE	APR 04, 2009 APR 09, 2009
020990 001	SEPTALINE HYDROCHLORIDE; ZOLOFT	6727283	OCT 11, 2019		DP US580	
020926 001	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 11, 2013			
021179 001	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 11, 2013			
020632 001	SI BUTRAMINE HYDROCHLORIDE; MERIDIA	4746680	JUN 11, 2007			
020632 002	SI BUTRAMINE HYDROCHLORIDE; MERIDIA	4929629	MAY 29, 2007		JUL 25, 2012	U439
020632 003	SI BUTRAMINE HYDROCHLORIDE; MERIDIA	5436272	JUL 25, 2012		DEC 11, 2007	
021110 003	SIRHOLIMUS; RAPAMUNE	4746680*PED	DEC 11, 2007		NOV 29, 2007	
020955 001	SODIUM FERRIC GLUCONATE COMPLEX; FERRLECIT	4929629*PED	NOV 29, 2007		JAN 25, 2013	
021196 001	SODIUM OXYBATE; XYREM	5436272*PED	JUN 11, 2007		JUN 11, 2013	
020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	4746680	JUN 11, 2007		JUN 11, 2007	
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN	4929629	MAY 29, 2007		JUL 25, 2012	U439
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN	5436272	JUL 25, 2012		DEC 11, 2007	
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN	4746680*PED	DEC 11, 2007		NOV 29, 2007	
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN	4929629*PED	NOV 29, 2007		JAN 25, 2013	
021148 001	SOMATROPIN RECOMBINANT; NORDITROPIN	5436272*PED	JAN 25, 2013		NCE	SEP 15, 2004
021148 002	SOMATROPIN RECOMBINANT; NORDITROPIN	4746680	NOV 29, 2007		I-386	APR 11, 2006
021148 003	SOMATROPIN RECOMBINANT; NORDITROPIN	4929629	JUN 11, 2007		NPP	AUG 13, 2007
021148 004	SOMATROPIN RECOMBINANT; NORDITROPIN	5037889	DEC 22, 2019		PED	FEB 13, 2008
021148 005	SOMATROPIN RECOMBINANT; NORDITROPIN	4968299	JUN 28, 2008			
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN					
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN					
>ADD>	SOMATROPIN RECOMBINANT; NORDITROPIN					
020168 001	SOMATROPIN RECOMBINANT; NUTROFIN	5096885	MAR 17, 2009		DP	
020168 002	SOMATROPIN RECOMBINANT; NUTROFIN	5096885	MAR 17, 2009		DP	
020522 001	SOMATROPIN RECOMBINANT; NUTROFIN AQ	5763394	JUN 09, 2015		DP	
020522 002	SOMATROPIN RECOMBINANT; NUTROFIN AQ PEN	5763394	JUN 09, 2015		DP	
>ADD>	SOMATROPIN RECOMBINANT; SAIZEN					
>ADD>	SOMATROPIN RECOMBINANT; SAIZEN					
019764 001	SOMATROPIAN SUCCINATE; IMITREX	4816470	DEC 28, 2006		DP	
019764 002	SOMATROPIAN SUCCINATE; IMITREX	5037845	AUG 06, 2008		DP	
>ADD>	SOMATROPIAN SUCCINATE; IMITREX	4816470*PED	JUN 28, 2007		DP	
>ADD>	SOMATROPIAN SUCCINATE; IMITREX	5037845*PED	FEB 06, 2009		DP	
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	DEC 28, 2006		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	5037845	AUG 06, 2008		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	4816470	JUN 28, 2007		DP	
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	6020001*PED	DEC 28, 2006		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	6368627	AUG 06, 2008		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 02, 2012		DP	
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	5863559	JAN 26, 2016		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	6020001	MAR 02, 2012		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	6020001*PED	SEP 02, 2012		DP	
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	6368627*PED	SEP 02, 2012		DP	
>ADD>	SUMATRIPTAN SUCCINATE; IMITREX	4816470	SEP 02, 2012		DP	
020080 001	SUMATRIPTAN SUCCINATE; IMITREX	5037845	FEB 06, 2009		DP	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

For information regarding report content, see notes.

THEORY AND PRACTICE IN THE FIELD OF CULTURAL HERITAGE

PREScription AND OTC DRUG PRODUCT

¹See report footnotes for information regarding report content.

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**
Footnote for information regarding report content

SCHENK, HANKE, AND PETERSON

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnotes for information regarding report content

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/ PED EXCL EXPIRES	PATENT CODE (S)	EXCLUS CODE	EXCLUS EXPIRES
---------------------	-----------------------------	------------------	--------------------------------	--------------------	----------------	-------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d) (5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at
<http://www.fda.gov/cder/orange/patex.htm>
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 24TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION. THE MOST CURRENT COMPLETE LIST OF ALL PATENT AND EXCLUSIVITY TERMS IS AVAILABLE AT [HTTP://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM](http://WWW.FDA.GOV/CDER/ORANGE/PATEX.HTM).

PATENT & EXCLUSIVITY ABBREVIATIONS

- W EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED
- D-89 ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME

EXCLUSIVITY INDICATION

- I-417 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-418 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
- I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
- I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
- I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
- I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
- I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- I-424 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
- I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
- I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
- I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
- I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
- I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS

- I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
- I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
- I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
- I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
- I-435 CHRONIC IDIOPATHIC CONSTIPATION
- I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
- I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
- I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
- I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY

EXCLUSIVITY MISCELLANEOUS

- M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
- M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
- M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
- M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
- M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
- M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
- M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS

PATENT USE

- U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
- U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
- U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
- U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
- U-550 TREATMENT OF BIPOLAR MANIA AND SCHIZOPHRENIA
- U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
- U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
- U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
- U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
- U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
- U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
- U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
- U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
- U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
- U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM
- U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOcular PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS

- U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS
WITH AIDS
- U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND
EMPHYSEMA
- U-567 METHOD OF TREATING INFERTILITY
U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN
THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
- U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN
THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
- U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
U-572 INTENSIVE CARE UNIT SEDATION
- U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND
TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC
PATIENTS 12 YEARS OF AGE AND OLDER
- U-575 LOTEMAX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH
A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A
RISK OF BACTERIAL OCULAR INFECTION EXISTS
- U-576 ALREX IS INDICATED FOR STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A
CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK
OF BACTERIAL OCULAR INFECTION EXISTS.
- U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS,
AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED
MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
- U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-
RELATED DISORDERS
- U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA,
COMPRISED OF ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
- U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISED
OF ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A
METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
- U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISED
OF ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION
FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
- U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT
OF PAIN FOLLOWING MAJOR SURGERY
- U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION
ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED
HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
- U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR
(AND OPTIONALY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
- U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER
SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIONAL ESOPHAGITIS;
MAINTENANCE OF HEALING OF EROSIONAL ESOPHAGITIS
- U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISED
OF ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A
METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
- U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISED
OF ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE
METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
- U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH
PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
- U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA (HOFA)
- U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35

- U-596 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
- U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
- U-598 PROPHYLACTIC TREATMENT OF MIGRAINE
- U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
- U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
- U-601 TREATMENT OF BIPOLAR DISORDERS
- U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
- U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
- U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
- U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
- U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER
- U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
- U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
- U-610 RELIEF OF NAUSEA AND VOMITTING



**United States Government
INFORMATION**
PUBLICATIONS • PERIODICALS • ELECTRONIC PRODUCTS

**Approved Drug Products, ADP
SUBSCRIPTION ORDER FORM**

Order Processing
Code: 8392

Order Processing
Code: 8392

**Easy Secure Internet:
bookstore.gpo.gov**

Toll Free: 866 512-1800
Phone: 202 512-1800
Fax: 202 512-2250

Mail: Superintendent of Documents
PO Box 371954
Pittsburgh, PA 15250-7954

YES, enter my subscription(s) as follows:

Subscription(s) of the **Approved Drug products with Therapeutic Equivalence Evaluations, ADPE**, and the monthly Cumulative Supplements, for \$108.00 per year. The total cost of my order is \$ _____. Price includes regular shipping and handling and is subject to change. International customers please add 40%.



卷之三

Gulliver

Cultivating 11

Discover/NOW **American Express**

卷二十一

City, State, Zip code

ANSWER

Thank you for your order!

11

Deadline shown including area code

ABHIDHIKARIS

Bürohochzeits-Dinner Winter





ST. LOUIS COLLEGE OF PHARMACY



3 2201 90044 0120

Approved drug products with
therapeutic equivalence evaluations.
Cumulative supplement.

RM 301.45 .A66 2004 v.24 suppl.10

LIBRARY

ST. LOUIS COLLEGE OF PHARMACY

4528 PARKVIEW PL.

ST. LOUIS, MO. 63110

 Library Use Only